{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 199,
   "id": "7ea24346",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.support import expected_conditions as EC\n",
    "from selenium.webdriver import ActionChains\n",
    "import selenium\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.common.keys import Keys\n",
    "import time\n",
    "from webdriver_manager.chrome import ChromeDriverManager"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "id": "497f411f",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver=webdriver.Chrome()\n",
    "driver.get(\"https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal/session/calendar\")\n",
    "driver.maximize_window()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "37bc16b4",
   "metadata": {},
   "outputs": [],
   "source": [
    "days=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "57d8460f",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# for i in range():\n",
    "ll=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[7]/div/div/div/div[2]/div[2]')\n",
    "lin=ll.find_elements(By.TAG_NAME,'a')\n",
    "k=[]\n",
    "for l in range(len(lin)):\n",
    "    k.append(lin[l].get_attribute('href'))\n",
    "for l in range(len(k)):\n",
    "    if('esmo.org' not in k[l]):\n",
    "        days.append(k[l])\n",
    "#     driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/ul/li['+str(i)+']/a').click()\n",
    "#     driver.implicitly_wait(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "id": "dab0cc82",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "215"
      ]
     },
     "execution_count": 201,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(days)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "0f6181b6",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[7]/div/div/div/div[2]/div[2]/div[2]/div/ul/li[1]/div/div[1]/div[2]/a').click()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "58eb3aef",
   "metadata": {},
   "outputs": [],
   "source": [
    "/html/body/div[1]/div[3]/div/div/div/div[3]/div[1]/div[2]/div[1]/h4/a\n",
    "/html/body/div[1]/div[3]/div/div/div/div[3]/div[2]/div[2]/div[1]/h4/a\n",
    "/html/body/div[1]/div[3]/div/div/div/div[3]/div[27]/div[2]/div[1]/h4/a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "cb034532",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(1,28):\n",
    "    ll=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div['+str(i)+']/div[2]/div[1]/h4/a')\n",
    "    days.append(ll.get_attribute('href'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b9f4b86f",
   "metadata": {},
   "outputs": [],
   "source": [
    "/html/body/div[1]/div[3]/div/div/div/div[7]/div/div/div/div[2]/div[2]/div[2]/div/ul/li[2]/div/div[1]/div[2]/a\n",
    "/html/body/div[1]/div[3]/div/div/div/div[3]/div[20]/div[2]/div[1]/h4/a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "46b14d04",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[7]/div/div/div/div[2]/div[2]/div[2]/div/ul/li[2]/div/div[1]/div[2]/a').click()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "fd0848ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(1,21):\n",
    "    ll=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div['+str(i)+']/div[2]/div[1]/h4/a')\n",
    "    days.append(ll.get_attribute('href'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "1a1e775a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "47"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(days)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "270210e1",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[7]/div/div/div/div[2]/div[2]/div[2]/div/ul/li[3]/div/div[1]/div[2]/a').click()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f7cc8a84",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(1,20):\n",
    "    ll=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div['+str(i)+']/div[2]/div[1]/h4/a')\n",
    "    days.append(ll.get_attribute('href'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "16975bd0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "66"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(days)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "4657d02d",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.get(days[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 203,
   "id": "da9d84f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "SESSION=[]\n",
    "SUB_SESSION=[]\n",
    "TIME=[]\n",
    "PERSONS=[]\n",
    "DATE=[]\n",
    "ROLE=[]\n",
    "COUNTRY=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5660d148",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a60b3264",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7b94b531",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "id": "34fc7384",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 1\n",
      "0 2\n",
      "0 3\n",
      "0 4\n",
      "p:  0\n",
      "1 1\n",
      "1 2\n",
      "1 3\n",
      "1 4\n",
      "p:  1\n",
      "2 1\n",
      "2 2\n",
      "2 3\n",
      "2 4\n",
      "p:  2\n",
      "3 1\n",
      "3 2\n",
      "3 3\n",
      "3 4\n",
      "p:  3\n",
      "4 1\n",
      "4 2\n",
      "4 3\n",
      "p:  4\n",
      "5 1\n",
      "5 2\n",
      "5 3\n",
      "5 4\n",
      "p:  5\n",
      "6 1\n",
      "6 2\n",
      "6 3\n",
      "6 4\n",
      "p:  6\n",
      "7 1\n",
      "7 2\n",
      "7 3\n",
      "7 4\n",
      "p:  7\n",
      "8 1\n",
      "8 2\n",
      "8 3\n",
      "8 4\n",
      "p:  8\n",
      "9 1\n",
      "9 2\n",
      "9 3\n",
      "p:  9\n",
      "10 1\n",
      "10 2\n",
      "10 3\n",
      "10 4\n",
      "p:  10\n",
      "11 1\n",
      "11 2\n",
      "11 3\n",
      "11 4\n",
      "p:  11\n",
      "12 1\n",
      "12 2\n",
      "12 3\n",
      "12 4\n",
      "p:  12\n",
      "13 1\n",
      "13 2\n",
      "13 3\n",
      "13 4\n",
      "p:  13\n",
      "14 1\n",
      "14 2\n",
      "14 3\n",
      "14 4\n",
      "p:  14\n",
      "15 1\n",
      "15 2\n",
      "15 3\n",
      "15 4\n",
      "p:  15\n",
      "16 1\n",
      "16 2\n",
      "16 3\n",
      "16 4\n",
      "p:  16\n",
      "17 1\n",
      "17 2\n",
      "17 3\n",
      "17 4\n",
      "p:  17\n",
      "18 1\n",
      "18 2\n",
      "18 3\n",
      "18 4\n",
      "p:  18\n",
      "19 1\n",
      "19 2\n",
      "19 3\n",
      "19 4\n",
      "p:  19\n",
      "20 1\n",
      "20 2\n",
      "20 3\n",
      "20 4\n",
      "p:  20\n",
      "21 1\n",
      "21 2\n",
      "21 3\n",
      "21 4\n",
      "21 5\n",
      "p:  21\n",
      "22 1\n",
      "22 2\n",
      "22 3\n",
      "22 4\n",
      "22 5\n",
      "22 6\n",
      "22 7\n",
      "p:  22\n",
      "23 1\n",
      "23 2\n",
      "23 3\n",
      "23 4\n",
      "p:  23\n",
      "24 1\n",
      "24 2\n",
      "24 3\n",
      "24 4\n",
      "p:  24\n",
      "25 1\n",
      "25 2\n",
      "25 3\n",
      "25 4\n",
      "p:  25\n",
      "26 1\n",
      "26 2\n",
      "26 3\n",
      "26 4\n",
      "p:  26\n",
      "27 1\n",
      "27 2\n",
      "27 3\n",
      "27 4\n",
      "p:  27\n",
      "28 1\n",
      "28 2\n",
      "28 3\n",
      "28 4\n",
      "28 5\n",
      "p:  28\n",
      "29 1\n",
      "29 2\n",
      "29 3\n",
      "29 4\n",
      "29 5\n",
      "p:  29\n",
      "30 1\n",
      "30 2\n",
      "30 3\n",
      "30 4\n",
      "30 5\n",
      "p:  30\n",
      "31 1\n",
      "31 2\n",
      "31 3\n",
      "31 4\n",
      "31 5\n",
      "p:  31\n",
      "32 1\n",
      "32 2\n",
      "32 3\n",
      "32 4\n",
      "32 5\n",
      "p:  32\n",
      "33 1\n",
      "33 2\n",
      "33 3\n",
      "33 4\n",
      "33 5\n",
      "p:  33\n",
      "34 1\n",
      "34 2\n",
      "34 3\n",
      "34 4\n",
      "34 5\n",
      "p:  34\n",
      "35 1\n",
      "35 2\n",
      "35 3\n",
      "35 4\n",
      "35 5\n",
      "p:  35\n",
      "36 1\n",
      "36 2\n",
      "36 3\n",
      "36 4\n",
      "36 5\n",
      "p:  36\n",
      "37 1\n",
      "37 2\n",
      "37 3\n",
      "37 4\n",
      "37 5\n",
      "p:  37\n",
      "38 1\n",
      "38 2\n",
      "38 3\n",
      "38 4\n",
      "38 5\n",
      "p:  38\n",
      "39 1\n",
      "39 2\n",
      "39 3\n",
      "39 4\n",
      "p:  39\n",
      "40 1\n",
      "40 2\n",
      "40 3\n",
      "40 4\n",
      "40 5\n",
      "p:  40\n",
      "41 1\n",
      "41 2\n",
      "41 3\n",
      "41 4\n",
      "41 5\n",
      "p:  41\n",
      "42 1\n",
      "42 2\n",
      "42 3\n",
      "42 4\n",
      "42 5\n",
      "p:  42\n",
      "43 1\n",
      "43 2\n",
      "43 3\n",
      "43 4\n",
      "43 5\n",
      "p:  43\n",
      "44 1\n",
      "44 2\n",
      "44 3\n",
      "44 4\n",
      "44 5\n",
      "p:  44\n",
      "45 1\n",
      "45 2\n",
      "45 3\n",
      "45 4\n",
      "45 5\n",
      "45 6\n",
      "p:  45\n",
      "46 1\n",
      "46 2\n",
      "46 3\n",
      "46 4\n",
      "46 5\n",
      "p:  46\n",
      "47 1\n",
      "47 2\n",
      "47 3\n",
      "47 4\n",
      "p:  47\n",
      "48 1\n",
      "48 2\n",
      "48 3\n",
      "48 4\n",
      "48 5\n",
      "p:  48\n",
      "49 1\n",
      "49 2\n",
      "49 3\n",
      "49 4\n",
      "p:  49\n",
      "50 1\n",
      "50 2\n",
      "50 3\n",
      "50 4\n",
      "p:  50\n",
      "51 1\n",
      "51 2\n",
      "51 3\n",
      "51 4\n",
      "p:  51\n",
      "52 1\n",
      "52 2\n",
      "52 3\n",
      "52 4\n",
      "p:  52\n",
      "53 1\n",
      "53 2\n",
      "53 3\n",
      "53 4\n",
      "p:  53\n",
      "54 1\n",
      "54 2\n",
      "54 3\n",
      "54 4\n",
      "54 5\n",
      "p:  54\n",
      "55 1\n",
      "55 2\n",
      "55 3\n",
      "55 4\n",
      "p:  55\n",
      "56 1\n",
      "56 2\n",
      "56 3\n",
      "56 4\n",
      "56 5\n",
      "p:  56\n",
      "57 1\n",
      "57 2\n",
      "57 3\n",
      "57 4\n",
      "p:  57\n",
      "58 1\n",
      "58 2\n",
      "58 3\n",
      "58 4\n",
      "58 5\n",
      "58 6\n",
      "58 7\n",
      "58 8\n",
      "p:  58\n",
      "59 1\n",
      "59 2\n",
      "59 3\n",
      "59 4\n",
      "59 5\n",
      "p:  59\n",
      "60 1\n",
      "60 2\n",
      "60 3\n",
      "60 4\n",
      "p:  60\n",
      "61 1\n",
      "61 2\n",
      "61 3\n",
      "61 4\n",
      "p:  61\n",
      "62 1\n",
      "62 2\n",
      "62 3\n",
      "62 4\n",
      "p:  62\n",
      "63 1\n",
      "63 2\n",
      "63 3\n",
      "63 4\n",
      "p:  63\n",
      "64 1\n",
      "64 2\n",
      "64 3\n",
      "64 4\n",
      "p:  64\n",
      "65 1\n",
      "65 2\n",
      "65 3\n",
      "65 4\n",
      "p:  65\n",
      "66 1\n",
      "66 2\n",
      "66 3\n",
      "66 4\n",
      "p:  66\n",
      "67 1\n",
      "67 2\n",
      "p:  67\n",
      "68 1\n",
      "68 2\n",
      "68 3\n",
      "68 4\n",
      "68 5\n",
      "68 6\n",
      "68 7\n",
      "p:  68\n",
      "69 1\n",
      "69 2\n",
      "69 3\n",
      "69 4\n",
      "69 5\n",
      "69 6\n",
      "69 7\n",
      "69 8\n",
      "p:  69\n",
      "70 1\n",
      "p:  70\n",
      "p:  71\n",
      "72 1\n",
      "72 2\n",
      "72 3\n",
      "72 4\n",
      "72 5\n",
      "72 6\n",
      "72 7\n",
      "72 8\n",
      "72 9\n",
      "p:  72\n",
      "73 1\n",
      "73 2\n",
      "p:  73\n",
      "74 1\n",
      "74 2\n",
      "74 3\n",
      "74 4\n",
      "74 5\n",
      "74 6\n",
      "74 7\n",
      "74 8\n",
      "p:  74\n",
      "75 1\n",
      "p:  75\n",
      "p:  76\n",
      "77 1\n",
      "77 2\n",
      "77 3\n",
      "77 4\n",
      "77 5\n",
      "77 6\n",
      "77 7\n",
      "77 8\n",
      "p:  77\n",
      "78 1\n",
      "78 2\n",
      "p:  78\n",
      "79 1\n",
      "79 2\n",
      "79 3\n",
      "79 4\n",
      "79 5\n",
      "79 6\n",
      "79 7\n",
      "79 8\n",
      "p:  79\n",
      "80 1\n",
      "p:  80\n",
      "p:  81\n",
      "82 1\n",
      "82 2\n",
      "82 3\n",
      "82 4\n",
      "82 5\n",
      "82 6\n",
      "82 7\n",
      "82 8\n",
      "p:  82\n",
      "83 1\n",
      "83 2\n",
      "p:  83\n",
      "84 1\n",
      "84 2\n",
      "84 3\n",
      "84 4\n",
      "84 5\n",
      "84 6\n",
      "84 7\n",
      "84 8\n",
      "p:  84\n",
      "p:  85\n",
      "86 1\n",
      "86 2\n",
      "86 3\n",
      "86 4\n",
      "86 5\n",
      "86 6\n",
      "86 7\n",
      "86 8\n",
      "86 9\n",
      "p:  86\n",
      "87 1\n",
      "87 2\n",
      "87 3\n",
      "87 4\n",
      "87 5\n",
      "87 6\n",
      "87 7\n",
      "87 8\n",
      "p:  87\n",
      "p:  88\n",
      "89 1\n",
      "89 2\n",
      "89 3\n",
      "89 4\n",
      "89 5\n",
      "89 6\n",
      "89 7\n",
      "89 8\n",
      "89 9\n",
      "p:  89\n",
      "90 1\n",
      "90 2\n",
      "90 3\n",
      "90 4\n",
      "90 5\n",
      "90 6\n",
      "p:  90\n",
      "91 1\n",
      "91 2\n",
      "91 3\n",
      "91 4\n",
      "91 5\n",
      "91 6\n",
      "p:  91\n",
      "92 1\n",
      "92 2\n",
      "92 3\n",
      "92 4\n",
      "92 5\n",
      "p:  92\n",
      "93 1\n",
      "93 2\n",
      "93 3\n",
      "93 4\n",
      "93 5\n",
      "93 6\n",
      "p:  93\n",
      "p:  94\n",
      "95 1\n",
      "95 2\n",
      "95 3\n",
      "95 4\n",
      "95 5\n",
      "95 6\n",
      "p:  95\n",
      "96 1\n",
      "96 2\n",
      "96 3\n",
      "96 4\n",
      "96 5\n",
      "96 6\n",
      "96 7\n",
      "96 8\n",
      "p:  96\n",
      "p:  97\n",
      "98 1\n",
      "98 2\n",
      "98 3\n",
      "98 4\n",
      "98 5\n",
      "98 6\n",
      "98 7\n",
      "98 8\n",
      "p:  98\n",
      "99 1\n",
      "99 2\n",
      "p:  99\n",
      "100 1\n",
      "100 2\n",
      "100 3\n",
      "100 4\n",
      "100 5\n",
      "100 6\n",
      "100 7\n",
      "100 8\n",
      "p:  100\n",
      "101 1\n",
      "101 2\n",
      "101 3\n",
      "101 4\n",
      "101 5\n",
      "101 6\n",
      "p:  101\n",
      "102 1\n",
      "p:  102\n",
      "p:  103\n",
      "104 1\n",
      "104 2\n",
      "104 3\n",
      "104 4\n",
      "104 5\n",
      "104 6\n",
      "104 7\n",
      "p:  104\n",
      "105 1\n",
      "105 2\n",
      "105 3\n",
      "p:  105\n",
      "106 1\n",
      "106 2\n",
      "106 3\n",
      "106 4\n",
      "106 5\n",
      "106 6\n",
      "106 7\n",
      "106 8\n",
      "p:  106\n",
      "107 1\n",
      "p:  107\n",
      "p:  108\n",
      "109 1\n",
      "109 2\n",
      "109 3\n",
      "109 4\n",
      "109 5\n",
      "109 6\n",
      "109 7\n",
      "109 8\n",
      "109 9\n",
      "109 10\n",
      "p:  109\n",
      "110 1\n",
      "110 2\n",
      "110 3\n",
      "110 4\n",
      "110 5\n",
      "110 6\n",
      "110 7\n",
      "110 8\n",
      "110 9\n",
      "p:  110\n",
      "111 1\n",
      "p:  111\n",
      "p:  112\n",
      "113 1\n",
      "113 2\n",
      "113 3\n",
      "113 4\n",
      "113 5\n",
      "113 6\n",
      "113 7\n",
      "113 8\n",
      "113 9\n",
      "p:  113\n",
      "114 1\n",
      "114 2\n",
      "114 3\n",
      "114 4\n",
      "114 5\n",
      "114 6\n",
      "114 7\n",
      "p:  114\n",
      "p:  115\n",
      "116 1\n",
      "116 2\n",
      "116 3\n",
      "116 4\n",
      "116 5\n",
      "116 6\n",
      "116 7\n",
      "p:  116\n",
      "117 1\n",
      "117 2\n",
      "117 3\n",
      "117 4\n",
      "117 5\n",
      "117 6\n",
      "117 7\n",
      "117 8\n",
      "p:  117\n",
      "p:  118\n",
      "119 1\n",
      "119 2\n",
      "119 3\n",
      "119 4\n",
      "119 5\n",
      "119 6\n",
      "119 7\n",
      "119 8\n",
      "p:  119\n",
      "120 1\n",
      "120 2\n",
      "120 3\n",
      "120 4\n",
      "120 5\n",
      "120 6\n",
      "120 7\n",
      "p:  120\n",
      "121 1\n",
      "121 2\n",
      "121 3\n",
      "121 4\n",
      "121 5\n",
      "121 6\n",
      "p:  121\n",
      "122 1\n",
      "122 2\n",
      "122 3\n",
      "122 4\n",
      "122 5\n",
      "122 6\n",
      "p:  122\n",
      "123 1\n",
      "123 2\n",
      "123 3\n",
      "123 4\n",
      "p:  123\n",
      "124 1\n",
      "124 2\n",
      "124 3\n",
      "124 4\n",
      "124 5\n",
      "124 6\n",
      "p:  124\n",
      "p:  125\n",
      "126 1\n",
      "126 2\n",
      "126 3\n",
      "126 4\n",
      "126 5\n",
      "126 6\n",
      "p:  126\n",
      "127 1\n",
      "127 2\n",
      "p:  127\n",
      "128 1\n",
      "128 2\n",
      "128 3\n",
      "128 4\n",
      "128 5\n",
      "128 6\n",
      "128 7\n",
      "p:  128\n",
      "129 1\n",
      "129 2\n",
      "129 3\n",
      "129 4\n",
      "129 5\n",
      "129 6\n",
      "129 7\n",
      "p:  129\n",
      "130 1\n",
      "p:  130\n",
      "p:  131\n",
      "132 1\n",
      "132 2\n",
      "132 3\n",
      "132 4\n",
      "132 5\n",
      "132 6\n",
      "132 7\n",
      "132 8\n",
      "p:  132\n",
      "133 1\n",
      "133 2\n",
      "133 3\n",
      "p:  133\n",
      "134 1\n",
      "134 2\n",
      "134 3\n",
      "134 4\n",
      "134 5\n",
      "134 6\n",
      "134 7\n",
      "134 8\n",
      "p:  134\n",
      "135 1\n",
      "p:  135\n",
      "p:  136\n",
      "137 1\n",
      "137 2\n",
      "137 3\n",
      "137 4\n",
      "137 5\n",
      "137 6\n",
      "p:  137\n",
      "138 1\n",
      "138 2\n",
      "138 3\n",
      "138 4\n",
      "138 5\n",
      "138 6\n",
      "138 7\n",
      "p:  138\n",
      "p:  139\n",
      "140 1\n",
      "140 2\n",
      "140 3\n",
      "140 4\n",
      "140 5\n",
      "140 6\n",
      "140 7\n",
      "p:  140\n",
      "141 1\n",
      "141 2\n",
      "141 3\n",
      "141 4\n",
      "141 5\n",
      "141 6\n",
      "141 7\n",
      "141 8\n",
      "141 9\n",
      "141 10\n",
      "p:  141\n",
      "p:  142\n",
      "143 1\n",
      "143 2\n",
      "143 3\n",
      "143 4\n",
      "143 5\n",
      "143 6\n",
      "143 7\n",
      "143 8\n",
      "p:  143\n",
      "144 1\n",
      "144 2\n",
      "144 3\n",
      "144 4\n",
      "144 5\n",
      "144 6\n",
      "144 7\n",
      "144 8\n",
      "p:  144\n",
      "p:  145\n",
      "146 1\n",
      "146 2\n",
      "146 3\n",
      "146 4\n",
      "146 5\n",
      "146 6\n",
      "146 7\n",
      "146 8\n",
      "146 9\n",
      "p:  146\n",
      "147 1\n",
      "147 2\n",
      "147 3\n",
      "147 4\n",
      "147 5\n",
      "147 6\n",
      "p:  147\n",
      "148 1\n",
      "148 2\n",
      "148 3\n",
      "148 4\n",
      "148 5\n",
      "148 6\n",
      "p:  148\n",
      "149 1\n",
      "149 2\n",
      "149 3\n",
      "149 4\n",
      "149 5\n",
      "149 6\n",
      "p:  149\n",
      "p:  150\n",
      "151 1\n",
      "151 2\n",
      "151 3\n",
      "151 4\n",
      "151 5\n",
      "151 6\n",
      "p:  151\n",
      "152 1\n",
      "152 2\n",
      "p:  152\n",
      "153 1\n",
      "153 2\n",
      "153 3\n",
      "153 4\n",
      "153 5\n",
      "153 6\n",
      "153 7\n",
      "153 8\n",
      "p:  153\n",
      "154 1\n",
      "154 2\n",
      "154 3\n",
      "154 4\n",
      "154 5\n",
      "154 6\n",
      "154 7\n",
      "p:  154\n",
      "155 1\n",
      "p:  155\n",
      "p:  156\n",
      "157 1\n",
      "157 2\n",
      "157 3\n",
      "157 4\n",
      "157 5\n",
      "157 6\n",
      "157 7\n",
      "157 8\n",
      "157 9\n",
      "p:  157\n",
      "158 1\n",
      "158 2\n",
      "158 3\n",
      "p:  158\n",
      "159 1\n",
      "159 2\n",
      "159 3\n",
      "159 4\n",
      "159 5\n",
      "159 6\n",
      "159 7\n",
      "159 8\n",
      "p:  159\n",
      "160 1\n",
      "p:  160\n",
      "p:  161\n",
      "162 1\n",
      "162 2\n",
      "162 3\n",
      "162 4\n",
      "162 5\n",
      "162 6\n",
      "162 7\n",
      "p:  162\n",
      "163 1\n",
      "163 2\n",
      "163 3\n",
      "163 4\n",
      "163 5\n",
      "163 6\n",
      "163 7\n",
      "p:  163\n",
      "164 1\n",
      "164 2\n",
      "164 3\n",
      "164 4\n",
      "164 5\n",
      "164 6\n",
      "164 7\n",
      "p:  164\n",
      "165 1\n",
      "p:  165\n",
      "p:  166\n",
      "167 1\n",
      "167 2\n",
      "167 3\n",
      "167 4\n",
      "167 5\n",
      "167 6\n",
      "167 7\n",
      "167 8\n",
      "167 9\n",
      "p:  167\n",
      "168 1\n",
      "168 2\n",
      "168 3\n",
      "168 4\n",
      "168 5\n",
      "168 6\n",
      "168 7\n",
      "168 8\n",
      "p:  168\n",
      "p:  169\n",
      "170 1\n",
      "170 2\n",
      "170 3\n",
      "170 4\n",
      "170 5\n",
      "170 6\n",
      "170 7\n",
      "p:  170\n",
      "171 1\n",
      "171 2\n",
      "171 3\n",
      "171 4\n",
      "171 5\n",
      "171 6\n",
      "171 7\n",
      "171 8\n",
      "p:  171\n",
      "p:  172\n",
      "173 1\n",
      "173 2\n",
      "173 3\n",
      "173 4\n",
      "173 5\n",
      "173 6\n",
      "173 7\n",
      "p:  173\n",
      "174 1\n",
      "174 2\n",
      "174 3\n",
      "174 4\n",
      "174 5\n",
      "174 6\n",
      "p:  174\n",
      "175 1\n",
      "175 2\n",
      "175 3\n",
      "175 4\n",
      "175 5\n",
      "175 6\n",
      "p:  175\n",
      "176 1\n",
      "176 2\n",
      "176 3\n",
      "176 4\n",
      "176 5\n",
      "176 6\n",
      "p:  176\n",
      "177 1\n",
      "177 2\n",
      "177 3\n",
      "177 4\n",
      "177 5\n",
      "177 6\n",
      "p:  177\n",
      "p:  178\n",
      "179 1\n",
      "179 2\n",
      "179 3\n",
      "179 4\n",
      "179 5\n",
      "179 6\n",
      "p:  179\n",
      "180 1\n",
      "180 2\n",
      "p:  180\n",
      "181 1\n",
      "181 2\n",
      "181 3\n",
      "181 4\n",
      "181 5\n",
      "p:  181\n",
      "182 1\n",
      "182 2\n",
      "182 3\n",
      "182 4\n",
      "p:  182\n",
      "p:  183\n",
      "184 1\n",
      "184 2\n",
      "184 3\n",
      "p:  184\n",
      "185 1\n",
      "185 2\n",
      "185 3\n",
      "185 4\n",
      "185 5\n",
      "185 6\n",
      "185 7\n",
      "185 8\n",
      "p:  185\n",
      "186 1\n",
      "186 2\n",
      "186 3\n",
      "186 4\n",
      "186 5\n",
      "186 6\n",
      "186 7\n",
      "186 8\n",
      "p:  186\n",
      "187 1\n",
      "187 2\n",
      "187 3\n",
      "187 4\n",
      "187 5\n",
      "187 6\n",
      "187 7\n",
      "187 8\n",
      "187 9\n",
      "p:  187\n",
      "p:  188\n",
      "189 1\n",
      "189 2\n",
      "189 3\n",
      "189 4\n",
      "189 5\n",
      "189 6\n",
      "189 7\n",
      "189 8\n",
      "p:  189\n",
      "190 1\n",
      "190 2\n",
      "190 3\n",
      "190 4\n",
      "190 5\n",
      "p:  190\n",
      "191 1\n",
      "191 2\n",
      "191 3\n",
      "191 4\n",
      "191 5\n",
      "191 6\n",
      "p:  191\n",
      "p:  192\n",
      "193 1\n",
      "193 2\n",
      "193 3\n",
      "193 4\n",
      "193 5\n",
      "193 6\n",
      "193 7\n",
      "193 8\n",
      "p:  193\n",
      "194 1\n",
      "194 2\n",
      "194 3\n",
      "p:  194\n",
      "195 1\n",
      "p:  195\n",
      "p:  196\n",
      "197 1\n",
      "197 2\n",
      "197 3\n",
      "197 4\n",
      "197 5\n",
      "197 6\n",
      "197 7\n",
      "197 8\n",
      "p:  197\n",
      "198 1\n",
      "198 2\n",
      "198 3\n",
      "198 4\n",
      "198 5\n",
      "198 6\n",
      "p:  198\n",
      "199 1\n",
      "199 2\n",
      "199 3\n",
      "199 4\n",
      "199 5\n",
      "199 6\n",
      "p:  199\n",
      "p:  200\n",
      "201 1\n",
      "201 2\n",
      "201 3\n",
      "201 4\n",
      "201 5\n",
      "201 6\n",
      "p:  201\n",
      "202 1\n",
      "202 2\n",
      "202 3\n",
      "202 4\n",
      "202 5\n",
      "202 6\n",
      "p:  202\n",
      "203 1\n",
      "203 2\n",
      "203 3\n",
      "203 4\n",
      "203 5\n",
      "203 6\n",
      "p:  203\n",
      "204 1\n",
      "204 2\n",
      "204 3\n",
      "204 4\n",
      "204 5\n",
      "204 6\n",
      "p:  204\n",
      "p:  205\n",
      "206 1\n",
      "206 2\n",
      "206 3\n",
      "206 4\n",
      "206 5\n",
      "206 6\n",
      "206 7\n",
      "p:  206\n",
      "207 1\n",
      "207 2\n",
      "207 3\n",
      "207 4\n",
      "207 5\n",
      "207 6\n",
      "p:  207\n",
      "208 1\n",
      "208 2\n",
      "208 3\n",
      "208 4\n",
      "208 5\n",
      "208 6\n",
      "p:  208\n",
      "209 1\n",
      "209 2\n",
      "209 3\n",
      "209 4\n",
      "p:  209\n",
      "210 1\n",
      "210 2\n",
      "210 3\n",
      "210 4\n",
      "210 5\n",
      "210 6\n",
      "p:  210\n",
      "211 1\n",
      "211 2\n",
      "211 3\n",
      "211 4\n",
      "211 5\n",
      "211 6\n",
      "p:  211\n",
      "212 1\n",
      "212 2\n",
      "212 3\n",
      "212 4\n",
      "212 5\n",
      "212 6\n",
      "p:  212\n",
      "213 1\n",
      "213 2\n",
      "213 3\n",
      "213 4\n",
      "213 5\n",
      "213 6\n",
      "p:  213\n",
      "214 1\n",
      "214 2\n",
      "214 3\n",
      "214 4\n",
      "214 5\n",
      "214 6\n",
      "p:  214\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(days)):\n",
    "    driver.get(days[i])\n",
    "    driver.implicitly_wait(3)\n",
    "    \n",
    "    ch=driver.find_element(By.CLASS_NAME,'internal_moderators')\n",
    "    chai=ch.find_elements(By.TAG_NAME,'li')\n",
    "    cc=[]\n",
    "    for l in range(len(chai)):\n",
    "        cc.append(chai[l].text)\n",
    "    tchairs=[]\n",
    "    country=[]\n",
    "    for n in range(len(cc)):\n",
    "        lc=cc[n].split('(')\n",
    "        tchairs.append(lc[0])\n",
    "        try:\n",
    "            lc[1]=lc[1].replace(')','')\n",
    "            country.append(lc[1])\n",
    "        except:\n",
    "            country.append('')\n",
    "            \n",
    "    for l in range(len(tchairs)):\n",
    "        PERSONS.append(tchairs[l])\n",
    "        COUNTRY.append(country[l])\n",
    "        SESSION.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[1]/h4').text)\n",
    "        SUB_SESSION.append('Introduction')\n",
    "        try:\n",
    "            TIME.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[2]/div[2]').text)  \n",
    "        except:\n",
    "            TIME.append('')\n",
    "        try:\n",
    "            DATE.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[4]/div[2]').text)\n",
    "        except:\n",
    "            try:\n",
    "                DATE.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[1]/div[2]').text)\n",
    "            except:\n",
    "                DATE.append('')\n",
    "                                                      \n",
    "        ROLE.append('Chair')  \n",
    "        \n",
    "    for j in range(1,20):\n",
    "        try:\n",
    "            driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']')\n",
    "            try:\n",
    "#                 spp=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/div[1]/div[1]/div[2]/ul')                                                \n",
    "                spp=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']')\n",
    "                li=spp.find_element(By.CLASS_NAME,'persons')\n",
    "                sp=li.find_elements(By.TAG_NAME,'li')\n",
    "                tsp=[]\n",
    "                for s in range(len(sp)):\n",
    "                    tsp.append(sp[s].text)\n",
    "                speak=[]\n",
    "                place=[]\n",
    "                for m in range(len(tsp)):\n",
    "                    lc=tsp[m].split('(')\n",
    "                    speak.append(lc[0])\n",
    "                    try:\n",
    "                        lc[1]=lc[1].replace(')','')\n",
    "                        place.append(lc[1])\n",
    "                    except:\n",
    "                        place.append('')\n",
    "\n",
    "                for m in range(len(speak)):\n",
    "                    s=spp.find_element(By.CLASS_NAME,'card-title').text\n",
    "                    SESSION.append(driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[1]/h4').text)\n",
    "                    PERSONS.append(speak[m])\n",
    "                    COUNTRY.append(place[m])\n",
    "                    #speakers..............................\n",
    "                    try:\n",
    "                        su=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/h4').text\n",
    "                        SUB_SESSION.append(su)\n",
    "                    except:\n",
    "                        SUB_SESSION.append(None)\n",
    "                    try:\n",
    "                        t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/div[1]/div[2]/div[2]').text\n",
    "                        TIME.append(t)\n",
    "                    except:\n",
    "                        TIME.append(None)\n",
    "                    try:\n",
    "                        d=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[4]/div[2]').text\n",
    "                        DATE.append(d)\n",
    "                    except:\n",
    "                        DATE.append(None)\n",
    "                    ROLE.append('Speaker')\n",
    "                \n",
    "            except:\n",
    "                s=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[1]/h4').text                            \n",
    "                SESSION.append(s)\n",
    "                PERSONS.append('')\n",
    "                COUNTRY.append('')\n",
    "                ROLE.append('')\n",
    "                #speakers..............................\n",
    "                try:\n",
    "                    su=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/h4').text\n",
    "                    SUB_SESSION.append(su)\n",
    "                except:\n",
    "                    SUB_SESSION.append(None)\n",
    "                try:\n",
    "                    t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div['+str(j)+']/div[2]/div[1]/div[2]/div[2]').text\n",
    "#                                                     /html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]/div[3]/div[2]    \n",
    "                    TIME.append(t)\n",
    "                except:\n",
    "                    TIME.append(None)\n",
    "                try:\n",
    "                    d=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[2]/div[4]/div[2]').text\n",
    "                    DATE.append(d)\n",
    "                except:\n",
    "                    DATE.append(None)\n",
    "            print(i,j)\n",
    "        except:\n",
    "            break\n",
    "    print('p: ',i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 205,
   "id": "e4714bf1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Basic science\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Basic science\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Breast cancer, early stage\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Breast cancer, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "CNS tumours\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Developmental therapeutics\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gastrointestinal tumours, colorectal\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gastrointestinal tumours, non-colorectal\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Genitourinary tumours, non-prostate\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Genitourinary tumours, non-prostate\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Genitourinary tumours, prostate\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gynaecological cancers\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Haematological malignancies\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Head and neck cancer, excl. thyroid\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Investigational immunotherapy\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Melanoma and other skin tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NETs and endocrine tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Non-metastatic NSCLC and other thoracic malignancies\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NSCLC, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NSCLC, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Public policy\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Public policy\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Public policy\n",
      "5 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "Sarcoma\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Supportive and palliative care\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Translational research\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Translational research\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Basic science\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Breast cancer, early stage\n",
      "10 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Breast cancer, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "CNS tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Developmental therapeutics\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gastrointestinal tumours, colorectal\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gastrointestinal tumours, non-colorectal\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Genitourinary tumours, prostate\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gynaecological cancers\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Haematological malignancies\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Head and neck cancer, excl. thyroid\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Investigational immunotherapy\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Melanoma and other skin tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NETs and endocrine tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Non-metastatic NSCLC and other thoracic malignancies\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NSCLC, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Sarcoma\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Supportive and palliative care\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Translational research\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Basic science\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Breast cancer, early stage\n",
      "5 Minutes\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Breast cancer, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "CNS tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Developmental therapeutics\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gastrointestinal tumours, colorectal\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gastrointestinal tumours, non-colorectal\n",
      "5 Minutes\n",
      "20 Minutes\n",
      "20 Minutes\n",
      "20 Minutes\n",
      "Genitourinary tumours, non-prostate\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Genitourinary tumours, prostate\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Gynaecological cancers\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Haematological malignancies\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Head and neck cancer, excl. thyroid\n",
      "5 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "5 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "10 Minutes\n",
      "Investigational immunotherapy\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Melanoma and other skin tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NETs and endocrine tumours\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Non-metastatic NSCLC and other thoracic malignancies\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "NSCLC, metastatic\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Sarcoma\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Supportive and palliative care\n",
      "5 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "15 Minutes\n",
      "Solange Peters (Lausanne, Switzerland)\n",
      "Tony S.K. Mok (Sha Tin, Hong Kong PRC)\n",
      "Pasi A. Jänne (Boston, MA, United States of America)\n",
      "Giuseppe Curigliano (Milan, Italy)\n",
      "12:45 - 13:15\n",
      "Andres Cervantes (Valencia, Valencia, Spain)\n",
      "Lisa F. Licitra (Milan, Italy)\n",
      "13:30 - 14:40\n",
      "Thomas B. Powles (London, United Kingdom)\n",
      "Srikala Sridhar (Toronto, Ontario, Canada)\n",
      "Silke Gillessen (Bellinzona, Switzerland)\n",
      "Sarmad Sadeghi (Los Angeles, CA, United States of America)\n",
      "Christian Pfister (Rouen, France)\n",
      "Enrique Grande Pulido (Madrid, Spain)\n",
      "Silke Gillessen (Bellinzona, Switzerland)\n",
      "15:05 - 16:35\n",
      "15:05 - 16:35\n",
      "Pasi A. Jänne (Boston, MA, United States of America)\n",
      "Ross Soo (Singapore, Singapore)\n",
      "Lisa A. Carey (Chapel Hill, NC, United States of America)\n",
      "Peter Schmid (London, United Kingdom)\n",
      "Marina Chiara C. Garassino (Milan, Italy)\n",
      "Solange Peters (Lausanne, Switzerland)\n",
      "Rosalind M. Glasspool (Glasgow, United Kingdom)\n",
      "Krishnansu S Tewari (Irvine, CA, United States of America)\n",
      "16:45 - 17:15\n",
      "Sibylle Loibl (Neu-Isenburg, Germany) Lisa A. Carey (Chapel Hill, NC, United States of America) Peter Schmid (London, United Kingdom)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany) Lisa A. Carey (Chapel Hill, NC, United States of America) Peter Schmid (London, United Kingdom)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany) Lisa A. Carey (Chapel Hill, NC, United States of America) Peter Schmid (London, United Kingdom)\n",
      "Lin Shen (Beijing, China)\n",
      "Jianming Xu (Beijing, China)\n",
      "Alexander Stein (Hamburg, Germany)\n",
      "Eric Van Cutsem (Leuven, Belgium)\n",
      "Yelena Y. Janjigian (New York, NY, United States of America)\n",
      "Rui-Hua Xu (Guangzhou, China)\n",
      "Lukas Perkhofer (Ulm, Germany)\n",
      "Arndt Vogel (Hannover, Germany)\n",
      "Changhoon Yoo (Seoul, Songpa-gu, Korea, Republic of)\n",
      "12:45 - 13:15\n",
      "Giuseppe Curigliano (Milan, Italy)\n",
      "George Coukos (Epalinges, Switzerland)\n",
      "Cécile Le Pechoux (Villejuif, CEDEX, France)\n",
      "Solange Peters (Lausanne, Switzerland)\n",
      "Pilar Garrido Lopez (Madrid, Spain)\n",
      "Pilar Garrido Lopez (Madrid, Spain)\n",
      "Nicolas Girard (Paris, France)\n",
      "Alexandre Martinez-Marti (Barcelona, Spain)\n",
      "Oliver Gautschi (Luzern, Switzerland)\n",
      "Oliver Gautschi (Luzern, Switzerland)\n",
      "16:45 - 17:15\n",
      "16:45 - 17:15\n",
      "Pasi A. Jänne (Boston, MA, United States of America) Ross Soo (Singapore, Singapore) Marina Chiara C. Garassino (Milan, Italy) Solange Peters (Lausanne, Switzerland)\n",
      "Pasi A. Jänne (Boston, MA, United States of America) Ross Soo (Singapore, Singapore) Marina Chiara C. Garassino (Milan, Italy) Solange Peters (Lausanne, Switzerland)\n",
      "Pasi A. Jänne (Boston, MA, United States of America) Ross Soo (Singapore, Singapore) Marina Chiara C. Garassino (Milan, Italy) Solange Peters (Lausanne, Switzerland)\n",
      "Pasi A. Jänne (Boston, MA, United States of America) Ross Soo (Singapore, Singapore) Marina Chiara C. Garassino (Milan, Italy) Solange Peters (Lausanne, Switzerland)\n",
      "Daniel V. Catenacci (Chicago, IL, United States of America)\n",
      "Marshall R. Posner (New York, NY, United States of America)\n",
      "Julia Katharina Schwarze (Jette, Belgium)\n",
      "Thomas F. Gajewski (Chicago, United States of America)\n",
      "Jaume Mora (Barcelona, Spain)\n",
      "Evanthia T. Roussos Torres (Los Angeles, United States of America)\n",
      "Jeffrey S. Miller (Minneapolis, United States of America)\n",
      "Christian U. Blank (Amsterdam, Netherlands)\n",
      "12:45 - 13:15\n",
      "Josep Tabernero (Barcelona, Spain)\n",
      "Rebecca A. Dent (Singapore, Singapore)\n",
      "Susana Banerjee (London, United Kingdom)\n",
      "Domenica Lorusso (Rome, Italy)\n",
      "Rosalind M. Glasspool (Glasgow, United Kingdom)\n",
      "Rosalind M. Glasspool (Glasgow, United Kingdom)\n",
      "Shibani Nicum (Oxford, United Kingdom)\n",
      "Eric Pujade-Lauraine (Paris, CEDEX 4, France)\n",
      "Clare L. Scott (Parkville, Australia)\n",
      "Clare L. Scott (Parkville, Australia)\n",
      "16:45 - 17:15\n",
      "Rosalind M. Glasspool (Glasgow, United Kingdom) Krishnansu S Tewari (Irvine, CA, United States of America)\n",
      "Rosalind M. Glasspool (Glasgow, United Kingdom) Krishnansu S Tewari (Irvine, CA, United States of America)\n",
      "Hye Ryun Kim (Seoul, Korea, Republic of)\n",
      "Joseph M. Curry (Philadelphia, United States of America)\n",
      "Loris De Cecco (Milan, Italy)\n",
      "Sara Pai (Boston, United States of America)\n",
      "Michael Z. Kharouta (Cleveland, United States of America)\n",
      "Paolo Bossi (Brescia, Italy)\n",
      "Nandini S. Menon (Mumbai, India)\n",
      "Sjoukje Oosting (Groningen, Netherlands)\n",
      "12:45 - 13:15\n",
      "Solange Peters (Lausanne, Switzerland)\n",
      "Alex A. Adjei (Rochester, MN, United States of America)\n",
      "Petri Bono (Helsinki, Finland)\n",
      "James Gulley (Bethesda, MD, United States of America)\n",
      "Aurélien Marabelle (Villejuif, France)\n",
      "Sebastian Kobold (Munich, Germany)\n",
      "Aurélien Marabelle (Villejuif, France)\n",
      "David S. Hong (Houston, TX, United States of America)\n",
      "Alessandra Curioni (Zurich, Switzerland)\n",
      "Alessandra Curioni (Zurich, Switzerland)\n",
      "Chiara Alessandra Cella (Milan, Italy)\n",
      "Yukako Hattori (Yamato, Japan)\n",
      "Juliane Brandt (Heidelberg, Germany)\n",
      "Lawson Eng (Toronto, Ontario, Canada)\n",
      "Marie Fallon (Edinburgh, United Kingdom)\n",
      "Florian Scotté (Villejuif, France)\n",
      "Kazuhiro Shimomura (Nagoya, Japan)\n",
      "Zhigang Liu (Zhuhai, China)\n",
      "Gudrun M. Kreye (Krems an der Donau, Austria)\n",
      "Helena M. Earl (Cambridge, Cambridgeshire, United Kingdom)\n",
      "Valentina Guarneri (Padova, Italy)\n",
      "Antonio Llombart Cussac (Valencia, Spain)\n",
      "Antonio Llombart Cussac (Valencia, Spain)\n",
      "Lucia Del Mastro (Genova, Italy)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany)\n",
      "Monica Arnedos (Bordeaux, France)\n",
      "Monica Arnedos (Bordeaux, France)\n",
      "Marion DEBAUDRINGHIEN (Lille, France)\n",
      "Sylvie Bonvalot (Paris, CEDEX, France)\n",
      "Bernd Kasper (Mannheim, Germany)\n",
      "Brahmi Mehdi (Lyon, CEDEX, France)\n",
      "Rastislav Bahleda (Villejuif, CEDEX, France)\n",
      "Anna Maria Frezza (Milan, Italy)\n",
      "Alannah Smrke (Vancouver, Canada)\n",
      "Nicholas D. Klemen (New York, United States of America)\n",
      "Olivier Mir (Villejuif, France)\n",
      "13:30 - 14:05\n",
      "Clara Montagut Viladot (Barcelona, Spain)\n",
      "Clara Montagut Viladot (Barcelona, Spain)\n",
      "Sara Lonardi (Padova, Italy)\n",
      "Rodrigo Dienstmann (Sao Paulo, Brazil)\n",
      "Clara Montagut Viladot (Barcelona, Spain)\n",
      "Clara Montagut Viladot (Barcelona, Spain)\n",
      "14:20 - 14:55\n",
      "Florian Lordick (Leipzig, Germany)\n",
      "Florian Lordick (Leipzig, Germany)\n",
      "John Reynolds (Dublin, Ireland)\n",
      "Yelena Y. Janjigian (New York, NY, United States of America)\n",
      "Florian Lordick (Leipzig, Germany)\n",
      "Florian Lordick (Leipzig, Germany)\n",
      "Grazia Scocca (Brussels, Belgium)\n",
      "Isabelle Lebrocquy (Den Haag, Netherlands)\n",
      "Martijn Ludwig (Amsterdam, Netherlands)\n",
      "Agata I. Polinska (Warsaw, Poland)\n",
      "Agata I. Polinska (Warsaw, Poland)\n",
      "16:45 - 17:20\n",
      "Jordi Rodon (Houston, United States of America)\n",
      "Jordi Rodon (Houston, United States of America)\n",
      "Lillian L Siu (Toronto, ON, Canada)\n",
      "Anastasios Stathis (Bellinzona, Switzerland)\n",
      "Jordi Rodon (Houston, United States of America)\n",
      "Jordi Rodon (Houston, United States of America)\n",
      "17:35 - 18:10\n",
      "Sibylle Loibl (Neu-Isenburg, Germany)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany)\n",
      "Jonas Bergh (Stockholm, Sweden)\n",
      "Michael Untch (Berlin, Germany)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany)\n",
      "Guillaume Canaud (Paris, France)\n",
      "Rahul Aggarwal (San Francisco, United States of America)\n",
      "Christophe Massard (Villejuif, France)\n",
      "Christophe Massard (Villejuif, France)\n",
      "Melissa L. Johnson (Nashville, TN, United States of America)\n",
      "Jordi Rodon (Houston, United States of America)\n",
      "Elena Garralda (Barcelona, Spain)\n",
      "Elena Garralda (Barcelona, Spain)\n",
      "Zeynep B. Zengin (Duarte, United States of America)\n",
      "Kentaro Sawada (Sapporo, Japan)\n",
      "Katsuya Tsuchihara (Chuo-ku, Japan)\n",
      "Afaf Abed (Perth, Australia)\n",
      "Khalil Hodroj (Lyon, Cedex 08, France)\n",
      "Rosalin Cooper (Oxford, United Kingdom)\n",
      "Julie N. Graff (Portland, United States of America)\n",
      "Bertrand Routy (Montreal, Canada)\n",
      "12:45 - 13:15\n",
      "Thomas B. Powles (London, United Kingdom)\n",
      "William Kaelin (Boston, United States of America)\n",
      "Maria Carmela Piccirillo (Napoli, Italy)\n",
      "Hirotsugu Kenmotsu (Shizuoka, Shizuoka, Japan)\n",
      "Natasha Leighl (Toronto, Canada)\n",
      "Natasha Leighl (Toronto, Canada)\n",
      "Bob T. Li (New York, NY, United States of America)\n",
      "Robin Cornelissen (Rotterdam, Netherlands)\n",
      "Daniel Shao Weng Tan (Singapore, Singapore)\n",
      "Daniel Shao Weng Tan (Singapore, Singapore)\n",
      "15:05 - 16:35\n",
      "15:05 - 16:35\n",
      "Javier Cortés (Madrid, Spain)\n",
      "Shanu Modi (New York, NY, United States of America)\n",
      "Nicoletta Colombo (Milan, Italy)\n",
      "Mansoor Raza Mirza (Copenhagen, Denmark)\n",
      "Jason J. Luke (Pittsburgh, United States of America)\n",
      "Omid Hamid (Los Angeles, CA, United States of America)\n",
      "16:45 - 17:15\n",
      "Fabrice André (Villejuif, France) Javier Cortés (Madrid, Spain) Shanu Modi (New York, NY, United States of America)\n",
      "Fabrice André (Villejuif, France) Javier Cortés (Madrid, Spain) Shanu Modi (New York, NY, United States of America)\n",
      "Fabrice André (Villejuif, France) Javier Cortés (Madrid, Spain) Shanu Modi (New York, NY, United States of America)\n",
      "Binghe Xu (Beijing, China)\n",
      "Miguel Martin Jimenez (Madrid, Spain)\n",
      "Maria Vittoria Dieci (Padova, Italy)\n",
      "Matthew G. Krebs (Manchester, United Kingdom)\n",
      "Ana Mafalda Antunes De Melo e Oliveira (Barcelona, Spain)\n",
      "Sibylle Loibl (Neu-Isenburg, Germany)\n",
      "Sung-Bae Kim (Seoul, Korea, Republic of)\n",
      "Cristiana Sessa (Bellinzona, Switzerland)\n",
      "Alfredo Addeo (Geneva, Switzerland)\n",
      "Laurence Albiges (Villejuif, Cedex, CEDEX, France)\n",
      "Jenny Seligmann (Leeds, Yorkshire, United Kingdom)\n",
      "Salvatore Siena (Milan, Italy)\n",
      "Pierre Laurent-Puig (Paris, France)\n",
      "Pierre Laurent-Puig (Paris, France)\n",
      "Chiara Cremolini (Pisa, Italy)\n",
      "Filippo Pietrantonio (Milan, Italy)\n",
      "Dominik P. Modest (Berlin, Germany)\n",
      "Dominik P. Modest (Berlin, Germany)\n",
      "16:45 - 17:15\n",
      "Andres Cervantes (Valencia, Valencia, Spain) Nicoletta Colombo (Milan, Italy) Mansoor Raza Mirza (Copenhagen, Denmark)\n",
      "Andres Cervantes (Valencia, Valencia, Spain) Nicoletta Colombo (Milan, Italy) Mansoor Raza Mirza (Copenhagen, Denmark)\n",
      "Andres Cervantes (Valencia, Valencia, Spain) Nicoletta Colombo (Milan, Italy) Mansoor Raza Mirza (Copenhagen, Denmark)\n",
      "Giuseppe Procopio (Milan, Italy)\n",
      "Giulia Baciarello (Milan, CEDEX, Italy)\n",
      "David F. McDermott (Boston, MA, United States of America)\n",
      "Samra Turajlic (London, United Kingdom)\n",
      "Lisa Derosa (Villejuif, France)\n",
      "Matthew D. Galsky (New York, United States of America)\n",
      "Sumanta K. Pal (Duarte, CA, United States of America)\n",
      "Nieves Martinez Chanza (Brussels, Belgium)\n",
      "Jeroen Van Dorp (Amsterdam, Netherlands)\n",
      "Ignacio Duran (Cantabria, Spain)\n",
      "Neeraj Agarwal (Salt Lake City, United States of America)\n",
      "Cora N. Sternberg (New York, United States of America)\n",
      "Cora N. Sternberg (New York, United States of America)\n",
      "Shahneen K. Sandhu (Melbourne, VIC, Australia)\n",
      "Joaquin Mateo (Barcelona, Spain)\n",
      "Joaquin Mateo (Barcelona, Spain)\n",
      "Andrew J. Armstrong (Durham, United States of America)\n",
      "Stephane M. Oudard (Paris, France)\n",
      "Stephane M. Oudard (Paris, France)\n",
      "16:45 - 17:15\n",
      "Olivier A. Michielin (Lausanne, Switzerland) Jason J. Luke (Pittsburgh, United States of America) Omid Hamid (Los Angeles, CA, United States of America)\n",
      "Olivier A. Michielin (Lausanne, Switzerland) Jason J. Luke (Pittsburgh, United States of America) Omid Hamid (Los Angeles, CA, United States of America)\n",
      "Olivier A. Michielin (Lausanne, Switzerland) Jason J. Luke (Pittsburgh, United States of America) Omid Hamid (Los Angeles, CA, United States of America)\n",
      "Marie Wislez (Paris, Cedex 20, France)\n",
      "François-Xavier DANLOS (Villejuif, France)\n",
      "Michael Thomas (Heidelberg, Germany)\n",
      "Yi-Long Wu (Guangzhou, Guangdong, China)\n",
      "Nicolas Girard (Paris, France)\n",
      "Lizza E. Hendriks (Maastricht, Netherlands)\n",
      "Luis Paz-Ares (Madrid, Spain)\n",
      "Mariona Riudavets Melia (Villejuif, France)\n",
      "Alfredo Addeo (Geneva, Switzerland)\n",
      "F. Stephen Hodi (Boston, United States of America)\n",
      "Jeffrey S. Weber (New York City, United States of America)\n",
      "Olivier A. Michielin (Lausanne, Switzerland)\n",
      "Olivier A. Michielin (Lausanne, Switzerland)\n",
      "Helen J. Gogas (Athens, Greece)\n",
      "James Larkin (London, United Kingdom)\n",
      "James Larkin (London, United Kingdom)\n",
      "Hélène Blons (Paris, France)\n",
      "Debora Basile (Vicenza, Italy)\n",
      "James Glasbey (Birmingham, United Kingdom)\n",
      "Gunnar Folprecht (Dresden, Germany) Clara Montagut Viladot (Barcelona, Spain)\n",
      "Gunnar Folprecht (Dresden, Germany) Clara Montagut Viladot (Barcelona, Spain)\n",
      "Mustapha Tehfe (Montreal, Canada)\n",
      "Elisabeth S. Bergen (Vienna, Austria)\n",
      "Astrid Lièvre (Rennes, France)\n",
      "Eric Vivier (Marseille, France)\n",
      "Baiyong Li (Zhongshan, China)\n",
      "Sophie Papa (London, United Kingdom)\n",
      "Sophie Papa (London, United Kingdom)\n",
      "Shengli Ding (Durham, United States of America)\n",
      "Álvaro Quintanal-Villalonga (New York, United States of America)\n",
      "Jan Korbel (Heidelberg, Germany)\n",
      "None\n",
      "Nicola Normanno (Luxembourg, Luxembourg)\n",
      "Anja Tüchler (Köln, Germany)\n",
      "Mario Di Palma (Villejuif, CEDEX, France)\n",
      "Christoph Benedikt Westphalen (Munich, Germany)\n",
      "Lucia Notario Rincon (Barcelona, Spain)\n",
      "Justin T. Moyers (Houston, United States of America)\n",
      "Paraskevas Kosmidis (Marousi, Greece)\n",
      "Dario Trapani (Milan, Italy)\n",
      "18:45 - 20:15\n",
      "18:45 - 20:15\n",
      "Jens Bedke (Tuebingen, Germany)\n",
      "Jens Bedke (Tuebingen, Germany)\n",
      "Masafumi Ikeda (Kashiwa, Chiba, Japan)\n",
      "Cristiana Sessa (Bellinzona, Switzerland)\n",
      "Giuseppe Procopio (Milan, Italy)\n",
      "Tim Meyer (London, United Kingdom)\n",
      "Jens Bedke (Tuebingen, Germany)\n",
      "13:30 - 14:05\n",
      "Fabrice André (Villejuif, France)\n",
      "Fabrice André (Villejuif, France)\n",
      "Cristina Saura Manich (Barcelona, Spain)\n",
      "Evandro De Azambuja (Brussels, Belgium)\n",
      "Fabrice André (Villejuif, France)\n",
      "Fabrice André (Villejuif, France)\n",
      "14:20 - 14:55\n",
      "Javier Martin-Broto (Madrid, Spain)\n",
      "None\n",
      "Jean-Yves Blay (Lyon, France)\n",
      "Silvia Stacchiotti (Milan, Italy)\n",
      "Javier Martin-Broto (Madrid, Spain)\n",
      "Javier Martin-Broto (Madrid, Spain)\n",
      "15:10 - 16:10\n",
      "Alan A. Melcher (London, United Kingdom)\n",
      "Piotr J. Wysocki (Krakow, Poland)\n",
      "Ulrich Keilholz (Berlin, Germany)\n",
      "Tanja Spanic (Ljubljana, Slovenia)\n",
      "16:45 - 17:20\n",
      "Emilie Le Rhun (Zurich, CEDEX, Switzerland)\n",
      "Emilie Le Rhun (Zurich, CEDEX, Switzerland)\n",
      "Giuseppe Minniti (Roma, Italy)\n",
      "Matthias Preusser (Vienna, Austria)\n",
      "Emilie Le Rhun (Zurich, CEDEX, Switzerland)\n",
      "Emilie Le Rhun (Zurich, CEDEX, Switzerland)\n",
      "17:35 - 18:10\n",
      "Florence Joly (Caen, France)\n",
      "Florence Joly (Caen, France)\n",
      "Isabelle L. Ray-Coquard (Lyon, CEDEX, France)\n",
      "Antonio Jose Gonzalez Martin (Madrid, Spain)\n",
      "Florence Joly (Caen, France)\n",
      "Florence Joly (Caen, France)\n",
      "12:45 - 13:15\n",
      "Jordi Rodon (Houston, United States of America)\n",
      "Jean-Charles Soria (Villejuif, CEDEX, France)\n",
      "Cristina Saura Manich (Barcelona, Spain)\n",
      "Barbara Pistilli (Villejuif, France)\n",
      "Barbara Pistilli (Villejuif, France)\n",
      "Hope S. Rugo (San Francisco, CA, United States of America)\n",
      "Gabriel N. Hortobagyi (Houston, TX, United States of America)\n",
      "Gonzalo Gomez-Abuin (Buenos Aires, Argentina)\n",
      "Gonzalo Gomez-Abuin (Buenos Aires, Argentina)\n",
      "15:05 - 16:37\n",
      "15:05 - 16:37\n",
      "Gerhardt Attard (London, United Kingdom)\n",
      "Karim Fizazi (Villejuif, Cedex, France)\n",
      "Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Jared Weiss (Chapel Hill, United States of America)\n",
      "Federica Di Nicolantonio (Torino, (TO), Italy)\n",
      "Yelena Y. Janjigian (New York, NY, United States of America)\n",
      "Florian Lordick (Leipzig, Germany)\n",
      "16:45 - 17:15\n",
      "Silke Gillessen (Bellinzona, Switzerland) Gerhardt Attard (London, United Kingdom) Karim Fizazi (Villejuif, Cedex, France) Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Silke Gillessen (Bellinzona, Switzerland) Gerhardt Attard (London, United Kingdom) Karim Fizazi (Villejuif, Cedex, France) Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Silke Gillessen (Bellinzona, Switzerland) Gerhardt Attard (London, United Kingdom) Karim Fizazi (Villejuif, Cedex, France) Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Silke Gillessen (Bellinzona, Switzerland) Gerhardt Attard (London, United Kingdom) Karim Fizazi (Villejuif, Cedex, France) Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Edward B. Garon (Santa Monica, CA, United States of America)\n",
      "Natasha B. Leighl (Toronto, ON, Canada)\n",
      "Catherine A. Shu (New York, NY, United States of America)\n",
      "Sai-Hong I. Ou (Orange, CA, United States of America)\n",
      "Anne-Marie C. Dingemans (Rotterdam, Netherlands)\n",
      "Miranda Gogishvili (Tbilisi, Georgia)\n",
      "Luis Paz-Ares (Madrid, Spain)\n",
      "David R. Gandara (Sacramento, CA, United States of America)\n",
      "Edward B. Garon (Santa Monica, CA, United States of America)\n",
      "Julien Taieb (Paris, France)\n",
      "Omid Hamid (Los Angeles, CA, United States of America)\n",
      "13:30 - 14:50\n",
      "13:30 - 14:50\n",
      "13:30 - 14:50\n",
      "Janet E. Brown (Sheffield, Yorkshire, United Kingdom)\n",
      "Naveen S. Vasudev (Leeds, Yorkshire, United Kingdom)\n",
      "Toni K. Choueiri (Boston, United States of America)\n",
      "Brian I. Rini (Nashville, TN, United States of America)\n",
      "Laurence Albiges (Villejuif, Cedex, CEDEX, France)\n",
      "Alexandros Papachristofilou (Basel, Switzerland)\n",
      "Christian K. Kollmannsberger (Vancouver, British Columbia, Canada)\n",
      "Laurence Albiges (Villejuif, Cedex, CEDEX, France)\n",
      "16:45 - 17:15\n",
      "Josep Tabernero (Barcelona, Spain) Jared Weiss (Chapel Hill, United States of America) Federica Di Nicolantonio (Torino, (TO), Italy) Yelena Y. Janjigian (New York, NY, United States of America) Florian Lordick (Leipzig, Germany)\n",
      "Josep Tabernero (Barcelona, Spain) Jared Weiss (Chapel Hill, United States of America) Federica Di Nicolantonio (Torino, (TO), Italy) Yelena Y. Janjigian (New York, NY, United States of America) Florian Lordick (Leipzig, Germany)\n",
      "Josep Tabernero (Barcelona, Spain) Jared Weiss (Chapel Hill, United States of America) Federica Di Nicolantonio (Torino, (TO), Italy) Yelena Y. Janjigian (New York, NY, United States of America) Florian Lordick (Leipzig, Germany)\n",
      "Josep Tabernero (Barcelona, Spain) Jared Weiss (Chapel Hill, United States of America) Federica Di Nicolantonio (Torino, (TO), Italy) Yelena Y. Janjigian (New York, NY, United States of America) Florian Lordick (Leipzig, Germany)\n",
      "Josep Tabernero (Barcelona, Spain) Jared Weiss (Chapel Hill, United States of America) Federica Di Nicolantonio (Torino, (TO), Italy) Yelena Y. Janjigian (New York, NY, United States of America) Florian Lordick (Leipzig, Germany)\n",
      "Karim Fizazi (Villejuif, Cedex, France)\n",
      "Richard Cathomas (Chur, Switzerland)\n",
      "Boris A. Hadaschik (Essen, Germany)\n",
      "Mark C. Markowski (Baltimore, United States of America)\n",
      "Daniel P. Petrylak (New Heaven, CT, United States of America)\n",
      "Giulia Baciarello (Milan, CEDEX, Italy)\n",
      "Emre Kocakavuk (Farmington, United States of America)\n",
      "Monika E. Hegi (Lausanne, Switzerland)\n",
      "Monika E. Hegi (Lausanne, Switzerland)\n",
      "Nader Sanai (Phoenix, AZ, United States of America)\n",
      "Bart Neyns (Brussel, Belgium)\n",
      "Patrick Roth (Zurich, Switzerland)\n",
      "Patrick Roth (Zurich, Switzerland)\n",
      "Shan-Shan Li (Guangzhou, China)\n",
      "Ismael Fernandez-Miranda (Majadahonda, Spain)\n",
      "Ting-zhi Liu (Guangzhou, China)\n",
      "Andrew J. Davies (Southampton, United Kingdom)\n",
      "Yuan-Kai Shi (Beijing, China)\n",
      "Liudmila Fedorova (Saint-Petersburg, Russian Federation)\n",
      "Ingrid Glimelius (Uppsala, Sweden)\n",
      "13:30 - 14:50\n",
      "Thomas Seufferlein (Ulm, Germany)\n",
      "Thierry Conroy (Vandoeuvre-lès-Nancy, CEDEX, France)\n",
      "Andrew H. Ko (San Francisco, United States of America)\n",
      "Elizabeth Smyth (Cambridge, United Kingdom)\n",
      "Beate Rau (Berlin, Germany)\n",
      "Brian Badgwell (Houston, United States of America)\n",
      "Elizabeth Smyth (Cambridge, United Kingdom)\n",
      "Changsong Qi (Beijing, China)\n",
      "Kohei Shitara (Kashiwa, Chiba, Japan)\n",
      "Elizabeth Smyth (Cambridge, United Kingdom)\n",
      "Lei Yin (Beijing, China)\n",
      "Inken Salewski (Rostock, Germany)\n",
      "Vincenzo Quagliariello (Napoli, Italy)\n",
      "Ruth Plummer (Newcastle-upon-Tyne, Tyne and Wear, United Kingdom)\n",
      "Diana V. Yuzhakova (Nizhny Novgorod, Russian Federation)\n",
      "Laetitia Nebot (Villejuif, Cedex, France)\n",
      "Letizia Gnetti (Parma, Italy)\n",
      "Christian H. Ottensmeier (Liverpool, United Kingdom)\n",
      "Minetta C. Liu (Rochester, MN, United States of America)\n",
      "Alexander N. Shoushtari (New York, United States of America)\n",
      "Christian D. Rolfo (Baltimore, United States of America)\n",
      "Christian D. Rolfo (Baltimore, United States of America)\n",
      "Kaysia Ludford (Houston, United States of America)\n",
      "Ingrid J. Garberis (Villejuif, France)\n",
      "Sherene Loi (Melbourne, VIC, Australia)\n",
      "Sherene Loi (Melbourne, VIC, Australia)\n",
      "Ignace B. Vergote (Leuven, Belgium)\n",
      "David O'Malley (Columbus, United States of America)\n",
      "Ana Oaknin (Barcelona, Spain)\n",
      "Susana Banerjee (London, United Kingdom)\n",
      "Nicoletta Colombo (Milan, Italy)\n",
      "David SP Tan (Singapore, Singapore)\n",
      "Joyce Liu (Boston, MA, United States of America)\n",
      "David O'Malley (Columbus, United States of America)\n",
      "Naveena Singh (London, United Kingdom)\n",
      "13:30 - 14:05\n",
      "Omid Hamid (Los Angeles, CA, United States of America)\n",
      "Omid Hamid (Los Angeles, CA, United States of America)\n",
      "Paolo A. Ascierto (Napoli, Italy)\n",
      "Reinhard Dummer (Zurich, Switzerland)\n",
      "Omid Hamid (Los Angeles, CA, United States of America)\n",
      "Omid Hamid (Los Angeles, CA, United States of America)\n",
      "15:10 - 16:10\n",
      "Gilliosa Spurrier-Bernard (Teilhet, France)\n",
      "Piret Hirv (Tallinn, Estonia)\n",
      "Mozziyar Etemadi (Chicago, United States of America)\n",
      "Jan Geissler (Riemerling, Germany)\n",
      "Misha Tyulenev (Tallinn, Estonia)\n",
      "Jana Pelouchova (Prague, 2, Czech Republic)\n",
      "16:45 - 17:20\n",
      "Marianne E. Pavel (Erlangen, Germany)\n",
      "Marianne E. Pavel (Erlangen, Germany)\n",
      "Eric Baudin (Villejuif, CEDEX, France)\n",
      "Jonathan R. Strosberg (Tampa, United States of America)\n",
      "Marianne E. Pavel (Erlangen, Germany)\n",
      "Marianne E. Pavel (Erlangen, Germany)\n",
      "17:35 - 18:10\n",
      "Kevin J. Harrington (London, United Kingdom)\n",
      "Kevin J. Harrington (London, United Kingdom)\n",
      "Denis Soulieres (Montreal, Canada)\n",
      "Paolo Bossi (Brescia, Italy)\n",
      "Kevin J. Harrington (London, United Kingdom)\n",
      "Kevin J. Harrington (London, United Kingdom)\n",
      "12:45 - 13:15\n",
      "Pedro Romero (Lausanne, Switzerland)\n",
      "Carl H. June (Philadelphia, PA, United States of America)\n",
      "Jean Bourhis (Lausanne, Switzerland)\n",
      "Athanassios Argiris (Marousi, Greece)\n",
      "Amanda Psyrri (Haidari, Greece)\n",
      "Amanda Psyrri (Haidari, Greece)\n",
      "Anthony T.C. T. Chan (Sha Tin, Hong Kong PRC)\n",
      "Wang-Zhong Li (Guangzhou, China)\n",
      "Lisa F. Licitra (Milan, Italy)\n",
      "Lisa F. Licitra (Milan, Italy)\n",
      "15:05 - 16:35\n",
      "15:05 - 16:35\n",
      "Eric Baudin (Villejuif, CEDEX, France)\n",
      "Rocio Garcia-Carbonero (Madrid, Spain)\n",
      "Scott T. Shepherd (London, United Kingdom)\n",
      "Sjoukje Oosting (Groningen, Netherlands)\n",
      "Marie Von Lilienfeld-Toal (Jena, Germany)\n",
      "Enriqueta Felip (Barcelona, Spain)\n",
      "Benjamin Besse (Villejuif, CEDEX, France)\n",
      "Eric Baudin (Villejuif, CEDEX, France) Rocio Garcia-Carbonero (Madrid, Spain)\n",
      "Eric Baudin (Villejuif, CEDEX, France) Rocio Garcia-Carbonero (Madrid, Spain)\n",
      "Giampaolo Bianchini (Milan, Italy)\n",
      "Aranzazu Fernandez-Martinez (Chapel Hill, United States of America)\n",
      "Nadia Harbeck (Munich, Germany)\n",
      "Marleen Kok (Amsterdam, Netherlands)\n",
      "Sara A. Hurvitz (Santa Monica, CA, United States of America)\n",
      "Sofia Rivera (Villejuif, France)\n",
      "José A. García-Saenz (Madrid, Spain)\n",
      "Peter Schmid (London, United Kingdom)\n",
      "Véronique Diéras (Rennes, CEDEX, France)\n",
      "Fabrice André (Villejuif, France)\n",
      "Lam S. Chan (Sha Tin, Hong Kong PRC)\n",
      "Richard Cathomas (Chur, Switzerland)\n",
      "Mary F. Mulcahy (Chicago, IL, United States of America)\n",
      "Robert S. Fichtinger (Maastricht, Netherlands)\n",
      "Thomas Gruenberger (Vienna, Austria)\n",
      "Thomas Gruenberger (Vienna, Austria)\n",
      "Pei-Rong Ding (Guangzhou, China)\n",
      "Frederik Großerüschkamp (Bochum, Germany)\n",
      "Julien Taieb (Paris, France)\n",
      "Julien Taieb (Paris, France)\n",
      "16:45 - 17:15\n",
      "Emanuela Romano (Paris, CEDEX 5, France) Scott T. Shepherd (London, United Kingdom) Sjoukje Oosting (Groningen, Netherlands) Marie Von Lilienfeld-Toal (Jena, Germany)\n",
      "Emanuela Romano (Paris, CEDEX 5, France) Scott T. Shepherd (London, United Kingdom) Sjoukje Oosting (Groningen, Netherlands) Marie Von Lilienfeld-Toal (Jena, Germany)\n",
      "Emanuela Romano (Paris, CEDEX 5, France) Scott T. Shepherd (London, United Kingdom) Sjoukje Oosting (Groningen, Netherlands) Marie Von Lilienfeld-Toal (Jena, Germany)\n",
      "Emanuela Romano (Paris, CEDEX 5, France) Scott T. Shepherd (London, United Kingdom) Sjoukje Oosting (Groningen, Netherlands) Marie Von Lilienfeld-Toal (Jena, Germany)\n",
      "Ivan Marquez-Rodas (Madrid, Spain)\n",
      "Kim A. Margolin (Duarte, CA, United States of America)\n",
      "Teresa Petrella (Toronto, Ontario, Canada)\n",
      "Christian U. Blank (Amsterdam, Netherlands)\n",
      "Paolo A. Ascierto (Napoli, Italy)\n",
      "Reinhard Dummer (Zurich, Switzerland)\n",
      "Teresa Troiani (Napoli, Italy)\n",
      "08:45 - 10:15\n",
      "08:45 - 10:15\n",
      "Umberto Malapelle (Napoli, Italy)\n",
      "Maria Gabriela Oliveira Fernandes (Porto, Portugal)\n",
      "Albrecht Stenzinger (Heidelberg, Germany)\n",
      "Rodrigo Dienstmann (Sao Paulo, Brazil)\n",
      "Emiliano Calvo (Madrid, Spain)\n",
      "Emiliano Calvo (Madrid, Spain)\n",
      "Umberto Malapelle (Napoli, Italy)\n",
      "Mingyuan Sun (Tianjin, China)\n",
      "Markus G. Manz (Zurich, Switzerland)\n",
      "Markus G. Manz (Zurich, Switzerland)\n",
      "Muhit Özcan (Ankara, Turkey)\n",
      "Junning Cao (shanghai, China)\n",
      "Lena Specht (Copenhagen, Denmark)\n",
      "Lena Specht (Copenhagen, Denmark)\n",
      "16:45 - 17:15\n",
      "Solange Peters (Lausanne, Switzerland) Enriqueta Felip (Barcelona, Spain) Benjamin Besse (Villejuif, CEDEX, France)\n",
      "Solange Peters (Lausanne, Switzerland) Enriqueta Felip (Barcelona, Spain) Benjamin Besse (Villejuif, CEDEX, France)\n",
      "Solange Peters (Lausanne, Switzerland) Enriqueta Felip (Barcelona, Spain) Benjamin Besse (Villejuif, CEDEX, France)\n",
      "Joline S. Lim (Singapore, Singapore)\n",
      "Haeseong Park (St. Louis, MO, United States of America)\n",
      "Aung Naing (Houston, TX, United States of America)\n",
      "Natalie Cook (Manchester, United Kingdom)\n",
      "Manish Sharma (Grand Rapids, AL, United States of America)\n",
      "Richard F. Schlenk (Heidelberg, Germany)\n",
      "Hidenori Kage (Bunkyo-ku, Japan)\n",
      "Julia E. Lai-Kwon (Melbourne, VIC, Australia)\n",
      "Richard D. Baird (Cambridge, Cambridgeshire, United Kingdom)\n",
      "Benjamin Besse (Villejuif, CEDEX, France)\n",
      "Rafal Dziadziuszko (Gdansk, Poland)\n",
      "Lyudmila Bazhenova (La Jolla, CA, United States of America)\n",
      "Lyudmila Bazhenova (La Jolla, CA, United States of America)\n",
      "Trevor Feinstein (Atlanta, GA, United States of America)\n",
      "Ticiana A. Leal (Madison, United States of America)\n",
      "Maurice Pérol (Lyon, CEDEX, France)\n",
      "Maurice Pérol (Lyon, CEDEX, France)\n",
      "Maximilian J. Mair (Vienna, Austria)\n",
      "Maria Vieito Villar (Barcelona, La Coruña, Spain)\n",
      "Enrico Franceschi (Bologna, Italy)\n",
      "Ariane Steindl (Vienna, Austria)\n",
      "Carme Balaña (Barcelona, Spain)\n",
      "Nader Sanai (Phoenix, United States of America)\n",
      "Lakshmi Nayak (Boston, United States of America)\n",
      "Tadeusz A. Dyba (Ispra, Italy)\n",
      "Irit Ben-Aharon (Haifa, Israel)\n",
      "Olga Husson (Amsterdam, Netherlands)\n",
      "Olga Husson (Amsterdam, Netherlands)\n",
      "Joseph M. Unger (Seattle, United States of America)\n",
      "Krishnamani Kalpathi (Hyderabad, Andhra Pradesh, India)\n",
      "Ophira Ginsburg (Lyon, France)\n",
      "Ophira Ginsburg (Lyon, France)\n",
      "Jaume Capdevila Castillon (Barcelona, Spain)\n",
      "Sophie Leboulleux (Villejuif, France)\n",
      "Laura D. Locati (Milan, Italy)\n",
      "Jorge Hernando (Barcelona, Spain)\n",
      "Halfdan Sorbye (Bergen, Norway)\n",
      "Barbara Mandriani (Bari, Italy)\n",
      "Chris Verslype (Leuven, Belgium)\n",
      "13:30 - 14:05\n",
      "Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Eleni Efstathiou (Houston, TX, United States of America)\n",
      "Karim Fizazi (Villejuif, Cedex, France)\n",
      "Ronald De Wit (Rotterdam, Netherlands)\n",
      "Eleni Efstathiou (Houston, TX, United States of America)\n",
      "None\n",
      "14:20 - 14:55\n",
      "Samra Turajlic (London, United Kingdom)\n",
      "None\n",
      "Nicola Valeri (Sutton, United Kingdom)\n",
      "Livio Trusolino (Candiolo, (TO), Italy)\n",
      "Samra Turajlic (London, United Kingdom)\n",
      "Samra Turajlic (London, United Kingdom)\n",
      "Paolo G. Casali (Milan, Italy)\n",
      "Jean-Yves Blay (Lyon, France)\n",
      "Ariane Weinman (Paris, France)\n",
      "Kathy Oliver (London, United Kingdom)\n",
      "Iwo Korycinski (Warsaw, Poland)\n",
      "Paolo G. Casali (Milan, Italy)\n",
      "16:45 - 17:20\n",
      "Arnaud Mejean (Paris, France)\n",
      "Arnaud Mejean (Paris, France)\n",
      "Thomas Powles (London, United Kingdom)\n",
      "Michiel S. Van der Heijden (Amsterdam, Netherlands)\n",
      "Arnaud Mejean (Paris, France)\n",
      "Arnaud Mejean (Paris, France)\n",
      "17:35 - 18:10\n",
      "Edward B. Garon (Santa Monica, CA, United States of America)\n",
      "None\n",
      "Federico Cappuzzo (Ravenna, Italy)\n",
      "Suresh S. Ramalingam (Atlanta, GA, United States of America)\n",
      "Edward B. Garon (Santa Monica, CA, United States of America)\n",
      "Edward B. Garon (Santa Monica, CA, United States of America)\n",
      "12:45 - 13:15\n",
      "Pasi A. Jänne (Boston, MA, United States of America)\n",
      "Olufunmilayo Olopade (Chicago, IL, United States of America)\n",
      "15:05 - 16:05\n",
      "Pilar Garrido (Madrid, Spain)\n",
      "Michelle Bachelet (Geneva, Switzerland)\n",
      "Pilar Garrido Lopez (Madrid, Spain)\n",
      "Ophira Ginsburg (Lyon, France)\n",
      "Solange Peters (Lausanne, Switzerland) Pilar Garrido Lopez (Madrid, Spain) Ophira Ginsburg (Lyon, France)\n",
      "Solange Peters (Lausanne, Switzerland) Pilar Garrido Lopez (Madrid, Spain) Ophira Ginsburg (Lyon, France)\n",
      "Solange Peters (Lausanne, Switzerland) Pilar Garrido Lopez (Madrid, Spain) Ophira Ginsburg (Lyon, France)\n",
      "16:20 - 17:20\n",
      "16:20 - 17:20\n",
      "Dario Trapani (Milan, Italy)\n",
      "Sjoukje Oosting (Groningen, Netherlands)\n",
      "Nathan I. Cherny (Jerusalem, Israel)\n",
      "Nathan I. Cherny (Jerusalem, Israel)\n",
      "Egbert F. F. Smit (Amsterdam, Netherlands)\n",
      "Kevin J. Harrington (London, United Kingdom)\n",
      "Erika Martinelli (Napoli, Italy)\n",
      "Florence Duffaud (Marseille, CEDEX 5, France)\n",
      "Patricia Pautier (Villejuif, CEDEX, France)\n",
      "Robin L. Jones (London, United Kingdom)\n",
      "Robin L. Jones (London, WA, United Kingdom)\n",
      "Javier Martin-Broto (Madrid, Spain)\n",
      "Yuki Kojima (Chuo-ku, Aichi, Japan)\n",
      "Sebastian Bauer (Essen, Germany)\n",
      "Sebastian Bauer (Essen, Germany)\n",
      "15:05 - 16:05\n",
      "15:05 - 16:05\n",
      "Giuseppe Curigliano (Milan, Italy)\n",
      "Dario Trapani (Milan, Italy)\n",
      "Peter Schmid (London, United Kingdom)\n",
      "Giuseppe Curigliano (Milan, Italy)\n",
      "Alfredo Addeo (Geneva, Switzerland)\n",
      "Enriqueta Felip (Barcelona, Spain)\n",
      "Giuseppe Curigliano (Milan, Italy)\n",
      "Cristiana Sessa (Bellinzona, Switzerland)\n",
      "Julie T. Wu (Stanford, United States of America)\n",
      "Radka Obermannova (Brno, South Moravian, Czech Republic)\n",
      "Sabrina K. Salgia (Duarte, United States of America)\n",
      "Luís Castelo-Branco (Faro, Portugal)\n",
      "Tom Drake (Edinburgh, United Kingdom)\n",
      "David J. Pinato (London, United Kingdom)\n",
      "James Glasbey (Birmingham, United Kingdom)\n",
      "Emanuela Romano (Paris, CEDEX 5, France)\n",
      "Petros Grivas (Seattle, United States of America)\n",
      "Thomas Walter (Paris, France)\n",
      "Maria Carmen Riesco-Martinez (Madrid, Ontario, Spain)\n",
      "Angela Lamarca (Manchester, United Kingdom)\n",
      "Angela Lamarca (Manchester, United Kingdom)\n",
      "Dieter Horsch (Bad Berka, Germany)\n",
      "Rocio Garcia-Carbonero (Madrid, Spain)\n",
      "Nicola Fazio (Milan, Italy)\n",
      "Nicola Fazio (Milan, Italy)\n",
      "15:05 - 16:05\n",
      "Michiel H. Strijbos (Wilrijk, Belgium)\n",
      "Barbara Kiesewetter-Wiederkehr (Vienna, Austria)\n",
      "Mike Clarke (Belfast, United Kingdom)\n",
      "Bettina Ryll (Uppsala, Sweden)\n",
      "Michiel H. Strijbos (Wilrijk, Belgium)\n",
      "16:20 - 17:20\n",
      "Hendrik K. Van Halteren (Goes, Netherlands)\n",
      "Alona Zer (Petah Tikva, Israel)\n",
      "Kevin Punie (Leuven, Belgium)\n",
      "Hendrik K. Van Halteren (Goes, Netherlands)\n",
      "Ursula Vogl (Bellinzona, Switzerland)\n",
      "Hendrik K. Van Halteren (Goes, Netherlands)\n",
      "Guro L. Astrup (Oslo, Norway)\n",
      "Prakhar Srivastava (London, United Kingdom)\n",
      "Jayne E. Wood (London, United Kingdom)\n",
      "Jayne E. Wood (London, United Kingdom)\n",
      "Qianwei Liu (Huddinge, Sweden)\n",
      "Martina E. Schmidt (Heidelberg, Germany)\n",
      "Dorothy Keefe (Surry Hills, SA, Australia)\n",
      "Dorothy Keefe (Surry Hills, SA, Australia)\n",
      "15:05 - 16:05\n",
      "15:05 - 16:05\n",
      "Emiliano Calvo (Madrid, Spain)\n",
      "Nathan I. Cherny (Jerusalem, Israel)\n",
      "Teresa M. Amaral (Tübingen, PT, Germany)\n",
      "16:20 - 17:20\n",
      "Solange Peters (Lausanne, Switzerland) Laura Mezquita (Barcelona, Spain) Matteo Lambertini (Genova, Italy)\n",
      "Solange Peters (Lausanne, Switzerland) Laura Mezquita (Barcelona, Spain) Matteo Lambertini (Genova, Italy)\n",
      "Solange Peters (Lausanne, Switzerland) Laura Mezquita (Barcelona, Spain) Matteo Lambertini (Genova, Italy)\n",
      "Stephen J. Thomas (Syracuse, United States of America)\n",
      "Ithai Waldhorn (Haifa, Israel)\n",
      "Rebecca Lee (Manchester, United Kingdom)\n",
      "Rebecca Lee (Manchester, United Kingdom)\n",
      "Alessio Cortellini (London, United Kingdom)\n",
      "Kok Haw Jonathan Lim (London, United Kingdom)\n",
      "Anne-Marie C. Dingemans (Rotterdam, Netherlands)\n",
      "Anne-Marie C. Dingemans (Rotterdam, Netherlands)\n",
      "15:05 - 16:05\n",
      "E.G. Elisabeth De Vries (Groningen, Netherlands)\n",
      "Bishal Gyawali (Kingston, Aichi, Canada)\n",
      "Christopher M. Booth (Kingston, Ontario, Canada)\n",
      "Lorenzo Moja (Geneva, Switzerland)\n",
      "Panagiotis Kanavos (London, United Kingdom)\n",
      "Elisabeth G. De Vries (Groningen, Netherlands)\n",
      "16:20 - 17:20\n",
      "16:20 - 17:20\n",
      "Demetris Papamichael (Nicosia, Nicosia, Cyprus)\n",
      "Siri Rostoft (Oslo, Norway)\n",
      "Elisabeth Quoix (Strasbourg, CEDEX, France)\n",
      "Demetris Papamichael (Nicosia, Nicosia, Cyprus)\n",
      "Siri Rostoft (Oslo, Norway)\n",
      "Demetris Papamichael (Nicosia, Nicosia, Cyprus)\n",
      "13:30 - 14:05\n",
      "Manju Sengar (Mumbai, India)\n",
      "Manju Sengar (Mumbai, India)\n",
      "Christoph Benedikt Westphalen (Munich, Germany)\n",
      "Felipe S. Roitberg (Sao Paulo, Brazil)\n",
      "Manju Sengar (Mumbai, India)\n",
      "Manju Sengar (Mumbai, India)\n",
      "14:20 - 14:55\n",
      "Nicolas Girard (Paris, France)\n",
      "None\n",
      "Heather Wakelee (Stanford, CA, United States of America)\n",
      "Martin Reck (Grosshansdorf, Germany)\n",
      "Nicolas Girard (Paris, France)\n",
      "Nicolas Girard (Paris, France)\n",
      "15:10 - 15:45\n",
      "Pedro Romero (Lausanne, Switzerland)\n",
      "Pedro Romero (Lausanne, Switzerland)\n",
      "Roch Houot (Rennes, France)\n",
      "Marcela Maus (Boston, MA, United States of America)\n",
      "Pedro Romero (Lausanne, Switzerland)\n",
      "Pedro Romero (Lausanne, Switzerland)\n",
      "16:20 - 16:55\n",
      "Lena Specht (Copenhagen, Denmark)\n",
      "Lena Specht (Copenhagen, Denmark)\n",
      "Thomas A. Lister (London, United Kingdom)\n",
      "Christian Buske (Ulm, Germany)\n",
      "Lena Specht (Copenhagen, Denmark)\n",
      "Lena Specht (Copenhagen, Denmark)\n",
      "13:00 - 14:20\n",
      "Johan De Munter (Gent, Belgium)\n",
      "Pascale Dielenseger (Villejuif, France)\n",
      "Johan De Munter (Gent, Belgium)\n",
      "Theresa Wiseman (London, United Kingdom)\n",
      "Johan De Munter (Gent, Belgium)\n",
      "Johan De Munter (Gent, Belgium)\n",
      "Johan De Munter (Gent, Belgium)\n",
      "14:40 - 16:00\n",
      "Elke Schneider (Bilbao, Spain)\n",
      "Mirjam Crul (Amsterdam, Netherlands)\n",
      "Pascale Dielenseger (Villejuif, France)\n",
      "Lena Sharp (Stockholm, Sweden)\n",
      "Matthias B. Naegele (Zurich, Switzerland)\n",
      "Johan De Munter (Gent, Belgium)\n",
      "16:20 - 17:40\n",
      "Jane Ewang (London, United Kingdom)\n",
      "Anna Theodorelou (Athens, Greece)\n",
      "Celia Díez de los Ríos de la Serna (Barcelona, Spain)\n",
      "Nikolina Dodlek (Osijek, Croatia)\n",
      "Johan De Munter (Gent, Belgium) Nikolina Dodlek (Osijek, Croatia) Amanda Drury (Dublin, Ireland) Bethany Maynard (Southampton, United Kingdom) Michaela Popelkova (Prague, Czech Republic) Lena Sharp (Stockholm, Sweden)\n",
      "Johan De Munter (Gent, Belgium) Nikolina Dodlek (Osijek, Croatia) Amanda Drury (Dublin, Ireland) Bethany Maynard (Southampton, United Kingdom) Michaela Popelkova (Prague, Czech Republic) Lena Sharp (Stockholm, Sweden)\n",
      "Johan De Munter (Gent, Belgium) Nikolina Dodlek (Osijek, Croatia) Amanda Drury (Dublin, Ireland) Bethany Maynard (Southampton, United Kingdom) Michaela Popelkova (Prague, Czech Republic) Lena Sharp (Stockholm, Sweden)\n",
      "Johan De Munter (Gent, Belgium) Nikolina Dodlek (Osijek, Croatia) Amanda Drury (Dublin, Ireland) Bethany Maynard (Southampton, United Kingdom) Michaela Popelkova (Prague, Czech Republic) Lena Sharp (Stockholm, Sweden)\n",
      "Johan De Munter (Gent, Belgium) Nikolina Dodlek (Osijek, Croatia) Amanda Drury (Dublin, Ireland) Bethany Maynard (Southampton, United Kingdom) Michaela Popelkova (Prague, Czech Republic) Lena Sharp (Stockholm, Sweden)\n",
      "Johan De Munter (Gent, Belgium) Nikolina Dodlek (Osijek, Croatia) Amanda Drury (Dublin, Ireland) Bethany Maynard (Southampton, United Kingdom) Michaela Popelkova (Prague, Czech Republic) Lena Sharp (Stockholm, Sweden)\n",
      "Merel Van Klinken (Amsterdam, Netherlands)\n",
      "18:00 - 18:25\n",
      "Johan De Munter (Gent, Belgium)\n",
      "Mary D. Van Zyl (Sutton, United Kingdom)\n",
      "Marco Di Nitto (Rome, Italy)\n",
      "Virpi Sulosaari (Turku, Finland)\n",
      "13:00 - 14:20\n",
      "Androniki Ioannou (Limassol, Cyprus)\n",
      "Roma Maguire (Glasgow, United Kingdom)\n",
      "André M. Lopes (Lausanne, Switzerland)\n",
      "Adeline Duflot Boukobza (Villejuif, Cedex, France)\n",
      "Jayesh Desai (Melbourne, VIC, Australia)\n",
      "Andreas Charalambous (Limassol, Cyprus)\n",
      "14:40 - 16:00\n",
      "Christa Rustler (Berlin, Germany)\n",
      "Andri Christou (Limassol, Cyprus)\n",
      "Mandy Van Rosmalen (Rotterdam, Netherlands)\n",
      "Isabelle Fromantin (Paris, France)\n",
      "Selma Musters (Amsterdam, Netherlands)\n",
      "Eugenia Trigoso Arjona (Valencia, Spain)\n",
      "16:20 - 17:40\n",
      "Hedi Chabanol (Paris, France)\n",
      "Elen Fytrou (Haidari, Greece)\n",
      "Judy Phillips (Asheville, United States of America)\n",
      "Mary A. Tanay (London, United Kingdom)\n",
      "Celia Díez de los Ríos de la Serna (Barcelona, Spain)\n",
      "Virpi Sulosaari (Turku, Finland)\n",
      "13:00 - 14:20\n",
      "Bettina Korn (Dublin, Ireland)\n",
      "Mary Nevin (Dublin, Ireland)\n",
      "Gaëlle Vanbutsele (Gent, Belgium)\n",
      "Karen Campbell (Edinburgh, United Kingdom)\n",
      "Georgia Ntavarinou (Athens, Greece)\n",
      "Wendy H. Oldenmenger (Rotterdam, Netherlands)\n",
      "14:40 - 16:00\n",
      "Manuela Eicher (Lausanne, Switzerland)\n",
      "Urska Kosir (Oxford, United Kingdom)\n",
      "Alina Comanescu (Bucharest, Romania)\n",
      "Richard T. O'Dwyer (Dublin, Ireland)\n",
      "Maura Dowling (Galway, Ireland)\n",
      "Amanda Drury (Dublin, Ireland)\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(TIME)):\n",
    "    print(TIME[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c9a88efa",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 206,
   "id": "056742b3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chery Arrowsmith \n",
      "Chery Arrowsmith \n",
      "James G. Christensen \n",
      "Chery Arrowsmith \n",
      "Benjamin Ebert \n",
      "Stefan Fröhling \n",
      "Stefan Fröhling \n",
      "Stefan M. Pfister \n",
      "Bernd Bodenmiller \n",
      "Todd Golub \n",
      "Sabine C. Linn \n",
      "Sabine C. Linn \n",
      "Sibylle Loibl \n",
      "Valentina Guarneri \n",
      "Sabine C. Linn \n",
      "Matteo Lambertini \n",
      "Matteo Lambertini \n",
      "Nicholas Turner \n",
      "Shanu Modi \n",
      "Hope S. Rugo \n",
      "Monika E. Hegi \n",
      "Andreas Von Deimling \n",
      "Monika E. Hegi \n",
      "Dieta Brandsma \n",
      "Victor Moreno Garcia \n",
      "Victor Moreno Garcia \n",
      "Victor Moreno Garcia \n",
      "Ana Vivancos \n",
      "Alexander Drilon \n",
      "Josep Tabernero \n",
      "Josep Tabernero \n",
      "Maria Elena Elez Fernandez \n",
      "Thierry André \n",
      "Chiara Cremolini \n",
      "Elizabeth Smyth \n",
      "Elizabeth Smyth \n",
      "Patrick Tan \n",
      "Elizabeth Smyth \n",
      "Maria Alsina \n",
      "Robert A. Huddart \n",
      "Robert A. Huddart \n",
      "Ronald De Wit \n",
      "Richard Cathomas \n",
      "Begona Perez Valderrama \n",
      "Thomas B. Powles \n",
      "Toni K. Choueiri \n",
      "Manuela Schmidinger \n",
      "Cristina Suarez Rodriguez \n",
      "Silke Gillessen \n",
      "Silke Gillessen \n",
      "Nicolas Mottet \n",
      "Piet Ost \n",
      "Heather A. Payne \n",
      "Jose Alejandro Perez Fidalgo \n",
      "Jose Alejandro Perez Fidalgo \n",
      "Silvia De Sanjosé \n",
      "Philippe Morice \n",
      "Jose Alejandro Perez Fidalgo \n",
      "Pieter Sonneveld \n",
      "Pieter Sonneveld \n",
      "Norma Gutierrez \n",
      "Francesca Gay \n",
      "Pieter Sonneveld \n",
      "Athanassios Argiris \n",
      "Athanassios Argiris \n",
      "Sara Pai \n",
      "Jean Bourhis \n",
      "Athanassios Argiris \n",
      "Sebastian Kobold \n",
      "Sebastian Kobold \n",
      "Hinrich Abken \n",
      "Crystal Mackall \n",
      "Tak W. Mak \n",
      "Teresa Petrella \n",
      "Teresa Petrella \n",
      "Manuel Valiente \n",
      "Isabella C. Glitza \n",
      "Teresa Petrella \n",
      "Eric Baudin \n",
      "Eric Baudin \n",
      "Sophie Leboulleux \n",
      "Alfredo Berruti \n",
      "Joakim Crona \n",
      "Luis Paz-Ares \n",
      "Luis Paz-Ares \n",
      "Matthew Callister \n",
      "Hilary Robbins \n",
      "Luis Paz-Ares \n",
      "Noemi Reguart Aransay \n",
      "Noemi Reguart Aransay \n",
      "Edward B. Garon \n",
      "Céline Mascaux \n",
      "Julien Mazieres \n",
      "Sanjay Popat \n",
      "Sanjay Popat \n",
      "Christine Lovly \n",
      "Herbert Ho Fung Loong \n",
      "Joop A. De Langen \n",
      "Jose M. Martin-Moreno \n",
      "Jose M. Martin-Moreno \n",
      "Carolina Espina \n",
      "Heinz Freisling \n",
      "John Burn \n",
      "Christopher M. Booth \n",
      "Christopher M. Booth \n",
      "Nathan I. Cherny \n",
      "Christopher M. Booth \n",
      "Francesco Pignatti \n",
      "Valery Lemmens \n",
      "Solange Peters \n",
      "Solange Peters \n",
      "Rosa Giuliani \n",
      "Ralf Herold \n",
      "John F. Ryan \n",
      "Ferenc Marofka \n",
      "Nathalie Moll \n",
      "Bettina Ryll \n",
      "Winette T. Van Der Graaf \n",
      "Winette T. Van Der Graaf \n",
      "Sebastian Bauer \n",
      "Armelle Dufresne \n",
      "Sandra Strauss \n",
      "Andrew Neil Tippings Davies \n",
      "Andrew Neil Tippings Davies \n",
      "Andrew Neil Tippings Davies \n",
      "Eva K. Masel \n",
      "Penelope Schofield \n",
      "Leticia De Mattos-Arruda \n",
      "Eliezer M. Van Allen \n",
      "Eliezer M. Van Allen \n",
      "Evis Sala \n",
      "Liz Salmi \n",
      "Bertrand Routy \n",
      "Bertrand Routy \n",
      "Laurence Zitvogel \n",
      "Jonathan Peled \n",
      "Bertrand Routy \n",
      "Sarah-Maria Fendt \n",
      "Sarah-Maria Fendt \n",
      "Elisa Oricchio \n",
      "Sarah-Maria Fendt \n",
      "Eva Gonzalez-Suarez \n",
      "Sibylle Loibl \n",
      "Sibylle Loibl \n",
      "Laurence Buisseret \n",
      "Wilbert Zwart \n",
      "Carsten Denkert \n",
      "Aleix Prat \n",
      "Carlos H. Barrios \n",
      "Carlos H. Barrios \n",
      "Sherene Loi \n",
      "Ian Krop \n",
      "Andrew Tutt \n",
      "Giuseppe Curigliano \n",
      "Simone P. Niclou \n",
      "Simone P. Niclou \n",
      "Lakshmi Nayak \n",
      "Manfred Westphal \n",
      "Simone P. Niclou \n",
      "Michael Weller \n",
      "Jordi Rodon \n",
      "Jordi Rodon \n",
      "Elena Garralda \n",
      "Udai Banerji \n",
      "Judith Michels \n",
      "Jordi Rodon \n",
      "Julien Taieb \n",
      "Julien Taieb \n",
      "Gunnar Folprecht \n",
      "Takayuki Yoshino \n",
      "Naureen Starling \n",
      "Mehdi Karoui \n",
      "Fatima Carneiro \n",
      "Fatima Carneiro \n",
      "Michael J. Pishvaian \n",
      "Angela Lamarca \n",
      "Arndt Vogel \n",
      "Ian Chau \n",
      "Laurence Albiges \n",
      "Christian K. Kollmannsberger \n",
      "Samra Turajlic \n",
      "Matthew D. Galsky \n",
      "Laurence Albiges \n",
      "Rodolfo Montironi \n",
      "Rodolfo Montironi \n",
      "Mark A. Rubin \n",
      "Jean Emmanuel Bibault \n",
      "Raquel Perez-Lopez \n",
      "Cora N. Sternberg \n",
      "Clare L. Scott \n",
      "Clare L. Scott \n",
      "Iain McNeish \n",
      "Clare L. Scott \n",
      "David SP Tan \n",
      "Florence Joly Lobbedez \n",
      "Lena Specht \n",
      "Lena Specht \n",
      "Ingrid Glimelius \n",
      "Richard Anderson \n",
      "Lena Specht \n",
      "Marco Ladetto \n",
      "Brigette B. Ma \n",
      "Brigette B. Ma \n",
      "Eric Deutsch \n",
      "Allen Chan \n",
      "Maura Gillison \n",
      "Ingeborg Tinhofer-Keilholz \n",
      "Leila Akkari \n",
      "Leila Akkari \n",
      "Leila Akkari \n",
      "Claudia Mauri \n",
      "Daniela Quail \n",
      "Georgina V. Long \n",
      "Georgina V. Long \n",
      "Georgina V. Long \n",
      "Alpaslan Tasdogan \n",
      "Michele Maio \n",
      "Ignacio Melero \n",
      "Rocio Garcia-Carbonero \n",
      "Rocio Garcia-Carbonero \n",
      "Aldo Scarpa \n",
      "Andreas Kjaer \n",
      "Juan W. Valle \n",
      "Emily Bergsland \n",
      "Michael Thomas \n",
      "Michael Thomas \n",
      "Patrick M. Forde \n",
      "Giulia Veronesi \n",
      "Keith M. Kerr \n",
      "Jamie Chaft \n",
      "Paul Baas \n",
      "Paul Baas \n",
      "Colin Lindsay \n",
      "Piro Lito \n",
      "Chiara Ambrogio \n",
      "Natasha Leighl \n",
      "Javier Martin-Broto \n",
      "Javier Martin-Broto \n",
      "Hans-Ulrich Schildhaus \n",
      "Sandra P. D'Angelo \n",
      "Antonio Pérez-Martìnez \n",
      "Olivier Mir \n",
      "Jarushka Naidoo \n",
      "Jarushka Naidoo \n",
      "Jarushka Naidoo \n",
      "Stephane Champiat \n",
      "Bettina Heidecker \n",
      "Matthias Preusser \n",
      "John B. Haanen \n",
      "Martijn P. Lolkema \n",
      "Martijn P. Lolkema \n",
      "Himisha Beltran \n",
      "Jeanine Roodhart \n",
      "Katerina Politi \n",
      "Martijn P. Lolkema \n",
      "Anna C. Obenauf \n",
      "Anna C. Obenauf \n",
      "Edwin Cuppen \n",
      "Anthony Chalmers \n",
      "Anna C. Obenauf \n",
      "Peter Dubsky \n",
      "Peter Dubsky \n",
      "Frederik Marmé \n",
      "Chin-Sheng Hung \n",
      "Boon Chua \n",
      "Frederik Marmé \n",
      "Peter Schmid \n",
      "Peter Schmid \n",
      "Anne Vincent-Salomon \n",
      "Peter Schmid \n",
      "Rebecca A. Dent \n",
      "Filip Y. De Vos \n",
      "Filip Y. De Vos \n",
      "Andreas F. Hottinger \n",
      "Slavka Lukacova \n",
      "Linda Dirven \n",
      "Elena Garralda \n",
      "Elena Garralda \n",
      "Emile E. Voest \n",
      "Christophe Massard \n",
      "Caterina Marchiò \n",
      "Christophe Tournigand \n",
      "Christophe Tournigand \n",
      "Thierry De Baere \n",
      "Graeme Poston \n",
      "Karin M. Haustermans \n",
      "Huichuan Sun \n",
      "Huichuan Sun \n",
      "Peter R. Galle \n",
      "Lam S. Chan \n",
      "Laura A. Dawson \n",
      "Manuela Schmidinger \n",
      "Manuela Schmidinger \n",
      "Arnaud Mejean \n",
      "Guillermo De Velasco \n",
      "Camillo Guglielmo Porta \n",
      "Karen Tipples \n",
      "Noel Clarke \n",
      "Boris A. Hadaschik \n",
      "Noel Clarke \n",
      "Chris Parker \n",
      "Silke Gillessen \n",
      "Stephanie De Boer \n",
      "Stephanie De Boer \n",
      "Naveena Singh \n",
      "Nadeem Abu-Rustum \n",
      "Stephanie De Boer \n",
      "Mansoor Raza Mirza \n",
      "Ulrich Jaeger \n",
      "Ulrich Jaeger \n",
      "Laurence De Leval \n",
      "Stefano Luminari \n",
      "Francesco D'Amore \n",
      "Paolo Bossi \n",
      "Paolo Bossi \n",
      "Christian Simon \n",
      "Mererid Evans \n",
      "Sandrine Faivre \n",
      "Paolo Bossi \n",
      "Christian Simon \n",
      "Mererid Evans \n",
      "Sandrine Faivre \n",
      "Alessandra Curioni \n",
      "Alessandra Curioni \n",
      "Thomas F. Gajewski \n",
      "Melvin Lee Kiang Chua \n",
      "Christian U. Blank \n",
      "Natalie I. Vokes \n",
      "Ana Arance \n",
      "Ana Arance \n",
      "Mark Faries \n",
      "Jeffrey S. Weber \n",
      "Alexander C. Van Akkooi \n",
      "Halfdan Sorbye \n",
      "Halfdan Sorbye \n",
      "Emilio Bertani \n",
      "Marianne E. Pavel \n",
      "Halfdan Sorbye \n",
      "Stephen V. Liu \n",
      "Stephen V. Liu \n",
      "Charles M. Rudin \n",
      "Stephen V. Liu \n",
      "Dirk De Ruysscher \n",
      "Noemi Reguart Aransay \n",
      "Noemi Reguart Aransay \n",
      "Jürgen Wolf \n",
      "Percy Lee \n",
      "Ramon Rami-Porta \n",
      "Sylvie Bonvalot \n",
      "Sylvie Bonvalot \n",
      "Dario Callegaro \n",
      "Rick L. Haas \n",
      "Nicolas Penel \n",
      "Snezana M. Bosnjak \n",
      "Snezana M. Bosnjak \n",
      "Manuela Eicher \n",
      "Janelle Yorke \n",
      "Karina D. Steffensen \n",
      "Solange Peters \n",
      "Tony S.K. Mok \n",
      "Pasi A. Jänne \n",
      "Giuseppe Curigliano \n",
      "Andres Cervantes \n",
      "Andres Cervantes \n",
      "Lisa F. Licitra \n",
      "Silke Gillessen \n",
      "Thomas B. Powles \n",
      "Srikala Sridhar \n",
      "Silke Gillessen \n",
      "Sarmad Sadeghi \n",
      "Christian Pfister \n",
      "Enrique Grande Pulido \n",
      "Silke Gillessen \n",
      "Pasi A. Jänne \n",
      "Tony S.K. Mok \n",
      "Pasi A. Jänne \n",
      "Ross Soo \n",
      "Lisa A. Carey \n",
      "Peter Schmid \n",
      "Marina Chiara C. Garassino \n",
      "Solange Peters \n",
      "Rosalind M. Glasspool \n",
      "Krishnansu S Tewari \n",
      "Sibylle Loibl \n",
      "Sibylle Loibl \n",
      "Lisa A. Carey \n",
      "Peter Schmid \n",
      "Lin Shen \n",
      "Jianming Xu \n",
      "Alexander Stein \n",
      "Eric Van Cutsem \n",
      "Yelena Y. Janjigian \n",
      "Rui-Hua Xu \n",
      "Lukas Perkhofer \n",
      "Arndt Vogel \n",
      "Changhoon Yoo \n",
      "Giuseppe Curigliano \n",
      "Giuseppe Curigliano \n",
      "George Coukos \n",
      "Cécile Le Pechoux \n",
      "Solange Peters \n",
      "Pilar Garrido Lopez \n",
      "Pilar Garrido Lopez \n",
      "Nicolas Girard \n",
      "Alexandre Martinez-Marti \n",
      "Oliver Gautschi \n",
      "Oliver Gautschi \n",
      "Tony S.K. Mok \n",
      "Pasi A. Jänne \n",
      "Pasi A. Jänne \n",
      "Ross Soo \n",
      "Marina Chiara C. Garassino \n",
      "Solange Peters \n",
      "Daniel V. Catenacci \n",
      "Marshall R. Posner \n",
      "Julia Katharina Schwarze \n",
      "Thomas F. Gajewski \n",
      "Jaume Mora \n",
      "Evanthia T. Roussos Torres \n",
      "Jeffrey S. Miller \n",
      "Christian U. Blank \n",
      "Josep Tabernero \n",
      "Josep Tabernero \n",
      "Rebecca A. Dent \n",
      "Susana Banerjee \n",
      "Domenica Lorusso \n",
      "Rosalind M. Glasspool \n",
      "Rosalind M. Glasspool \n",
      "Shibani Nicum \n",
      "Eric Pujade-Lauraine \n",
      "Clare L. Scott \n",
      "Clare L. Scott \n",
      "Cristiana Sessa \n",
      "Rosalind M. Glasspool \n",
      "Krishnansu S Tewari \n",
      "Hye Ryun Kim \n",
      "Joseph M. Curry \n",
      "Loris De Cecco \n",
      "Sara Pai \n",
      "Michael Z. Kharouta \n",
      "Paolo Bossi \n",
      "Nandini S. Menon \n",
      "Sjoukje Oosting \n",
      "Solange Peters \n",
      "Solange Peters \n",
      "Alex A. Adjei \n",
      "Petri Bono \n",
      "James Gulley \n",
      "Aurélien Marabelle \n",
      "Sebastian Kobold \n",
      "Aurélien Marabelle \n",
      "David S. Hong \n",
      "Alessandra Curioni \n",
      "Alessandra Curioni \n",
      "Chiara Alessandra Cella \n",
      "Yukako Hattori \n",
      "Juliane Brandt \n",
      "Lawson Eng \n",
      "Marie Fallon \n",
      "Florian Scotté \n",
      "Kazuhiro Shimomura \n",
      "Zhigang Liu \n",
      "Gudrun M. Kreye \n",
      "Helena M. Earl \n",
      "Valentina Guarneri \n",
      "Antonio Llombart Cussac \n",
      "Antonio Llombart Cussac \n",
      "Lucia Del Mastro \n",
      "Sibylle Loibl \n",
      "Monica Arnedos \n",
      "Monica Arnedos \n",
      "Marion DEBAUDRINGHIEN \n",
      "Sylvie Bonvalot \n",
      "Bernd Kasper \n",
      "Brahmi Mehdi \n",
      "Rastislav Bahleda \n",
      "Anna Maria Frezza \n",
      "Alannah Smrke \n",
      "Nicholas D. Klemen \n",
      "Olivier Mir \n",
      "Clara Montagut Viladot \n",
      "Clara Montagut Viladot \n",
      "Clara Montagut Viladot \n",
      "Sara Lonardi \n",
      "Rodrigo Dienstmann \n",
      "Clara Montagut Viladot \n",
      "Clara Montagut Viladot \n",
      "Florian Lordick \n",
      "Florian Lordick \n",
      "Florian Lordick \n",
      "John Reynolds \n",
      "Yelena Y. Janjigian \n",
      "Florian Lordick \n",
      "Florian Lordick \n",
      "Grazia Scocca \n",
      "Isabelle Lebrocquy \n",
      "Martijn Ludwig \n",
      "Agata I. Polinska \n",
      "Agata I. Polinska \n",
      "Jordi Rodon \n",
      "Jordi Rodon \n",
      "Jordi Rodon \n",
      "Lillian L Siu \n",
      "Anastasios Stathis \n",
      "Jordi Rodon \n",
      "Jordi Rodon \n",
      "Sibylle Loibl \n",
      "Sibylle Loibl \n",
      "Sibylle Loibl \n",
      "Jonas Bergh \n",
      "Michael Untch \n",
      "Sibylle Loibl \n",
      "Sibylle Loibl \n",
      "Guillaume Canaud \n",
      "Rahul Aggarwal \n",
      "Christophe Massard \n",
      "Christophe Massard \n",
      "Melissa L. Johnson \n",
      "Jordi Rodon \n",
      "Elena Garralda \n",
      "Elena Garralda \n",
      "Zeynep B. Zengin \n",
      "Kentaro Sawada \n",
      "Katsuya Tsuchihara \n",
      "Afaf Abed \n",
      "Khalil Hodroj \n",
      "Rosalin Cooper \n",
      "Julie N. Graff \n",
      "Bertrand Routy \n",
      "Thomas B. Powles \n",
      "Thomas B. Powles \n",
      "William Kaelin \n",
      "Maria Carmela Piccirillo \n",
      "Hirotsugu Kenmotsu \n",
      "Natasha Leighl \n",
      "Natasha Leighl \n",
      "Bob T. Li \n",
      "Robin Cornelissen \n",
      "Daniel Shao Weng Tan \n",
      "Daniel Shao Weng Tan \n",
      "Andres Cervantes \n",
      "Solange Peters \n",
      "Javier Cortés \n",
      "Shanu Modi \n",
      "Nicoletta Colombo \n",
      "Mansoor Raza Mirza \n",
      "Jason J. Luke \n",
      "Omid Hamid \n",
      "Fabrice André \n",
      "Fabrice André \n",
      "Javier Cortés \n",
      "Shanu Modi \n",
      "Binghe Xu \n",
      "Miguel Martin Jimenez \n",
      "Maria Vittoria Dieci \n",
      "Matthew G. Krebs \n",
      "Ana Mafalda Antunes De Melo e Oliveira \n",
      "Sibylle Loibl \n",
      "Sung-Bae Kim \n",
      "Cristiana Sessa \n",
      "Alfredo Addeo \n",
      "Laurence Albiges \n",
      "Jenny Seligmann \n",
      "Salvatore Siena \n",
      "Pierre Laurent-Puig \n",
      "Pierre Laurent-Puig \n",
      "Chiara Cremolini \n",
      "Filippo Pietrantonio \n",
      "Dominik P. Modest \n",
      "Dominik P. Modest \n",
      "Andres Cervantes \n",
      "Andres Cervantes \n",
      "Nicoletta Colombo \n",
      "Mansoor Raza Mirza \n",
      "Giuseppe Procopio \n",
      "Giulia Baciarello \n",
      "David F. McDermott \n",
      "Samra Turajlic \n",
      "Lisa Derosa \n",
      "Matthew D. Galsky \n",
      "Sumanta K. Pal \n",
      "Nieves Martinez Chanza \n",
      "Jeroen Van Dorp \n",
      "Ignacio Duran \n",
      "Neeraj Agarwal \n",
      "Cora N. Sternberg \n",
      "Cora N. Sternberg \n",
      "Shahneen K. Sandhu \n",
      "Joaquin Mateo \n",
      "Joaquin Mateo \n",
      "Andrew J. Armstrong \n",
      "Stephane M. Oudard \n",
      "Stephane M. Oudard \n",
      "Olivier A. Michielin \n",
      "Olivier A. Michielin \n",
      "Jason J. Luke \n",
      "Omid Hamid \n",
      "Marie Wislez \n",
      "François-Xavier DANLOS \n",
      "Michael Thomas \n",
      "Yi-Long Wu \n",
      "Nicolas Girard \n",
      "Lizza E. Hendriks \n",
      "Luis Paz-Ares \n",
      "Mariona Riudavets Melia \n",
      "Alfredo Addeo \n",
      "F. Stephen Hodi \n",
      "Jeffrey S. Weber \n",
      "Olivier A. Michielin \n",
      "Olivier A. Michielin \n",
      "Helen J. Gogas \n",
      "James Larkin \n",
      "James Larkin \n",
      "Hélène Blons \n",
      "Debora Basile \n",
      "James Glasbey \n",
      "Gunnar Folprecht \n",
      "Clara Montagut Viladot \n",
      "Mustapha Tehfe \n",
      "Elisabeth S. Bergen \n",
      "Astrid Lièvre \n",
      "Eric Vivier \n",
      "Baiyong Li \n",
      "Sophie Papa \n",
      "Sophie Papa \n",
      "Shengli Ding \n",
      "Álvaro Quintanal-Villalonga \n",
      "Jan Korbel \n",
      "\n",
      "Nicola Normanno \n",
      "Anja Tüchler \n",
      "Mario Di Palma \n",
      "Christoph Benedikt Westphalen \n",
      "Lucia Notario Rincon \n",
      "Justin T. Moyers \n",
      "Paraskevas Kosmidis \n",
      "Dario Trapani \n",
      "Jens Bedke \n",
      "Tim Meyer \n",
      "Jens Bedke \n",
      "Jens Bedke \n",
      "Masafumi Ikeda \n",
      "Cristiana Sessa \n",
      "Giuseppe Procopio \n",
      "Tim Meyer \n",
      "Jens Bedke \n",
      "Fabrice André \n",
      "Fabrice André \n",
      "Fabrice André \n",
      "Cristina Saura Manich \n",
      "Evandro De Azambuja \n",
      "Fabrice André \n",
      "Fabrice André \n",
      "Javier Martin-Broto \n",
      "Javier Martin-Broto \n",
      "\n",
      "Jean-Yves Blay \n",
      "Silvia Stacchiotti \n",
      "Javier Martin-Broto \n",
      "Javier Martin-Broto \n",
      "Tanja Spanic \n",
      "Alan A. Melcher \n",
      "Piotr J. Wysocki \n",
      "Ulrich Keilholz \n",
      "Tanja Spanic \n",
      "Emilie Le Rhun \n",
      "Emilie Le Rhun \n",
      "Emilie Le Rhun \n",
      "Giuseppe Minniti \n",
      "Matthias Preusser \n",
      "Emilie Le Rhun \n",
      "Emilie Le Rhun \n",
      "Florence Joly \n",
      "Florence Joly \n",
      "Florence Joly \n",
      "Isabelle L. Ray-Coquard \n",
      "Antonio Jose Gonzalez Martin \n",
      "Florence Joly \n",
      "Florence Joly \n",
      "Jordi Rodon \n",
      "Jordi Rodon \n",
      "Jean-Charles Soria \n",
      "Cristina Saura Manich \n",
      "Barbara Pistilli \n",
      "Barbara Pistilli \n",
      "Hope S. Rugo \n",
      "Gabriel N. Hortobagyi \n",
      "Gonzalo Gomez-Abuin \n",
      "Gonzalo Gomez-Abuin \n",
      "Andres Cervantes \n",
      "Pasi A. Jänne \n",
      "Gerhardt Attard \n",
      "Karim Fizazi \n",
      "Eleni Efstathiou \n",
      "Jared Weiss \n",
      "Federica Di Nicolantonio \n",
      "Yelena Y. Janjigian \n",
      "Florian Lordick \n",
      "Silke Gillessen \n",
      "Silke Gillessen \n",
      "Gerhardt Attard \n",
      "Karim Fizazi \n",
      "Eleni Efstathiou \n",
      "Edward B. Garon \n",
      "Natasha B. Leighl \n",
      "Catherine A. Shu \n",
      "Sai-Hong I. Ou \n",
      "Anne-Marie C. Dingemans \n",
      "Miranda Gogishvili \n",
      "Luis Paz-Ares \n",
      "David R. Gandara \n",
      "Edward B. Garon \n",
      "Julien Taieb \n",
      "Omid Hamid \n",
      "Laurence Albiges \n",
      "Brian I. Rini \n",
      "Christian K. Kollmannsberger \n",
      "Janet E. Brown \n",
      "Naveen S. Vasudev \n",
      "Toni K. Choueiri \n",
      "Brian I. Rini \n",
      "Laurence Albiges \n",
      "Alexandros Papachristofilou \n",
      "Christian K. Kollmannsberger \n",
      "Laurence Albiges \n",
      "Josep Tabernero \n",
      "Josep Tabernero \n",
      "Jared Weiss \n",
      "Federica Di Nicolantonio \n",
      "Yelena Y. Janjigian \n",
      "Florian Lordick \n",
      "Karim Fizazi \n",
      "Richard Cathomas \n",
      "Boris A. Hadaschik \n",
      "Mark C. Markowski \n",
      "Daniel P. Petrylak \n",
      "Giulia Baciarello \n",
      "Emre Kocakavuk \n",
      "Monika E. Hegi \n",
      "Monika E. Hegi \n",
      "Nader Sanai \n",
      "Bart Neyns \n",
      "Patrick Roth \n",
      "Patrick Roth \n",
      "Shan-Shan Li \n",
      "Ismael Fernandez-Miranda \n",
      "Ting-zhi Liu \n",
      "Andrew J. Davies \n",
      "Yuan-Kai Shi \n",
      "Liudmila Fedorova \n",
      "Ingrid Glimelius \n",
      "Elizabeth Smyth \n",
      "Thomas Seufferlein \n",
      "Thierry Conroy \n",
      "Andrew H. Ko \n",
      "Elizabeth Smyth \n",
      "Beate Rau \n",
      "Brian Badgwell \n",
      "Elizabeth Smyth \n",
      "Changsong Qi \n",
      "Kohei Shitara \n",
      "Elizabeth Smyth \n",
      "Lei Yin \n",
      "Inken Salewski \n",
      "Vincenzo Quagliariello \n",
      "Ruth Plummer \n",
      "Diana V. Yuzhakova \n",
      "Laetitia Nebot \n",
      "Letizia Gnetti \n",
      "Christian H. Ottensmeier \n",
      "Minetta C. Liu \n",
      "Alexander N. Shoushtari \n",
      "Christian D. Rolfo \n",
      "Christian D. Rolfo \n",
      "Kaysia Ludford \n",
      "Ingrid J. Garberis \n",
      "Sherene Loi \n",
      "Sherene Loi \n",
      "Ignace B. Vergote \n",
      "David O'Malley \n",
      "Ana Oaknin \n",
      "Susana Banerjee \n",
      "Nicoletta Colombo \n",
      "David SP Tan \n",
      "Joyce Liu \n",
      "David O'Malley \n",
      "Naveena Singh \n",
      "Omid Hamid \n",
      "Omid Hamid \n",
      "Omid Hamid \n",
      "Paolo A. Ascierto \n",
      "Reinhard Dummer \n",
      "Omid Hamid \n",
      "Omid Hamid \n",
      "Jana Pelouchova \n",
      "Gilliosa Spurrier-Bernard \n",
      "Piret Hirv \n",
      "Mozziyar Etemadi \n",
      "Jan Geissler \n",
      "Misha Tyulenev \n",
      "Jana Pelouchova \n",
      "Marianne E. Pavel \n",
      "Marianne E. Pavel \n",
      "Marianne E. Pavel \n",
      "Eric Baudin \n",
      "Jonathan R. Strosberg \n",
      "Marianne E. Pavel \n",
      "Marianne E. Pavel \n",
      "Kevin J. Harrington \n",
      "Kevin J. Harrington \n",
      "Kevin J. Harrington \n",
      "Denis Soulieres \n",
      "Paolo Bossi \n",
      "Kevin J. Harrington \n",
      "Kevin J. Harrington \n",
      "Pedro Romero \n",
      "Pedro Romero \n",
      "Carl H. June \n",
      "Jean Bourhis \n",
      "Athanassios Argiris \n",
      "Amanda Psyrri \n",
      "Amanda Psyrri \n",
      "Anthony T.C. T. Chan \n",
      "Wang-Zhong Li \n",
      "Lisa F. Licitra \n",
      "Lisa F. Licitra \n",
      "Solange Peters \n",
      "Pasi A. Jänne \n",
      "Eric Baudin \n",
      "Rocio Garcia-Carbonero \n",
      "Scott T. Shepherd \n",
      "Sjoukje Oosting \n",
      "Marie Von Lilienfeld-Toal \n",
      "Enriqueta Felip \n",
      "Benjamin Besse \n",
      "Eric Baudin \n",
      "Rocio Garcia-Carbonero \n",
      "Giampaolo Bianchini \n",
      "Aranzazu Fernandez-Martinez \n",
      "Nadia Harbeck \n",
      "Marleen Kok \n",
      "Sara A. Hurvitz \n",
      "Sofia Rivera \n",
      "José A. García-Saenz \n",
      "Peter Schmid \n",
      "Véronique Diéras \n",
      "Fabrice André \n",
      "Lam S. Chan \n",
      "Richard Cathomas \n",
      "Mary F. Mulcahy \n",
      "Robert S. Fichtinger \n",
      "Thomas Gruenberger \n",
      "Thomas Gruenberger \n",
      "Pei-Rong Ding \n",
      "Frederik Großerüschkamp \n",
      "Julien Taieb \n",
      "Julien Taieb \n",
      "Emanuela Romano \n",
      "Emanuela Romano \n",
      "Scott T. Shepherd \n",
      "Sjoukje Oosting \n",
      "Marie Von Lilienfeld-Toal \n",
      "Ivan Marquez-Rodas \n",
      "Kim A. Margolin \n",
      "Teresa Petrella \n",
      "Christian U. Blank \n",
      "Paolo A. Ascierto \n",
      "Reinhard Dummer \n",
      "Teresa Troiani \n",
      "Umberto Malapelle \n",
      "Emiliano Calvo \n",
      "Umberto Malapelle \n",
      "Maria Gabriela Oliveira Fernandes \n",
      "Albrecht Stenzinger \n",
      "Rodrigo Dienstmann \n",
      "Emiliano Calvo \n",
      "Emiliano Calvo \n",
      "Umberto Malapelle \n",
      "Mingyuan Sun \n",
      "Markus G. Manz \n",
      "Markus G. Manz \n",
      "Muhit Özcan \n",
      "Junning Cao \n",
      "Lena Specht \n",
      "Lena Specht \n",
      "Solange Peters \n",
      "Solange Peters \n",
      "Enriqueta Felip \n",
      "Benjamin Besse \n",
      "Joline S. Lim \n",
      "Haeseong Park \n",
      "Aung Naing \n",
      "Natalie Cook \n",
      "Manish Sharma \n",
      "Richard F. Schlenk \n",
      "Hidenori Kage \n",
      "Julia E. Lai-Kwon \n",
      "Richard D. Baird \n",
      "Benjamin Besse \n",
      "Rafal Dziadziuszko \n",
      "Lyudmila Bazhenova \n",
      "Lyudmila Bazhenova \n",
      "Trevor Feinstein \n",
      "Ticiana A. Leal \n",
      "Maurice Pérol \n",
      "Maurice Pérol \n",
      "Maximilian J. Mair \n",
      "Maria Vieito Villar \n",
      "Enrico Franceschi \n",
      "Ariane Steindl \n",
      "Carme Balaña \n",
      "Nader Sanai \n",
      "Lakshmi Nayak \n",
      "Tadeusz A. Dyba \n",
      "Irit Ben-Aharon \n",
      "Olga Husson \n",
      "Olga Husson \n",
      "Joseph M. Unger \n",
      "Krishnamani Kalpathi \n",
      "Ophira Ginsburg \n",
      "Ophira Ginsburg \n",
      "Jaume Capdevila Castillon \n",
      "Sophie Leboulleux \n",
      "Laura D. Locati \n",
      "Jorge Hernando \n",
      "Halfdan Sorbye \n",
      "Barbara Mandriani \n",
      "Chris Verslype \n",
      "Eleni Efstathiou \n",
      "Eleni Efstathiou \n",
      "Eleni Efstathiou \n",
      "Karim Fizazi \n",
      "Ronald De Wit \n",
      "Eleni Efstathiou \n",
      "\n",
      "Samra Turajlic \n",
      "Samra Turajlic \n",
      "\n",
      "Nicola Valeri \n",
      "Livio Trusolino \n",
      "Samra Turajlic \n",
      "Samra Turajlic \n",
      "Paolo G. Casali \n",
      "Jean-Yves Blay \n",
      "Ariane Weinman \n",
      "Kathy Oliver \n",
      "Iwo Korycinski \n",
      "Paolo G. Casali \n",
      "Arnaud Mejean \n",
      "Arnaud Mejean \n",
      "Arnaud Mejean \n",
      "Thomas Powles \n",
      "Michiel S. Van der Heijden \n",
      "Arnaud Mejean \n",
      "Arnaud Mejean \n",
      "Edward B. Garon \n",
      "Edward B. Garon \n",
      "\n",
      "Federico Cappuzzo \n",
      "Suresh S. Ramalingam \n",
      "Edward B. Garon \n",
      "Edward B. Garon \n",
      "Pasi A. Jänne \n",
      "Pasi A. Jänne \n",
      "Olufunmilayo Olopade \n",
      "Pilar Garrido Lopez \n",
      "Pilar Garrido \n",
      "Michelle Bachelet \n",
      "Pilar Garrido Lopez \n",
      "Ophira Ginsburg \n",
      "Solange Peters \n",
      "Pilar Garrido Lopez \n",
      "Ophira Ginsburg \n",
      "Nathan I. Cherny \n",
      "E.G. Elisabeth De Vries \n",
      "Dario Trapani \n",
      "Sjoukje Oosting \n",
      "Nathan I. Cherny \n",
      "Nathan I. Cherny \n",
      "Egbert F. F. Smit \n",
      "Kevin J. Harrington \n",
      "Erika Martinelli \n",
      "Florence Duffaud \n",
      "Patricia Pautier \n",
      "Robin L. Jones \n",
      "Robin L. Jones \n",
      "Javier Martin-Broto \n",
      "Yuki Kojima \n",
      "Sebastian Bauer \n",
      "Sebastian Bauer \n",
      "Giuseppe Curigliano \n",
      "Cristiana Sessa \n",
      "Giuseppe Curigliano \n",
      "Dario Trapani \n",
      "Peter Schmid \n",
      "Giuseppe Curigliano \n",
      "Alfredo Addeo \n",
      "Enriqueta Felip \n",
      "Giuseppe Curigliano \n",
      "Cristiana Sessa \n",
      "Julie T. Wu \n",
      "Radka Obermannova \n",
      "Sabrina K. Salgia \n",
      "Luís Castelo-Branco \n",
      "Tom Drake \n",
      "David J. Pinato \n",
      "James Glasbey \n",
      "Emanuela Romano \n",
      "Petros Grivas \n",
      "Thomas Walter \n",
      "Maria Carmen Riesco-Martinez \n",
      "Angela Lamarca \n",
      "Angela Lamarca \n",
      "Dieter Horsch \n",
      "Rocio Garcia-Carbonero \n",
      "Nicola Fazio \n",
      "Nicola Fazio \n",
      "Michiel H. Strijbos \n",
      "Michiel H. Strijbos \n",
      "Barbara Kiesewetter-Wiederkehr \n",
      "Mike Clarke \n",
      "Bettina Ryll \n",
      "Michiel H. Strijbos \n",
      "Hendrik K. Van Halteren \n",
      "Hendrik K. Van Halteren \n",
      "Alona Zer \n",
      "Kevin Punie \n",
      "Hendrik K. Van Halteren \n",
      "Ursula Vogl \n",
      "Hendrik K. Van Halteren \n",
      "Guro L. Astrup \n",
      "Prakhar Srivastava \n",
      "Jayne E. Wood \n",
      "Jayne E. Wood \n",
      "Qianwei Liu \n",
      "Martina E. Schmidt \n",
      "Dorothy Keefe \n",
      "Dorothy Keefe \n",
      "Teresa M. Amaral \n",
      "Claudia Cardone \n",
      "Emiliano Calvo \n",
      "Nathan I. Cherny \n",
      "Teresa M. Amaral \n",
      "Kok Haw Jonathan Lim \n",
      "Solange Peters \n",
      "Laura Mezquita \n",
      "Matteo Lambertini \n",
      "Stephen J. Thomas \n",
      "Ithai Waldhorn \n",
      "Rebecca Lee \n",
      "Rebecca Lee \n",
      "Alessio Cortellini \n",
      "Kok Haw Jonathan Lim \n",
      "Anne-Marie C. Dingemans \n",
      "Anne-Marie C. Dingemans \n",
      "E.G. Elisabeth De Vries \n",
      "E.G. Elisabeth De Vries \n",
      "Bishal Gyawali \n",
      "Christopher M. Booth \n",
      "Lorenzo Moja \n",
      "Panagiotis Kanavos \n",
      "Elisabeth G. De Vries \n",
      "Demetris Papamichael \n",
      "Siri Rostoft \n",
      "Demetris Papamichael \n",
      "Siri Rostoft \n",
      "Elisabeth Quoix \n",
      "Demetris Papamichael \n",
      "Siri Rostoft \n",
      "Demetris Papamichael \n",
      "Manju Sengar \n",
      "Manju Sengar \n",
      "Manju Sengar \n",
      "Christoph Benedikt Westphalen \n",
      "Felipe S. Roitberg \n",
      "Manju Sengar \n",
      "Manju Sengar \n",
      "Nicolas Girard \n",
      "Nicolas Girard \n",
      "\n",
      "Heather Wakelee \n",
      "Martin Reck \n",
      "Nicolas Girard \n",
      "Nicolas Girard \n",
      "Pedro Romero \n",
      "Pedro Romero \n",
      "Pedro Romero \n",
      "Roch Houot \n",
      "Marcela Maus \n",
      "Pedro Romero \n",
      "Pedro Romero \n",
      "Lena Specht \n",
      "Lena Specht \n",
      "Lena Specht \n",
      "Thomas A. Lister \n",
      "Christian Buske \n",
      "Lena Specht \n",
      "Lena Specht \n",
      "Johan De Munter \n",
      "Johan De Munter \n",
      "Pascale Dielenseger \n",
      "Johan De Munter \n",
      "Theresa Wiseman \n",
      "Johan De Munter \n",
      "Johan De Munter \n",
      "Johan De Munter \n",
      "Johan De Munter \n",
      "Elke Schneider \n",
      "Mirjam Crul \n",
      "Pascale Dielenseger \n",
      "Lena Sharp \n",
      "Matthias B. Naegele \n",
      "Johan De Munter \n",
      "Merel Van Klinken \n",
      "Jane Ewang \n",
      "Anna Theodorelou \n",
      "Celia Díez de los Ríos de la Serna \n",
      "Nikolina Dodlek \n",
      "Johan De Munter \n",
      "Nikolina Dodlek \n",
      "Amanda Drury \n",
      "Bethany Maynard \n",
      "Michaela Popelkova \n",
      "Lena Sharp \n",
      "Merel Van Klinken \n",
      "Virpi Sulosaari \n",
      "Johan De Munter \n",
      "Mary D. Van Zyl \n",
      "Marco Di Nitto \n",
      "Virpi Sulosaari \n",
      "Andreas Charalambous \n",
      "Androniki Ioannou \n",
      "Roma Maguire \n",
      "André M. Lopes \n",
      "Adeline Duflot Boukobza \n",
      "Jayesh Desai \n",
      "Andreas Charalambous \n",
      "Eugenia Trigoso Arjona \n",
      "Christa Rustler \n",
      "Andri Christou \n",
      "Mandy Van Rosmalen \n",
      "Isabelle Fromantin \n",
      "Selma Musters \n",
      "Eugenia Trigoso Arjona \n",
      "Virpi Sulosaari \n",
      "Hedi Chabanol \n",
      "Elen Fytrou \n",
      "Judy Phillips \n",
      "Mary A. Tanay \n",
      "Celia Díez de los Ríos de la Serna \n",
      "Virpi Sulosaari \n",
      "Wendy H. Oldenmenger \n",
      "Bettina Korn \n",
      "Mary Nevin \n",
      "Gaëlle Vanbutsele \n",
      "Karen Campbell \n",
      "Georgia Ntavarinou \n",
      "Wendy H. Oldenmenger \n",
      "Amanda Drury \n",
      "Manuela Eicher \n",
      "Urska Kosir \n",
      "Alina Comanescu \n",
      "Richard T. O'Dwyer \n",
      "Maura Dowling \n",
      "Amanda Drury \n"
     ]
    }
   ],
   "source": [
    "for i in range(len(PERSONS)):\n",
    "    print(PERSONS[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "id": "7e301a87",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Introduction\n",
      "Introduction (ID 5)\n",
      "Understanding or dissecting the biology to target K-RAS driven tumours (ID 2)\n",
      "Developing novel epigenetic inhibitory compounds (ID 3)\n",
      "Molecular glue degraders (ID 4)\n",
      "Introduction\n",
      "Introduction (ID 9)\n",
      "Integrative cancer (epi)genomics in real life (ID 6)\n",
      "Profiling cancer signaling networks at single-cell resolution (ID 7)\n",
      "Profiling the anti-cancer potential of non-oncology drugs (ID 8)\n",
      "Introduction\n",
      "Introduction (ID 27)\n",
      "State-of-the-art and new options in luminal breast cancer  (ID 24)\n",
      "State-of-the-art and new options in HER2+ breast cancer (ID 25)\n",
      "State-of-the-art and new options in triple negative breast cancer (TNBC) (ID 26)\n",
      "Introduction\n",
      "Introduction (ID 52)\n",
      "ER+ metastatic breast cancer  (ID 49)\n",
      "HER2+ MBC  (ID 50)\n",
      "Triple negative breast cancer (TNBC) (ID 51)\n",
      "Introduction\n",
      "Methylation analysis: From research tools to diagnostic application  (ID 67)\n",
      "Fusions detected by RNA sequencing  (ID 68)\n",
      "Liquid biopsy for CNS tumors: The view of the clinician (ID 69)\n",
      "Introduction\n",
      "Introduction (ID 88)\n",
      "Established and promising new gene fusions inhibitors and new drugs  (ID 85)\n",
      "The relative merits of different approaches to fusion testing  (ID 86)\n",
      "Confusion on fusion testing (ID 87)\n",
      "Introduction\n",
      "Introduction (ID 107)\n",
      "Targeted agents for small subgroups: When and how?  (ID 104)\n",
      "Immunotherapy for MSI and beyond: Promises and reality  (ID 105)\n",
      "What are best treatment choices for the remaining majority of patients? (ID 106)\n",
      "Introduction\n",
      "Introduction (ID 125)\n",
      "Precision oncology applications in gastric cancer (ID 122)\n",
      "Molecular analysis of upper GI cancers: Focus on immune biomarkers (ID 123)\n",
      "Non-immune molecular predictors of treatment response in gastric cancer (ID 124)\n",
      "Introduction\n",
      "Introduction (ID 142)\n",
      "New development in muscle-invasive disease (ID 139)\n",
      "How to choose first-line systemic therapy in advanced urothelial cancer    (ID 140)\n",
      "Novel treatment strategies (ID 141)\n",
      "Introduction\n",
      "Is there an optimal first-line combination approach for metastatic mRCC? (ID 143)\n",
      "Current status of personalised therapy in metastatic mRCC (ID 144)\n",
      "Future targets and combinations for mRCC (ID 145)\n",
      "Introduction\n",
      "Introduction (ID 166)\n",
      "Evidence-based treatment options in biochemically relapsed prostate cancer (ID 163)\n",
      "The role of imaging in selecting treatment  (ID 164)\n",
      "Quality of life (QoL) and long-term comorbidities   (ID 165)\n",
      "Introduction\n",
      "Introduction (ID 184)\n",
      "Prevention and screening for cervical cancer (ID 181)\n",
      "Traditional or mininvasive approaches in early cervical cancer  (ID 182)\n",
      "Incorporating immunotherapy and other innovative treatments in the management of cervical cancer  (ID 183)\n",
      "Introduction\n",
      "Introduction (ID 203)\n",
      "New insights in the genetics and biology of multiple myeloma  (ID 200)\n",
      "New treatment strategies: CAR T cell and more (ID 201)\n",
      "Treatment strategies and sequencing   (ID 202)\n",
      "Introduction\n",
      "Introduction (ID 221)\n",
      "Immune landscape in head and neck cancer: Rationale and opportunities for integrating immunotherapy in curative treatment protocols (ID 218)\n",
      "Clinical experience with radiotherapy plus immune checkpoint inhibitors (ID 219)\n",
      "Neoadjuvant and adjuvant approaches   (ID 220)\n",
      "Introduction\n",
      "Introduction (ID 242)\n",
      "Overview on synthetic immune receptors (ID 239)\n",
      "Resistance mechanisms to T-cells in solid tumours   (ID 240)\n",
      "Discoveries in T-cell antigen receptor (TCR) recognition  (ID 241)\n",
      "Introduction\n",
      "Introduction (ID 263)\n",
      "Preclinical models of brain M1: Translational implications  (ID 259)\n",
      "Current therapeutic regimens and future therapies  (ID 260)\n",
      "Leptomeningeal disease  (ID 261)\n",
      "Introduction\n",
      "Introduction (ID 281)\n",
      "Advanced thyroid cancer  (ID 278)\n",
      "Advanced adrenocortical cancer  (ID 279)\n",
      "Advanced pheochromocytoma and paraganglioma (ID 280)\n",
      "Introduction\n",
      "Introduction (ID 299)\n",
      "How should we screen optimally? (ID 296)\n",
      "Biomarkers of risk and early detection (ID 297)\n",
      "Early intervention and the concept of immune prophylaxis (ID 298)\n",
      "Introduction\n",
      "Introduction (ID 317)\n",
      "Current landscape: Did we learn how to select first-line strategy? (ID 314)\n",
      "Mechanisms of resistance and novel strategies (ID 315)\n",
      "Do we have any idea how to use these drugs in oncogene addicted patients yet? (ID 316)\n",
      "Introduction\n",
      "Introduction (ID 321)\n",
      "Broadening the horizons: EGFR, ALK, ROS-1, BRAF  (ID 318)\n",
      "Opening new horizons: RET, NTRK, MET, HER2…  (ID 319)\n",
      "How do we identify resistance mechanisms?  (ID 320)\n",
      "Introduction\n",
      "Introduction (ID 4628)\n",
      "Effect of primary prevention for the general population (ID 4629)\n",
      "Relevance to address obesity (ID 4630)\n",
      "Customized intervention: The case of acetylsalicylic acid and Lynch syndrome (ID 4631)\n",
      "Introduction\n",
      "Introduction (ID 4632)\n",
      "The limitations of clinical evidence from trials when data presented for HTA: Immature survival data, selected patient populations, phase II data for uncommon cancers etc... (ID 4633)\n",
      "Real-world evidence and regulatory drug approval (ID 4634)\n",
      "RWE: When should it be used by EMA? (ID 4635)\n",
      "Challenges of collecting RWE: Limitations of administrative data sets, complex methodological issues, responsibility for collecting data (ID 4636)\n",
      "Introduction\n",
      "Introduction (ID 4637)\n",
      "ESMO’s blueprint to tackle cancer (ID 4638)\n",
      "EMA/HMA strategy 2025 (ID 4639)\n",
      "Europe's Beating Cancer Plan (ID 4640)\n",
      "Pharmaceutical strategy for Europe and how to combine a thriving pharmaceutical landscape with affordable drug prices (ID 4641)\n",
      "Industry perspective (ID 4642)\n",
      "Patient perspective (ID 4643)\n",
      "Introduction\n",
      "Introduction (ID 378)\n",
      "GIST: No more unmet needs? (ID 375)\n",
      "Progressing desmoids fibromatosis: What is the best option? (ID 376)\n",
      "New therapeutic approaches in Ewing sarcoma (ID 377)\n",
      "Introduction\n",
      "Introduction (ID 396)\n",
      "What works (and for what)   (ID 393)\n",
      "Adverse events / drug interactions  (ID 394)\n",
      "“Fake news” and its impact  (ID 395)\n",
      "Introduction\n",
      "Introduction (ID 415)\n",
      "Genomics and machine learning for precision cancer medicine (ID 412)\n",
      "AI for image analysis of cancer therapy response (ID 413)\n",
      "Engaging with patients to expand data for cancer research (ID 414)\n",
      "Introduction\n",
      "Introduction (ID 419)\n",
      "From bench to bedside: Mechanisms and biomarkers (ID 416)\n",
      "Microbiome and hematopoietic cell transplantation (ID 417)\n",
      "Shifting the microbiome to improve immunotherapy efficacy clinical trial results (ID 418)\n",
      "Introduction\n",
      "Introduction\n",
      "Functional genomics and lymphoma\n",
      "Tumor metabolism\n",
      "Therapeutic response and resistance of breast cancer\n",
      "Introduction\n",
      "Introduction: Staging\n",
      "Impact of the immune system \n",
      "Impact of DNA alterations and regulation\n",
      "Impact of protein expression and heterogeneity\n",
      "Impact of RNA expression\n",
      "Introduction\n",
      "Introduction\n",
      "Emerging targets in metastatic breast cancer: What have we learnt from molecular analysis? \n",
      "New generation antibody drug conjugates (ADCs) \n",
      "Expanding indications of DNA damage agents  \n",
      "What comes after anti-PD1? \n",
      "Introduction\n",
      "Introduction\n",
      "Integrating molecular targeted therapies in gliomas\n",
      "Engineering oncolytic viruses for treatment of malignant gliomas\n",
      "Novel strategies targeting the brain tumour metabolism\n",
      "What does it take for success in immunotherapies in neuro-oncology? \n",
      "Introduction\n",
      "Introduction\n",
      "Monoclonal antibodies: Old and new targets\n",
      "ABCs of ADCs\n",
      "Bispecifics and fragments\n",
      "Antibody mimetics \n",
      "Introduction\n",
      "Introduction\n",
      "Stage III disease treatment: When, how and for how long? \n",
      "Stage II, lacking evidence: What to do in daily practice? \n",
      "Are circulating and tissue markers going to help in the future? \n",
      "How to best treat non-metastatic rectal cancer in 2021\n",
      "Introduction\n",
      "Introduction\n",
      "Pancreatic cancer \n",
      "Biliary tract cancer \n",
      "Hepatocellular cancer \n",
      "Squamous esophageal cancer\n",
      "Introduction\n",
      "MicroRNA in the management of testicular cancer  \n",
      "Tissue-based biomarker in renal cancer: Opportunities and challenges\n",
      "Tissue and blood-based biomarkers for urothelial cancer\n",
      "Incorporating biomarkers into clinical trials\n",
      "Introduction\n",
      "Introduction\n",
      "Molecular pathology to advance prostate cancer precision medicine \n",
      "Artificial Intelligence to guide prostate cancer therapeutic strategies\n",
      "Precision imaging for the \"elusive\" prostate cancer and its implication for therapy development\n",
      "Clinical perspectives for the individual patient and the community\n",
      "Introduction\n",
      "Introduction\n",
      "Genomic approaches in ovarian cancer \n",
      "Resistance to PARP inhibitors\n",
      "New targets in ovarian cancer\n",
      "Combinations with immune therapy in ovarian cancer\n",
      "Introduction\n",
      "Introduction\n",
      "Magnitude of late effects in lymphoma survivors and rationale for long term surveillance\n",
      "Childbearing, fertility and lymphoma \n",
      "Side-effects of modern radiotherapy  \n",
      "Adverse effects of novel targeted treatment for lymphoma\n",
      "Introduction\n",
      "Introduction\n",
      "Radiomic biomarkers in head and neck cancer\n",
      "Minimal residual disease and circulating biomarkers  \n",
      "Tissue-based biomarkers in head and neck cancer \n",
      "How can we use biomarkers to take clinical decisions?  \n",
      "Introduction\n",
      "Introduction\n",
      "Myeloid cell mediated resistance to immune therapy\n",
      "B cells infiltrating cancer\n",
      "Obesity-induced inflammation in immunotherapy response \n",
      "Introduction\n",
      "Introduction\n",
      "Approaches and early results tackling microenvironment structures \n",
      "Tackling tumour metabolism \n",
      "Epigenetic modulation as a strategy to overcome resistance \n",
      "Regulatory T cells and myeloid suppressive environment\n",
      "Introduction\n",
      "Introduction\n",
      "Molecular pathology: Implications for care \n",
      "Molecular imaging: A game-changer in management of NETs \n",
      "Advances in cytotoxic and targeted therapies \n",
      "Ongoing trials and future perspectives\n",
      "Introduction\n",
      "Introduction  \n",
      "What is the optimal systemic therapy? IO-mono, IO-IO, IO-chemo \n",
      "Surgical considerations \n",
      "Pathology & biomarker considerations \n",
      "The role of targeted therapy in the neo adjuvant setting\n",
      "Introduction\n",
      "Introduction \n",
      "Current status of G12C inhibitors  \n",
      "Mechanisms of resistance\n",
      "All things KRAS not G12C\n",
      "Combinations including KRAS inhibitors\n",
      "Introduction\n",
      "Introdcution\n",
      "Tumor microenvironment and predictive biomarkers for IO treatment in sarcomas\n",
      "PD-1 checkpoint inhibitors in sarcoma: Evidence and future indications \n",
      "CAR-T cells and other adaptive immune therapies in sarcoma  \n",
      "Can we take advantage of immunogenic death in soft tissue sarcomas?\n",
      "Introduction\n",
      "Introduction\n",
      "A multidiciplinary team (MDT) for dealing with immunotherapy toxicity \n",
      "Respiratory toxicity from immunotherapy \n",
      "Immunotherapy and the heart: What could possibly go wrong?\n",
      "Immunotherapy induced neurotoxicity: Current understanding\n",
      "What else does immunotherapy do?\n",
      "Introduction\n",
      "Introduction\n",
      "Role of lineage plasticity in response and resistance to therapies\n",
      "Recapitulating human cancer through organoid models: Therapeutic implications of cellular heterogeneity \n",
      "How representative mouse models can provide insights to therapeutic vulnerabilities\n",
      "Using repeated diagnostic leukapheresis to dissect resistance to treatment\n",
      "Introduction\n",
      "Introduction\n",
      "The value of genomics information for trial design\n",
      "Combining radiotherapy and DNA repair inhibition\n",
      "Combining immunotherapy and kinase inhibition\n",
      "Introduction\n",
      "Introduction and presentation of case/condition 1: TNBC \n",
      "Presentation of case/condition 2: HER2+ BC \n",
      "Tailored surgical therapy after NACT\n",
      "Tailored radiotherapy after NACT \n",
      "Tailored systemic therapy after NACT \n",
      "Introduction\n",
      "Introduction and presentation of case/condition \n",
      "The role of the pathologist in the optimal management of immunotherapeutics\n",
      "Opportunities for I-O combinations\n",
      "When does oligoprogression impact your treatment decisions?\n",
      "Introduction\n",
      "Introduction and presentation of case/condition \n",
      "Neurological complications of immunotherapy: Diagnosis and treatment\n",
      "Combined modality treatment: How to study new combinations and avoid complications\n",
      "Medical capacity of brain tumour patients: Can I enroll a brain tumor patient into a trial?\n",
      "Introduction\n",
      "Introduction and presentation of case/condition \n",
      "New models for creating access to on and off label drugs\n",
      "Avenues for accessing drugs in small patient population settings: Access to clinical trials, off-label and compassionate use in Europe\n",
      "Portfolio of tests for tumour-agnostic markers: Disease-specific or broad panels?   \n",
      "Introduction\n",
      "Introduction, definition of oligometastatic disease and presentation of case/condition\n",
      "Interventional radiology: Approaches that may help \n",
      "Surgical indications and limitations \n",
      "Radiotherapy for metastatic colorectal cancer (mCRC): When is it worth it?\n",
      "Introduction\n",
      "Introduction\n",
      "High-burdened Barcelona Clinic Liver Cancer (BCLC) B: TACE, systemic treatment or others\n",
      "BCLC Stage C HCC: Do we have the best sequence of treatment? \n",
      "The role of radiotherapy for intra-hepatic cholangiocarcinoma\n",
      "Introduction\n",
      "Introduction and presentation of case/condition \n",
      "The role of surgery in metastatic renal cancer\n",
      "The view of the medical oncologist: First-line choice \n",
      "Treatment for disease that has progressed on first-line treatment \n",
      "The role of stereotactic radiation\n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "What is the added value of surgery? \n",
      "The role of radiotherapy  \n",
      "Systemic treatments and novel approaches\n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "Molecular classification and its implications for clinical management\n",
      "Surgical approach to early endometrial cancer: When to avoid lymphadenectomy \n",
      "Role of adjuvant radiotherapy in early endometrial cancer\n",
      "Role of adjuvant systemic therapy \n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "Pathology of T-cell lymphomas: Where are we and where are we going?\n",
      "First-line treatment strategy\n",
      "Relapse treatment for T-cell lymphomas \n",
      "Introduction\n",
      "Introduction and presentation of case/condition 1: A young patient with oral cavity cancer\n",
      "Surgical opportunities \n",
      "De-escalation strategies in radiotherapy \n",
      "To add or not to add systemic treatment \n",
      "Presentation of case/condition 2: Old patient with locally advanced HPV positive disease\n",
      "Surgical opportunities \n",
      "De-escalation strategies in radiotherapy \n",
      "To add or not to add systemic treatment \n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "Mechanisms of acquired resistance \n",
      "Local regional treatment\n",
      "Novel systemic immune oncology (IO) options  \n",
      "Artificial intelligence (AI) approach and big data  \n",
      "Introduction\n",
      "Introduction and presentation of case/condition \n",
      "Neoadjuvant\n",
      "Adjuvant\n",
      "Current trials and future implications\n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "Is there a role for surgery? \n",
      "What is the role and optimal timing of radiation/PRRT?  \n",
      "What is the optimal systemic therapy? \n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "Biological classification of SCLC and clinical implications\n",
      "Novel systemic therapeutic approaches\n",
      "Optimal use of radiotherapy\n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "The medical oncologist’s point of view\n",
      "The radiation oncologist’s point of view\n",
      "The surgeon’s point of view\n",
      "Introduction\n",
      "Introduction and presentation of case/condition\n",
      "Decision making in retroperitoneal sarcoma surgery: Resectability, strategic delay and palliation\n",
      "Patient selection for preoperative radiotherapy: Lessons from the STRASS trial \n",
      "Systemic therapy in retroperitoneal sarcoma: Cure or palliation?\n",
      "Introduction\n",
      "Presentation of case/condition \n",
      "Tailored supportive care based on PROMs\n",
      "Assessment of adverse events (AEs) in clinical trials from the patient’s perspective\n",
      "The clinical benefits of the integration of PROm \n",
      "ESMO Presidential Address\n",
      "ESMO Congress 2021 Scientific Co-chair Address 1\n",
      "ESMO Congress 2021 Scientific Co-chair Address 2\n",
      "Introduction to the 2021 ESMO Awards\n",
      "Introduction\n",
      "Introduction to the ESMO Award 2021\n",
      "A medical oncologist vis-à-vis a disease\n",
      "Introduction\n",
      "LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study\n",
      "Invited Discussant LBA27\n",
      "Q&A and live discussion\n",
      "651O - Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)\n",
      "652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial\n",
      "Invited Discussant 651O and 652O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Invited Discussant VP3_2021\n",
      "VP3_2021 - A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial\n",
      "Invited Discussant VP7_2021\n",
      "VP7_2021 - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)\n",
      "Invited Discussant VP2_2021\n",
      "VP2_2021 - Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data\n",
      "Invited Discussant VP4_2021\n",
      "VP4_2021 - EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study\n",
      "LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study\n",
      "LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)\n",
      "LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen\n",
      "Discussion LBA52, LBA53, LBA54 and LBA55\n",
      "1373MO - JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)\n",
      "LBA10 - Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group\n",
      "LBA37 - IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)\n",
      "Discussion 1373MO, LBA10 and LBA37\n",
      "Introduction\n",
      "Introduction to the ESMO Translational Research Award 2021\n",
      "Mobilizing immunity against cancer: From bench to bedside\n",
      "1170O - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)\n",
      "LBA65 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743\n",
      "Invited Discussant 1170O and LBA65\n",
      "Q&A and live discussion\n",
      "LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial\n",
      "LBA42 - COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC\n",
      "Invited Discussant LBA66 and LBA42\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "960MO - Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC\n",
      "961MO - Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers\n",
      "962MO - A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma\n",
      "Discussion 960MO, 961MO and 962MO\n",
      "963MO - Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201\n",
      "964MO - Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)\n",
      "965MO - GTB-3550 tri-specific killer engager safely activates and delivers IL-15 to NK cells, but not T-cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3\n",
      "Discussion 963MO, 964MO and 965MO\n",
      "Introduction\n",
      "Introduction to the ESMO Women for Oncology Award 2021\n",
      "It takes a global village to raise a colleague\n",
      "LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma\n",
      "721O - Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study\n",
      "Invited Discussant LBA32 and 721O\n",
      "Q&A and live discussion\n",
      "722O - Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)\n",
      "LBA33 - Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial\n",
      "Invited Discussant 722O and LBA33\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "860MO - Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)\n",
      "861MO - Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)\n",
      "862MO - Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer\n",
      "Discussion 860MO, 861MO and 862MO\n",
      "863MO - Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016\n",
      "864MO - Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study\n",
      "865MO - RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation\n",
      "Discussion 863MO, 864MO and 865MO\n",
      "Introduction\n",
      "Introduction to the ESMO Lifetime Achievement Award 2021\n",
      "Flying blind: An odyssey in oncology drug development\n",
      "LBA38 - Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types\n",
      "957O - Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1\n",
      "958O - Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial\n",
      "Invited Discussant LBA38, 957O and 958O\n",
      "Q&A and live discussion\n",
      "959O - Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors\n",
      "Invited Discussant 959O\n",
      "Q&A and live discussion\n",
      "1670MO - Validation of a new risk-assessment model for prediction of venous thromboembolism in cancer outpatients: The ONKOTEV score\n",
      "1443MO - Differences in hematologists’ and palliative care physicians’ recommended indications and opinions on transfusion therapy for patients with hematological malignancy post-anticancer therapy\n",
      "Discussion 1670MO and 1443MO\n",
      "1671MO - Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study\n",
      "LBA62 - Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy\n",
      "Discussion 1671MO and LBA62\n",
      "LBA63 - Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial\n",
      "LBA64 - Olanzapine, an alternative to dexamethasone for preventing nausea and vomiting induced by cisplatin-based doublet highly emetogenic chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial\n",
      "Discussion LBA63 and LBA64\n",
      "LBA11 - Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer\n",
      "117O - Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials\n",
      "Invited Discussant LBA11 and 117O\n",
      "Q&A and live discussion\n",
      "118O - Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella\n",
      "119O - Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial\n",
      "Invited Discussant 118O and 119O\n",
      "Q&A and live discussion\n",
      "1522MO - Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF)\n",
      "1523MO - Initial active surveillance strategy for patients with peripheral sporadic desmoids: A multicentre phase II observational trial\n",
      "Discussion 1522MO and 1523MO\n",
      "1524MO - Patterns of care and outcomes of 64 CIC-rearranged sarcoma: A retrospective multicentre case-series within the French Sarcoma Group (FSG)\n",
      "1525MO - Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma\n",
      "Discussion 1524MO and 1525MO\n",
      "1526MO - GEMMK: A phase I study of gemcitabine (gem) and pembrolizumab (pem) in patients (pts) with leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma UPS)\n",
      "1527MO - Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade\n",
      "Discussion 1526MO and 1527MO\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Ending cancer patients’ discrimination, reducing the burden of financial toxicity, and the adoption of the right to be forgotten\n",
      "Successful story about patient advocacy for the right to be forgotten in the Netherlands\n",
      "The detrimental impact of financial toxicity, the (unjustified) lack of life insurance options, on patients’ quality of life and well-being\n",
      "Crowdfunding project by Piggy Bank Programme\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "LBA23 - EPIK-P1: Retrospective chart review study of patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programme\n",
      "512O - Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies\n",
      "Invited Discussant LBA23 and 512O\n",
      "Q&A and live discussion\n",
      "513O - A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors\n",
      "514O - An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors\n",
      "Invited Discussant 513O and 514O\n",
      "Q&A and live discussion\n",
      "1759MO - Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)\n",
      "60MO - Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN\n",
      "Discussion 1759MO and 60MO\n",
      "LBA68 - Clinical value of pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy\n",
      "1760MO - Impact of immune checkpoint blockade therapy according to CD274 copy number alterations: A retrospective study in the ProfiLER cohort\n",
      "1761MO - Defining subset-wise myeloid responses to immune checkpoint blockade in melanoma\n",
      "61MO - Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199\n",
      "Discussion LBA68, 1760MO, 1761MO and 61MO\n",
      "Introduction\n",
      "Introduction by the Chair\n",
      "(Re)emerging principles of cancer therapy\n",
      "1207O - Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial\n",
      "LBA44 - Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study\n",
      "Invited Discussant 1207O and LBA44\n",
      "Q&A and live discussion\n",
      "LBA45 - Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)\n",
      "LBA46 - Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)\n",
      "Invited Discussant LBA45 and LBA46\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study\n",
      "Invited Discussant LBA1\n",
      "LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study\n",
      "Invited Discussant LBA2_PR\n",
      "LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial\n",
      "Invited Discussant LBA3_PR\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "228MO - PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)\n",
      "229MO - Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study\n",
      "Discussion 228MO and 229MO\n",
      "230MO - First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies\n",
      "LBA18 - POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)\n",
      "LBA19 - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)\n",
      "Discussion 230MO, LBA18 and LBA19\n",
      "Breast cancer, early stage and Gynaecological cancers\n",
      "Investigational immunotherapy and Non-metastatic NSCLC and other thoracic malignancies\n",
      "GU, non-prostate\n",
      "382O - Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring\n",
      "386O - Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)\n",
      "Invited Discussant 382O and 386O\n",
      "Q&A and live discussion\n",
      "LBA20 - FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO\n",
      "383O - MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)\n",
      "Invited Discussant LBA20 and 383O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "654MO - A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)\n",
      "655MO - A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study\n",
      "656MO - Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)\n",
      "Discussion 654MO, 655MO and 656MO\n",
      "657MO - Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study\n",
      "658MO - Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)\n",
      "Discussion 657MO and 658MO\n",
      "659MO - Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)\n",
      "LBA31 - High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)\n",
      "Discussion 659MO and LBA31\n",
      "LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study\n",
      "Invited Discussant LBA24\n",
      "Q&A and live discussion\n",
      "577O - PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)\n",
      "Invited Discussant 577O\n",
      "Q&A and live discussion\n",
      "LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)\n",
      "Invited Discussant LBA25\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "1151MO - Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial\n",
      "1732MO - Pembrolizumab and nintedanib for patients with advanced mesothelioma\n",
      "Discussion 1151MO and 1732MO\n",
      "LBA43 - GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)\n",
      "1171MO - PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy\n",
      "Discussion LBA43 and 1171MO\n",
      "LBA61 - Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study\n",
      "1172MO - Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations\n",
      "Discussion LBA61 and 1172MO\n",
      "1036O - Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047\n",
      "1040O - Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma\n",
      "Invited Discussant 1036O and 1040O\n",
      "Q&A and live discussion\n",
      "1037O - MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)\n",
      "Invited Discussant 1037O\n",
      "Q&A and live discussion\n",
      "387MO - Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial\n",
      "388MO - Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy\n",
      "389MO - Risk of bowel obstruction in patients undergoing neoadjuvant chemotherapy for high-risk colon cancer: A nested case-control matched analysis of an international, multi-centre, randomised controlled trial (FOxTROT)\n",
      "Discussion 387MO, 388MO and 389MO\n",
      "Discussion 387MO, 388MO and 389MO\n",
      "390MO - Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada\n",
      "391MO - Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials\n",
      "Discussion 390MO and 391MO\n",
      "1O - Harnessing innate immunity in cancer therapies: The example of natural killer cell engagers\n",
      "2O - Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties\n",
      "Invited Discussant 1O and 2O\n",
      "Q&A and live discussion\n",
      "3O - Patient-derived micro-organospheres (MOS) recapitulate tumor microenvironment and heterogeneity for precision oncology\n",
      "1800O - Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation\n",
      "Invited Discussant 3O and 1800O\n",
      "Q&A and live discussion\n",
      "1505MO - Improving cancer care through broader access to quality biomarker testing: An IQN Path, ECPC and EFPIA initiative\n",
      "1506MO - Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result\n",
      "1507MO - Selection of quality indicators (QI) by non-hospital professionals for onco-hematology care pathway\n",
      "Discussion 1505MO, 1506MO and 1507MO\n",
      "1508MO - Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)\n",
      "1509MO - Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials\n",
      "1510MO_PR - European cancer patients’ perspectives on Immunotherapy\n",
      "Discussion 1508MO, 1509MO and 1510MO_PR\n",
      "Introduction\n",
      "Introduction\n",
      "Live introduction\n",
      "Optimal selection of patients with untreated advanced renal carcinoma for combination and monotherapy regimens: Agents, combinations and emerging biomarkers\n",
      "Optimal selection of patients with untreated advanced hepatocellular cancer for combination and monotherapy regimens: Agents, combinations and emerging biomarkers\n",
      "Optimal selection of patients with platinum-pretreated advanced endometrial carcinoma for combination and monotherapy regimens: Agents, combinations and emerging biomarkers\n",
      "Proactive and reactive strategies for improving patient compliance and safety of VEGFR-TKI/immune checkpoint inhibitor combinations\n",
      "Live conclusions\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Tumour agnostic\n",
      "Tumour dependent\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "What is immuno-oncology, what are the latest therapies, and what is the role of gene therapies\n",
      "Immuno-oncology: The latest scientific findings and future perspectives\n",
      "Precision immunotherapy: Soon a daily reality?\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the Chair\n",
      "Drug development: How can academia and industry work together\n",
      "LBA15 - Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer\n",
      "Invited Discussant LBA15\n",
      "Q&A and live discussion\n",
      "LBA16 - KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC\n",
      "LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)\n",
      "Invited Discussant LBA16 and LBA17_PR\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol\n",
      "LBA5_PR - A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1\n",
      "Invited Discussant LBA4 and LBA5\n",
      "LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation\n",
      "Invited Discussant LBA6\n",
      "LBA7 - Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study\n",
      "Invited Discussant LBA7\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "LBA49 - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study\n",
      "1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study\n",
      "1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2\n",
      "Discussion LBA49, 1192MO and 1193MO\n",
      "LBA50 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22\n",
      "LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)\n",
      "1194MO - Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results\n",
      "Discussion LBA50, LBA51 & 1194MO\n",
      "NSCLC, metastatic 1\n",
      "GI, colorectal\n",
      "Melanoma and other skin tumours\n",
      "Introduction\n",
      "Introduction\n",
      "Introduction\n",
      "LBA28 - STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)\n",
      "LBA29 - Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)\n",
      "653O - Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564\n",
      "Invited Discussant LBA28, LBA29 and 653O\n",
      "Q&A and live discussion\n",
      "LBA30 - Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10\n",
      "Invited Discussant LBA30\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "576MO - Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer\n",
      "LBA26 - Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16)\n",
      "Discussion 576MO and LBA26\n",
      "578MO - Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA)\n",
      "579MO - CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)\n",
      "Discussion 578MO and 579MO\n",
      "340O - Radiotherapy is associated with deletion signatures that contribute to poor survival outcomes in cancer patients\n",
      "Invited Discussant 340O\n",
      "Q&A and live discussion\n",
      "341O - A phase 0 ‘Trigger’ trial of CDK4/6 plus ERK1/2 inhibitors in recurrent glioblastoma\n",
      "342O - Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial\n",
      "Invited Discussant 341O and 342O\n",
      "Q&A and live discussion\n",
      "828MO - Exonic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma\n",
      "829MO - A gene signature to predict risk of transformation in patients with follicular lymphoma\n",
      "830MO - Integrated driver mutations profile of Chinese NK/T cell lymphoma\n",
      "Discussion 828MO, 829MO and 830MO\n",
      "831MO - Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial\n",
      "832MO - Immune microenvironment in classical Hodgkin lymphoma: Composition and dynamics in patients with relapsed/refractory disease\n",
      "Discussion 831MO and 832MO\n",
      "Introduction\n",
      "LBA56 - Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study\n",
      "LBA57 - Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)\n",
      "Invited Discussant LBA56 and LBA57\n",
      "Q&A and live discussion\n",
      "1376O - The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial)\n",
      "Invited Discussant 1376O\n",
      "Q&A and live discussion\n",
      "1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system\n",
      "Invited Discussant 1372O\n",
      "Q&A and live discussion\n",
      "4MO - Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models\n",
      "5MO - CDK4/6 blockade is as effective as immune-checkpoint inhibition in tumor growth control of Mlh1-/- and Msh2loxP/loxP villin-Cre mice\n",
      "6MO - PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways\n",
      "Discussion 4MO, 5MO and 6MO\n",
      "7MO - Effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model\n",
      "1801MO - Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors\n",
      "1802MO - Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort\n",
      "Discussion 7MO, 1801MO and 1802MO\n",
      "1123O - Evaluation of cell-free DNA approaches for multi-cancer early detection\n",
      "1757O - Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients\n",
      "Invited Discussant 1123O and 1757O\n",
      "Q&A and live discussion\n",
      "1758O - Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency\n",
      "1124O - Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides\n",
      "Invited Discussant 1758O and 1124O\n",
      "Q&A and live discussion\n",
      "723MO - Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study\n",
      "724MO - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)\n",
      "Discussion 723MO and 724MO\n",
      "725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer\n",
      "726MO - Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)\n",
      "Discussion 725MO and 726MO\n",
      "LBA34 - Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004\n",
      "795MO - Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158\n",
      "Discussion LBA34 and 795MO\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes, ready for primetime in the clinic\n",
      "No, appropriate for clinical trial/biomarker work at this time\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "The importance of patient involvement in designing patient-centric clinical trials\n",
      "National patient data protected with blockchain\n",
      "AI, targeted data and predictive analytics to monitor and proactively manage patient outcomes and validate the quality and benefit of cancer care\n",
      "How patients can support the qualitative empirical data and strengthen cancer health research\n",
      "OneRemission: An integrative oncologist in your pocket\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "177Lu-dotatate\n",
      "Hepatic arterial embolization\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the Chair\n",
      "New generation therapies\n",
      "LBA35 - Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial\n",
      "LBA36 - Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651\n",
      "Invited Discussant LBA35 and LBA36\n",
      "Q&A and live discussion\n",
      "858O - Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)\n",
      "859O - Refining TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: A multicenter cohort study\n",
      "Invited Discussant 858O and 859O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "567O_PR - First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib\n",
      "Invited Discussant 567O_PR\n",
      "1557O - Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study\n",
      "LBA8 - Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors\n",
      "Invited Discussant 1557O and LBA8\n",
      "LBA9 - IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC\n",
      "Invited Discussant LBA9\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "LBA12 - Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial\n",
      "120MO - Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials\n",
      "LBA13 - Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial\n",
      "Discussion LBA12, 120MO and LBA13\n",
      "LBA14 - Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study\n",
      "121MO - Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial\n",
      "122MO - Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib\n",
      "123MO - BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer\n",
      "Discussion LBA14, 121MO, 122MO and 123MO\n",
      "Breast cancer, metastatic\n",
      "GI, non-colorectal\n",
      "GU, prostate and non-prostate\n",
      "LBA21 - Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study)\n",
      "384O - Laparoscopic versus open hemihepatectomy: The ORANGE II PLUS multicenter randomized controlled trial\n",
      "Invited Discussant LBA21 and 384O\n",
      "Q&A and live discussion\n",
      "LBA22 - Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Initial results of a multicenter randomised, open-label, phase III trial\n",
      "385O - Automated detection of microsatellite status in early colon cancer (CC) using artificial intelligence (AI) integrated infrared (IR) imaging on unstained samples from the AIO ColoPredictPlus 2.0 (CPP) registry study\n",
      "Invited Discussant LBA22 and 385O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "1038MO - Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial\n",
      "1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)\n",
      "Discussion 1038MO and 1039MO\n",
      "LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study\n",
      "LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study\n",
      "1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma\n",
      "Discussion LBA39, LBA40 and 1041MO\n",
      "Introduction\n",
      "Introduction\n",
      "Live introduction\n",
      "A clinical case of a female patient with advanced RET-fused non-small cell lung adenocarcinoma: MRD, disease monitoring, secondary resistance\n",
      "Technologies for multiplex molecular testing and ESMO recommendations for practice and research application in solid tumours\n",
      "Molecular tumour boards and application in oncology networks: Challenges and opportunities on the road towards optimizing patient benefit\n",
      "Availability, turnaround times and report interpretation: Implementation barriers and knowledge gaps related to tumour molecular profiling in practice\n",
      "Live conclusions\n",
      "Q&A and live discussion\n",
      "825O - Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study\n",
      "Invited Discussant 825O\n",
      "Q&A and live discussion\n",
      "826O - Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial\n",
      "833O - A phase Ib study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma\n",
      "Invited Discussant 826O and 827O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)\n",
      "516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies\n",
      "Discussion 515MO and 516MO\n",
      "517MO - Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours\n",
      "518MO - Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors\n",
      "Discussion 517MO and 518MO\n",
      "519MO - Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards\n",
      "520MO - Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): Results from a global stakeholder survey and the National Cancer Research Institute (NCRI) Consumer Forum\n",
      "Discussion 519MO and 520MO\n",
      "LBA47 - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial\n",
      "1281O - Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C\n",
      "Invited Discussant LBA47 and 1281O\n",
      "Q&A and live discussion\n",
      "LBA48 - DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen\n",
      "1191O - MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy\n",
      "Invited Discussant LBA48 & 1191O\n",
      "Q&A and live discussion\n",
      "343MO - Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma\n",
      "344MO - Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma\n",
      "Discussion 343MO and 344MO\n",
      "345MO - Treatment associated changes in the inflammatory microenvironment composition of brain metastases\n",
      "346MO - Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial\n",
      "347MO - 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial\n",
      "Discussion 345MO, 346MO and 347MO\n",
      "1501O_PR - Long-term estimates of cancer incidence and mortality for the EU and EFTA countries according to different demographic scenarios\n",
      "1502O - OncoYoung program: A multidisciplinary program for young cancer patients\n",
      "Invited Discussant 1501O_PR and 1502O\n",
      "Q&A and live discussion\n",
      "1503O - Clinical and scientific impact of National Cancer Institute: Sponsored clinical trial network group treatment trials\n",
      "1504O - Anti-cancer drug price regulation in India: Financial implications and annual savings to patients\n",
      "Invited Discussant 1503O and 1504O\n",
      "Q&A and live discussion\n",
      "LBA67 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy\n",
      "1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation\n",
      "Discussion LBA67 and 1743MO\n",
      "1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)\n",
      "1100MO - Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms\n",
      "1101MO - Development of CAR T-cells for future treatment of NETs\n",
      "Discussion 1099MO, 1100MO and 1101MO\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "More merits\n",
      "More limitations\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Rare cancers: The main challenges, the recommendations, and the collaboration with the patient groups\n",
      "The European Refence Networks and the rare cancers\n",
      "How the integration of specific national rare cancers plans into national cancer control plans can support the patients’ journey from diagnosis to treatment\n",
      "Implementing clinical practice guidelines for rare cancers – mission accomplished?\n",
      "Coordinated care Programme for neurofibromatosis patients in Poland\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Consistent with regimens appropriate for initial treatment of metastatic disease\n",
      "As patients who progressed on both chemotherapy and immunotherapy for advanced disease\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the Chair\n",
      "Population risk stratification for early detection and personalized breast cancer treatment\n",
      "Introduction\n",
      "Welcome & updates from ESMO W4O\n",
      "UN High Commissioner Michelle Bachelet’s video contribution\n",
      "Introduction to second lecture\n",
      "Women, power, and cancer divide\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Identifying bias: Top tips when reading a paper\n",
      "ESMO-MCBS and quality of life: What is the impact on understanding value?\n",
      "ESMO-MCBS version 2: What is new and why?\n",
      "Q&A and live discussion\n",
      "NSCLC, metastatic 2\n",
      "Head and neck cancers\n",
      "GI, colorectal 2\n",
      "LBA58 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer\n",
      "LBA59 - LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study\n",
      "Invited Discussant LBA58 and LBA59\n",
      "Q&A and live discussion\n",
      "1520O - REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial\n",
      "1521O - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)\n",
      "Invited Discussant 1520O and 1521O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Welcome and Opening remarks\n",
      "Presentation of case 1: Patient with metastatic breast cancer\n",
      "Discussion of case 1: Patient with metastatic breast cancer\n",
      "Live Q&A\n",
      "Presentation of case 2: Patient with early, resected EGFR-mutated NSCLC and subsequent relapse\n",
      "Discussion of case 2: Patient with early, resected EGFR-mutated NSCLC and subsequent relapse\n",
      "Live Q&A\n",
      "Closing remarks\n",
      "1562MO - Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study\n",
      "1563MO - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity\n",
      "1564MO - Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers\n",
      "Discussion 1562MO, 1563MO and 1564MO\n",
      "LBA60 - Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK\n",
      "1565MO - Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry\n",
      "1566MO - Resilience of elective cancer surgery systems during COVID-19 lockdowns: International, prospective cohort study of planned surgery for 15 tumour types in 61 countries\n",
      "1567MO - COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)\n",
      "Discussion LBA60, 1565MO, 1566MO and 1567MO\n",
      "LBA41 - Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)\n",
      "1098O - Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)\n",
      "Invited Discussant LBA41\n",
      "Q&A and live discussion\n",
      "1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study\n",
      "1097O - The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs\n",
      "Invited Discussant 1096O and 1097O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Real-world experience using the ESMO-MCBS in clinical practice\n",
      "When does statistical significance become clinically relevant?\n",
      "Clinical benefit from a patient’s perspective\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Update in lung cancer\n",
      "Update in breast cancer\n",
      "Update in colorectal cancer\n",
      "Update in prostate cancer\n",
      "Q&A and live discussion\n",
      "1441O - Patient-reported outcomes in cancer patients newly diagnosed with brain metastases\n",
      "1442O - Proactive early palliative care referral for cancer patients in the intensive care unit: Implementing a novel “triggers” checklist\n",
      "Invited Discussant 1441O and 1442O\n",
      "Q&A and live discussion\n",
      "1488O - Cancer risk in individuals with intellectual disability\n",
      "1669O_PR - Late effects, long-term problems, and unmet needs of cancer survivors\n",
      "Invited Discussant 1488O and 1669O_PR\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Staring through the window-of-opportunity: Phase 0 trials in oncology\n",
      "Clinical trial designs fit for the future: How to address their integrity\n",
      "Discussion\n",
      "Introduction\n",
      "Live discussion\n",
      "Live discussion\n",
      "Live discussion\n",
      "1558O - COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine\n",
      "1559O - Efficacy and toxicity of BNT162b2 vaccine in cancer patients\n",
      "Invited Discussant 1558O and 1559O\n",
      "Q&A and live discussion\n",
      "1560O_PR - Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection\n",
      "1561O - The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series\n",
      "Invited Discussant 1560O_PR and 1561O\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Access to relevant drugs in LMICs\n",
      "The ten cancer therapeutics that front-line cancer physicians find most essential\n",
      "Role of cancer drugs on WHO EML\n",
      "ESMO’s reimbursement model\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction\n",
      "Welcome and introduction\n",
      "Ageing-related frailty: What does it mean?\n",
      "Lung cancer case\n",
      "Colon cancer case\n",
      "Concluding remarks\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Bispecific antibodies\n",
      "CAR T-cells\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Introduction by the chair\n",
      "Polling 1 (led by chair)\n",
      "Yes\n",
      "No\n",
      "Polling 2 (led by chair)\n",
      "Q&A\n",
      "Introduction\n",
      "Welcome by EONS\n",
      "Welcome by French Oncology Nursing Society\n",
      "From theory to implementation: The EU Beating Cancer Plan in motion\n",
      "Promoting patient and public involvement in cancer nursing research\n",
      "Lifetime Achievement Award\n",
      "RECaN Award\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Occupational Safety and Health Agency (EU OSHA): Actions in Europe to support healthcare workers\n",
      "Overview of occupational safety legislation for Europe (ESOP)\n",
      "French cancer nurses experience of occupational safety\n",
      "EONS cancer nursing index\n",
      "CN27 - Occupational safety of oncology nurses handling systemic anti-cancer therapies in Germany\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "How to become a clinical cancer nurse leader\n",
      "Standout cancer nurse leaders: What's in the research?\n",
      "Inspirational cancer nurse leaders mentor and being mentored\n",
      "Promoting leadership among young cancer nurses\n",
      "Promoting young cancer nurses into the future: Panel discussion\n",
      "Promoting young cancer nurses into the future: Panel discussion\n",
      "Promoting young cancer nurses into the future: Panel discussion\n",
      "Promoting young cancer nurses into the future: Panel discussion\n",
      "Promoting young cancer nurses into the future: Panel discussion\n",
      "Promoting young cancer nurses into the future: Panel discussion\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "A vision for the future of cancer nursing\n",
      "CN9 - An exploratory qualitative study to describe the experience of using a question prompt list for patients in early phase clinical trials\n",
      "CN12 - Describing self-care behaviours in cancer patients taking oral anticancer agents\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "How virtual reality can facilitate the navigation of patients through active treatment: Findings from a crossover control trial\n",
      "Results of eSMART project, a European Multicenter randomized controlled trial, using real time remote symptom monitoring of patients with cancer receiving chemotherapy\n",
      "Development of an ePRO based model of care for patients treated with immune-checkpoint inhibitors\n",
      "CN1 - Remote monitoring by Nurses Navigators (NNs): From experimentation to optimisation of routine practices\n",
      "CN2 - ROPRO – Real-World Data Prognostic Score: A novel tool to assess patients' performance status\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Coalition of Nurses and Healthcare Professionals against Tobacco and Nicotine\n",
      "Introducing a new scale for the routine assessment of sialadenitis in the radioiodine treatment context\n",
      "Nurse-led clinics and screening by cancer nurses (i.e. hereditary breast cancer)\n",
      "Cancer screening & detection with dogs\n",
      "CN11 - Impact of a surgical ward breakfast buffet on nutritional intake in postoperative (oncological) patients\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Capecitabine & hand-foot syndrome: Results of a retrospective study in patients treated for metastatic breast cancer from 2008 to 2018\n",
      "Biomarkers usage for prediction of symptom clusters in patients with colorectal cancer following chemotherapy\n",
      "Managing neuropathy in the oncology setting\n",
      "CN48 - A qualitative study of patient and clinician experiences of providing care, information and support for chemotherapy-induced peripheral neuropathy\n",
      "CN49 - A rapid review of patient reported outcomes for patients with renal cell cancer or hepatocellular cancer on treatment with targeted therapies\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "Palliative care in the time of Coronavirus\n",
      "Implementing indicators for non-specialist palliative care\n",
      "Early/integrative palliative care in context of haematological malignancies\n",
      "CN25 - The haemato-oncology patient experience of the process of palliative care: A constructivist grounded theory study\n",
      "CN26 - Do patients with advanced lung cancer have more palliative care needs than patients with severe chronic obstructive pulmonary disease (COPD)?\n",
      "Q&A and live discussion\n",
      "Introduction\n",
      "EONS RWG: Patients experiences during COVID-19\n",
      "Delays in screening and diagnosis of cancer during COVID: What can we expect for the next years?\n",
      "Cancer care in COVID from a patient perspective\n",
      "CN43 - Maintaining intravenous anti-cancer systemic therapy during COVID: Pharmacy and nursing factors\n",
      "CN44 - Exploring cancer patients' and survivors’ experiences of cancer care in COVID-19: A longitudinal qualitative study\n",
      "Q&A and live discussion\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(SUB_SESSION)):\n",
    "    print(SUB_SESSION[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "id": "af005551",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "None\n",
      "None\n",
      "None\n",
      "None\n",
      "None\n",
      "None\n",
      "None\n",
      "None\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(DATE)):\n",
    "        print(DATE[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 172,
   "id": "fa60bee7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Invited Discussant LBA45 and LBA46\\nSpeakers\\nDaniel Shao Weng Tan (Singapore, Singapore)\\nLecture Time\\n14:30 - 14:40'"
      ]
     },
     "execution_count": 172,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ff=driver.find_element(By.XPATH,\"/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[7]\")\n",
    "# ff.find_element(By.CLASS_NAME,'card-title').text\n",
    "ff.text\n",
    "\n",
    "# /html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 161,
   "id": "313deb5d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Neeraj Agarwal (Salt Lake City, United States of America)'"
      ]
     },
     "execution_count": 161,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]/div[2]/div[2]').text\n",
    "#                                                     /html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]/div[3]/div[2]  \n",
    "t"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 160,
   "id": "809ea238",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'13:30 - 13:40'"
      ]
     },
     "execution_count": 160,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]/div[3]/div[2]').text \n",
    "#                                 /html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]/div[2]/div[2]    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 164,
   "id": "01344253",
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"927c4503-fd63-4a6e-9894-21fa8dbfcde6\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"c62df117-4717-4cff-bb19-86ddcab24314\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"7e838e61-a5bd-4c5e-852e-837b3995f7c7\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"d1d5e0bc-12a6-4fe4-8c10-2495487fe1a8\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"6e16e9a7-0526-44b4-a8ce-09e3c1f18220\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"aecc742d-323a-4011-a9b6-48e66053ae7c\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"73ecd803-b949-447b-a90c-2e5e0b62e7ab\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"9963e456-38da-4790-849d-ddd41a17efc0\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"470cc1e9-0b54-4d31-8597-3e1fbf68071b\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"1bcfc4a0-0a06-472f-accf-f58fdfcf4f53\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"6f7f6e8f-0c21-48e6-b7cb-377c501a188a\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"be16b9e7-4b78-4292-bbaa-3dc45c630476\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"06576499-b95f-41ea-9d5f-f9f5ef1a766e\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"786b3ab9-76a7-4e16-a14f-7ebfa5605c83\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"d2720063-20a4-4162-ab17-bb9d2c19ef24\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"44cea01e-bdf5-4666-8af7-c98a9ca1dddb\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"29e6a695-1ebe-4a6c-86a6-7c4674a64e66\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"13a923c1-5f8a-4bbd-b920-650283ed0bf6\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"8ed2261a-63f5-4d3c-804c-ffc70ef7e95e\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"9db2a2e6-920f-496f-8e1f-0506bff6d4a2\")>,\n",
       " <selenium.webdriver.remote.webelement.WebElement (session=\"d7200e9bd513d20cb7cf17f694aac3b4\", element=\"38aff787-67ef-429d-be45-ddf4d54a25f3\")>]"
      ]
     },
     "execution_count": 164,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]')\n",
    "t.find_elements(By.TAG_NAME,'div')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0d9b292a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "058bce72",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "id": "f94090a8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Silke Gillessen (Bellinzona, Switzerland)'"
      ]
     },
     "execution_count": 150,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "li=ff.find_element(By.CLASS_NAME,'persons')\n",
    "sss=li.find_elements(By.TAG_NAME,'li')\n",
    "sss[0].text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 165,
   "id": "21583edf",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.get(days[100])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "c949c341",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'LBA24'"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ff.find_element(By.CLASS_NAME,'property').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "f4502170",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "574\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(SESSION)):\n",
    "    if(SESSION[i]=='Proffered Paper session - Genitourinary tumours, prostate'):\n",
    "        print(i)\n",
    "        break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "676c4137",
   "metadata": {},
   "outputs": [],
   "source": [
    "/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[1]/div[2]/div[1]/div[3]/div[2]\n",
    "/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[2]/div[2]/div[1]/div[3]/div[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "8b9ed31e",
   "metadata": {},
   "outputs": [
    {
     "ename": "NoSuchElementException",
     "evalue": "Message: no such element: Unable to locate element: {\"method\":\"xpath\",\"selector\":\"/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[2]/div[2]/div[1]/div[1]/div[2]/ul\"}\n  (Session info: chrome=109.0.5414.120)\nStacktrace:\nBacktrace:\n\t(No symbol) [0x008C6643]\n\t(No symbol) [0x0085BE21]\n\t(No symbol) [0x0075DA9D]\n\t(No symbol) [0x00791342]\n\t(No symbol) [0x0079147B]\n\t(No symbol) [0x007C8DC2]\n\t(No symbol) [0x007AFDC4]\n\t(No symbol) [0x007C6B09]\n\t(No symbol) [0x007AFB76]\n\t(No symbol) [0x007849C1]\n\t(No symbol) [0x00785E5D]\n\tGetHandleVerifier [0x00B3A142+2497106]\n\tGetHandleVerifier [0x00B685D3+2686691]\n\tGetHandleVerifier [0x00B6BB9C+2700460]\n\tGetHandleVerifier [0x00973B10+635936]\n\t(No symbol) [0x00864A1F]\n\t(No symbol) [0x0086A418]\n\t(No symbol) [0x0086A505]\n\t(No symbol) [0x0087508B]\n\tBaseThreadInitThunk [0x77D000F9+25]\n\tRtlGetAppContainerNamedObjectPath [0x77EB7BBE+286]\n\tRtlGetAppContainerNamedObjectPath [0x77EB7B8E+238]\n",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNoSuchElementException\u001b[0m                    Traceback (most recent call last)",
      "Input \u001b[1;32mIn [96]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[1;34m()\u001b[0m\n\u001b[1;32m----> 1\u001b[0m spp\u001b[38;5;241m=\u001b[39m\u001b[43mdriver\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfind_element\u001b[49m\u001b[43m(\u001b[49m\u001b[43mBy\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mXPATH\u001b[49m\u001b[43m,\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43m/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[2]/div[2]/div[1]/div[1]/div[2]/ul\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[0;32m      2\u001b[0m spp\u001b[38;5;241m.\u001b[39mtext\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python39\\site-packages\\selenium\\webdriver\\remote\\webdriver.py:857\u001b[0m, in \u001b[0;36mWebDriver.find_element\u001b[1;34m(self, by, value)\u001b[0m\n\u001b[0;32m    854\u001b[0m     by \u001b[38;5;241m=\u001b[39m By\u001b[38;5;241m.\u001b[39mCSS_SELECTOR\n\u001b[0;32m    855\u001b[0m     value \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m'\u001b[39m\u001b[38;5;124m[name=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m]\u001b[39m\u001b[38;5;124m'\u001b[39m \u001b[38;5;241m%\u001b[39m value\n\u001b[1;32m--> 857\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mexecute\u001b[49m\u001b[43m(\u001b[49m\u001b[43mCommand\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mFIND_ELEMENT\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    858\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43musing\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mby\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    859\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43mvalue\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mvalue\u001b[49m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mvalue\u001b[39m\u001b[38;5;124m'\u001b[39m]\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python39\\site-packages\\selenium\\webdriver\\remote\\webdriver.py:435\u001b[0m, in \u001b[0;36mWebDriver.execute\u001b[1;34m(self, driver_command, params)\u001b[0m\n\u001b[0;32m    433\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mcommand_executor\u001b[38;5;241m.\u001b[39mexecute(driver_command, params)\n\u001b[0;32m    434\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m response:\n\u001b[1;32m--> 435\u001b[0m     \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43merror_handler\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcheck_response\u001b[49m\u001b[43m(\u001b[49m\u001b[43mresponse\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    436\u001b[0m     response[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mvalue\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_unwrap_value(\n\u001b[0;32m    437\u001b[0m         response\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mvalue\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m))\n\u001b[0;32m    438\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python39\\site-packages\\selenium\\webdriver\\remote\\errorhandler.py:247\u001b[0m, in \u001b[0;36mErrorHandler.check_response\u001b[1;34m(self, response)\u001b[0m\n\u001b[0;32m    245\u001b[0m         alert_text \u001b[38;5;241m=\u001b[39m value[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124malert\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mtext\u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[0;32m    246\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exception_class(message, screen, stacktrace, alert_text)  \u001b[38;5;66;03m# type: ignore[call-arg]  # mypy is not smart enough here\u001b[39;00m\n\u001b[1;32m--> 247\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m exception_class(message, screen, stacktrace)\n",
      "\u001b[1;31mNoSuchElementException\u001b[0m: Message: no such element: Unable to locate element: {\"method\":\"xpath\",\"selector\":\"/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[2]/div[2]/div[1]/div[1]/div[2]/ul\"}\n  (Session info: chrome=109.0.5414.120)\nStacktrace:\nBacktrace:\n\t(No symbol) [0x008C6643]\n\t(No symbol) [0x0085BE21]\n\t(No symbol) [0x0075DA9D]\n\t(No symbol) [0x00791342]\n\t(No symbol) [0x0079147B]\n\t(No symbol) [0x007C8DC2]\n\t(No symbol) [0x007AFDC4]\n\t(No symbol) [0x007C6B09]\n\t(No symbol) [0x007AFB76]\n\t(No symbol) [0x007849C1]\n\t(No symbol) [0x00785E5D]\n\tGetHandleVerifier [0x00B3A142+2497106]\n\tGetHandleVerifier [0x00B685D3+2686691]\n\tGetHandleVerifier [0x00B6BB9C+2700460]\n\tGetHandleVerifier [0x00973B10+635936]\n\t(No symbol) [0x00864A1F]\n\t(No symbol) [0x0086A418]\n\t(No symbol) [0x0086A505]\n\t(No symbol) [0x0087508B]\n\tBaseThreadInitThunk [0x77D000F9+25]\n\tRtlGetAppContainerNamedObjectPath [0x77EB7BBE+286]\n\tRtlGetAppContainerNamedObjectPath [0x77EB7B8E+238]\n"
     ]
    }
   ],
   "source": [
    "spp=driver.find_element(By.XPATH,'/html/body/div[1]/div[3]/div/div/div/div[3]/div/div[2]/div[4]/div[2]/div[2]/div[1]/div[1]/div[2]/ul')\n",
    "spp.text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "id": "0899600c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1165"
      ]
     },
     "execution_count": 207,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "CONFERENCE=[]\n",
    "for i in range(len(SESSION)):\n",
    "    CONFERENCE.append('European society for Medical Oncology, ESMO - 2021')\n",
    "len(CONFERENCE)    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "id": "00e01f7c",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 209,
   "id": "a4314af4",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data=pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 210,
   "id": "b659f13c",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data[\"CONFERENCE\"]=CONFERENCE\n",
    "Data['SESSION_NAMES']=SESSION\n",
    "Data[\"SUB_SESSION\"]=SUB_SESSION\n",
    "Data[\"NAMES\"]=PERSONS\n",
    "Data[\"ROLE\"]=ROLE\n",
    "Data[\"COUNTRY\"]=COUNTRY\n",
    "Data[\"TIME\"]=TIME\n",
    "Data[\"DATE\"]=DATE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 211,
   "id": "315112bd",
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "index 8 is out of bounds for axis 0 with size 8",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Input \u001b[1;32mIn [211]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[1;34m()\u001b[0m\n\u001b[1;32m----> 1\u001b[0m Data\u001b[38;5;241m=\u001b[39mData\u001b[38;5;241m.\u001b[39mdrop(\u001b[43mData\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcolumns\u001b[49m\u001b[43m[\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m8\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m,axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n",
      "File \u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\pandas\\core\\indexes\\base.py:5055\u001b[0m, in \u001b[0;36mIndex.__getitem__\u001b[1;34m(self, key)\u001b[0m\n\u001b[0;32m   5048\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m com\u001b[38;5;241m.\u001b[39mis_bool_indexer(key):\n\u001b[0;32m   5049\u001b[0m     \u001b[38;5;66;03m# if we have list[bools, length=1e5] then doing this check+convert\u001b[39;00m\n\u001b[0;32m   5050\u001b[0m     \u001b[38;5;66;03m#  takes 166 µs + 2.1 ms and cuts the ndarray.__getitem__\u001b[39;00m\n\u001b[0;32m   5051\u001b[0m     \u001b[38;5;66;03m#  time below from 3.8 ms to 496 µs\u001b[39;00m\n\u001b[0;32m   5052\u001b[0m     \u001b[38;5;66;03m# if we already have ndarray[bool], the overhead is 1.4 µs or .25%\u001b[39;00m\n\u001b[0;32m   5053\u001b[0m     key \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39masarray(key, dtype\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mbool\u001b[39m)\n\u001b[1;32m-> 5055\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mgetitem\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkey\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   5056\u001b[0m \u001b[38;5;66;03m# Because we ruled out integer above, we always get an arraylike here\u001b[39;00m\n\u001b[0;32m   5057\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m result\u001b[38;5;241m.\u001b[39mndim \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m1\u001b[39m:\n",
      "\u001b[1;31mIndexError\u001b[0m: index 8 is out of bounds for axis 0 with size 8"
     ]
    }
   ],
   "source": [
    "Data=Data.drop(Data.columns[[8]],axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 212,
   "id": "cc8a895b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CONFERENCE</th>\n",
       "      <th>SESSION_NAMES</th>\n",
       "      <th>SUB_SESSION</th>\n",
       "      <th>NAMES</th>\n",
       "      <th>ROLE</th>\n",
       "      <th>COUNTRY</th>\n",
       "      <th>TIME</th>\n",
       "      <th>DATE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Emerging therapeutic concepts and molecules</td>\n",
       "      <td>Introduction</td>\n",
       "      <td>Chery Arrowsmith</td>\n",
       "      <td>Chair</td>\n",
       "      <td>Toronto, Canada</td>\n",
       "      <td>Basic science</td>\n",
       "      <td>Thu, 16.09.2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Emerging therapeutic concepts and molecules</td>\n",
       "      <td>Introduction (ID 5)</td>\n",
       "      <td>Chery Arrowsmith</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Toronto, Canada</td>\n",
       "      <td>5 Minutes</td>\n",
       "      <td>Thu, 16.09.2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Emerging therapeutic concepts and molecules</td>\n",
       "      <td>Understanding or dissecting the biology to tar...</td>\n",
       "      <td>James G. Christensen</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>San Diego, United States of America</td>\n",
       "      <td>15 Minutes</td>\n",
       "      <td>Thu, 16.09.2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Emerging therapeutic concepts and molecules</td>\n",
       "      <td>Developing novel epigenetic inhibitory compoun...</td>\n",
       "      <td>Chery Arrowsmith</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Toronto, Canada</td>\n",
       "      <td>15 Minutes</td>\n",
       "      <td>Thu, 16.09.2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>Emerging therapeutic concepts and molecules</td>\n",
       "      <td>Molecular glue degraders (ID 4)</td>\n",
       "      <td>Benjamin Ebert</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Boston, United States of America</td>\n",
       "      <td>15 Minutes</td>\n",
       "      <td>Thu, 16.09.2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1160</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>SARS-CoV-2 and cancer (EONS-ECPC)</td>\n",
       "      <td>Delays in screening and diagnosis of cancer du...</td>\n",
       "      <td>Urska Kosir</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Oxford, United Kingdom</td>\n",
       "      <td>Urska Kosir (Oxford, United Kingdom)</td>\n",
       "      <td>Amanda Drury (Dublin, Ireland)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1161</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>SARS-CoV-2 and cancer (EONS-ECPC)</td>\n",
       "      <td>Cancer care in COVID from a patient perspective</td>\n",
       "      <td>Alina Comanescu</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Bucharest, Romania</td>\n",
       "      <td>Alina Comanescu (Bucharest, Romania)</td>\n",
       "      <td>Amanda Drury (Dublin, Ireland)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1162</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>SARS-CoV-2 and cancer (EONS-ECPC)</td>\n",
       "      <td>CN43 - Maintaining intravenous anti-cancer sys...</td>\n",
       "      <td>Richard T. O'Dwyer</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Dublin, Ireland</td>\n",
       "      <td>Richard T. O'Dwyer (Dublin, Ireland)</td>\n",
       "      <td>Amanda Drury (Dublin, Ireland)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1163</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>SARS-CoV-2 and cancer (EONS-ECPC)</td>\n",
       "      <td>CN44 - Exploring cancer patients' and survivor...</td>\n",
       "      <td>Maura Dowling</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Galway, Ireland</td>\n",
       "      <td>Maura Dowling (Galway, Ireland)</td>\n",
       "      <td>Amanda Drury (Dublin, Ireland)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1164</th>\n",
       "      <td>European society for Medical Oncology, ESMO - ...</td>\n",
       "      <td>SARS-CoV-2 and cancer (EONS-ECPC)</td>\n",
       "      <td>Q&amp;A and live discussion</td>\n",
       "      <td>Amanda Drury</td>\n",
       "      <td>Speaker</td>\n",
       "      <td>Dublin, Ireland</td>\n",
       "      <td>Amanda Drury (Dublin, Ireland)</td>\n",
       "      <td>Amanda Drury (Dublin, Ireland)</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1165 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                             CONFERENCE  \\\n",
       "0     European society for Medical Oncology, ESMO - ...   \n",
       "1     European society for Medical Oncology, ESMO - ...   \n",
       "2     European society for Medical Oncology, ESMO - ...   \n",
       "3     European society for Medical Oncology, ESMO - ...   \n",
       "4     European society for Medical Oncology, ESMO - ...   \n",
       "...                                                 ...   \n",
       "1160  European society for Medical Oncology, ESMO - ...   \n",
       "1161  European society for Medical Oncology, ESMO - ...   \n",
       "1162  European society for Medical Oncology, ESMO - ...   \n",
       "1163  European society for Medical Oncology, ESMO - ...   \n",
       "1164  European society for Medical Oncology, ESMO - ...   \n",
       "\n",
       "                                    SESSION_NAMES  \\\n",
       "0     Emerging therapeutic concepts and molecules   \n",
       "1     Emerging therapeutic concepts and molecules   \n",
       "2     Emerging therapeutic concepts and molecules   \n",
       "3     Emerging therapeutic concepts and molecules   \n",
       "4     Emerging therapeutic concepts and molecules   \n",
       "...                                           ...   \n",
       "1160            SARS-CoV-2 and cancer (EONS-ECPC)   \n",
       "1161            SARS-CoV-2 and cancer (EONS-ECPC)   \n",
       "1162            SARS-CoV-2 and cancer (EONS-ECPC)   \n",
       "1163            SARS-CoV-2 and cancer (EONS-ECPC)   \n",
       "1164            SARS-CoV-2 and cancer (EONS-ECPC)   \n",
       "\n",
       "                                            SUB_SESSION  \\\n",
       "0                                          Introduction   \n",
       "1                                   Introduction (ID 5)   \n",
       "2     Understanding or dissecting the biology to tar...   \n",
       "3     Developing novel epigenetic inhibitory compoun...   \n",
       "4                       Molecular glue degraders (ID 4)   \n",
       "...                                                 ...   \n",
       "1160  Delays in screening and diagnosis of cancer du...   \n",
       "1161    Cancer care in COVID from a patient perspective   \n",
       "1162  CN43 - Maintaining intravenous anti-cancer sys...   \n",
       "1163  CN44 - Exploring cancer patients' and survivor...   \n",
       "1164                            Q&A and live discussion   \n",
       "\n",
       "                      NAMES     ROLE                              COUNTRY  \\\n",
       "0         Chery Arrowsmith     Chair                      Toronto, Canada   \n",
       "1         Chery Arrowsmith   Speaker                      Toronto, Canada   \n",
       "2     James G. Christensen   Speaker  San Diego, United States of America   \n",
       "3         Chery Arrowsmith   Speaker                      Toronto, Canada   \n",
       "4           Benjamin Ebert   Speaker     Boston, United States of America   \n",
       "...                     ...      ...                                  ...   \n",
       "1160           Urska Kosir   Speaker               Oxford, United Kingdom   \n",
       "1161       Alina Comanescu   Speaker                   Bucharest, Romania   \n",
       "1162    Richard T. O'Dwyer   Speaker                      Dublin, Ireland   \n",
       "1163         Maura Dowling   Speaker                      Galway, Ireland   \n",
       "1164          Amanda Drury   Speaker                      Dublin, Ireland   \n",
       "\n",
       "                                      TIME                            DATE  \n",
       "0                            Basic science                 Thu, 16.09.2021  \n",
       "1                                5 Minutes                 Thu, 16.09.2021  \n",
       "2                               15 Minutes                 Thu, 16.09.2021  \n",
       "3                               15 Minutes                 Thu, 16.09.2021  \n",
       "4                               15 Minutes                 Thu, 16.09.2021  \n",
       "...                                    ...                             ...  \n",
       "1160  Urska Kosir (Oxford, United Kingdom)  Amanda Drury (Dublin, Ireland)  \n",
       "1161  Alina Comanescu (Bucharest, Romania)  Amanda Drury (Dublin, Ireland)  \n",
       "1162  Richard T. O'Dwyer (Dublin, Ireland)  Amanda Drury (Dublin, Ireland)  \n",
       "1163       Maura Dowling (Galway, Ireland)  Amanda Drury (Dublin, Ireland)  \n",
       "1164        Amanda Drury (Dublin, Ireland)  Amanda Drury (Dublin, Ireland)  \n",
       "\n",
       "[1165 rows x 8 columns]"
      ]
     },
     "execution_count": 212,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "id": "217b56fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data.to_excel(\"ESMO_2021.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "144a9eb4",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "29386331",
   "metadata": {},
   "outputs": [],
   "source": [
    "tt = pd.ExcelFile('ESMO_2021.xlsx').parse('Sheet1')\n",
    "sub=tt['SUB_SESSION']\n",
    "names=tt['NAMES']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "e2ef97d6",
   "metadata": {},
   "outputs": [],
   "source": [
    "Initial=[]\n",
    "First=[]\n",
    "Middle=[]\n",
    "Last=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "1cb79c87",
   "metadata": {},
   "outputs": [],
   "source": [
    "def NameDivider(Name):\n",
    "    inti=\"\"\n",
    "    first=\"\"\n",
    "    last=\"\"\n",
    "    midd=[]\n",
    "    temp=str(Name).split(\" \")\n",
    "    for i in range(len(temp)):\n",
    "        if(len(temp[i])==2 and i==1):\n",
    "            if(temp[i][1]=='.'):\n",
    "                inti=temp[i][0]\n",
    "            continue\n",
    "        if(i==0):\n",
    "           first=temp[i]\n",
    "           continue\n",
    "        if(i==len(temp)-1):\n",
    "           last=temp[i]\n",
    "           continue\n",
    "        else:\n",
    "           midd.append(temp[i])\n",
    "    if(midd==[]):\n",
    "           mid=\"\"\n",
    "    if(midd!=[]):\n",
    "           mid=\" \".join(midd)\n",
    "    return inti,first,mid,last\n",
    "\n",
    "\n",
    "for j in range(len(names)):\n",
    "    inti,first,mid,lst=NameDivider(names[j])\n",
    "    Initial.append(inti)\n",
    "    First.append(first)\n",
    "    Middle.append(mid)\n",
    "    Last.append(lst)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "60ff4582",
   "metadata": {},
   "outputs": [],
   "source": [
    "search=['Gadolinium',\n",
    "'MRI+Contrast Agent',\n",
    "'Focal liver lesions',\n",
    "'Liver metastases',\n",
    "'Nephrogenic Systemic Fibrosis',\n",
    "'Colorectal Cancer+Liver Metastasis'\n",
    "'Breast Cancer+Liver Metastasis',\n",
    "'Lung Cancer+Liver Metastatsis',\n",
    "'Gastric Cancer+Liver Metastasis',\n",
    "'Primary Liver Cancer',\n",
    "'Gadolinium toxicity',\n",
    "'Gadolinium deposition']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "e478979c",
   "metadata": {},
   "outputs": [],
   "source": [
    "s_ele=[]\n",
    "found=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "4861e23b",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(len(sub)):\n",
    "    f=-1\n",
    "    for j in range(len(search)):\n",
    "        if(('+' not in search[j]) and (type(sub[i])!=float)):\n",
    "            if(search[j].lower() in sub[i].lower()):\n",
    "                f=j\n",
    "        else:\n",
    "            if(type(sub[i])!=float):\n",
    "                temp=search[j].split('+')\n",
    "                if((temp[0] in sub[i].lower()) and (temp[1] in sub[i].lower())):\n",
    "                    f=j\n",
    "    if(f!=-1):\n",
    "        s_ele.append(search[j])\n",
    "        found.append('Found')\n",
    "    else:\n",
    "        s_ele.append('No search term')\n",
    "        found.append('Not found')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "40a00c69",
   "metadata": {},
   "outputs": [],
   "source": [
    "bt=pd.DataFrame()\n",
    "bt['Session ST']=found\n",
    "bt['InSession']=s_ele\n",
    "# bt['Abstract ST']=ab_found\n",
    "# bt['InAbstract']=ab_s_ele\n",
    "bt['Initial']=Initial\n",
    "bt['First Name']=First\n",
    "bt['Middle Name']=Middle\n",
    "bt['Last Name']=Last"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "0ee3531b",
   "metadata": {},
   "outputs": [],
   "source": [
    "bt.to_excel('search_terms_2021.xlsx')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e4ebc59d",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
